

APPLICATION
FOR
UNITED STATES LETTERS PATENT

TITLE: COMPOSITIONS AND METHODS FOR INHIBITING G2
CELL CYCLE ARREST AND SENSITIZING CELLS TO
DNA DAMAGING AGENTS

APPLICANT: Masashi Saganuma, a citizen of Japan
Residing at 1-1-16 Shibuya-cho, Toyota City, Japan 471-0808

Takumi Kawabe, a citizen of Japan
Residing at 1-44-1 Mikanyama-cho, Mizuho-ku, Nagoya City, Japan 467-0041

ASSIGNEE: CanBas Co., Ltd.
709-1 Aza Takanomisaki Sanmaibashi, Numazu-city, Shizuoka, Japan 410-0031


Fish & Richardson P.C.
4350 La Jolla Village Drive, Suite 500
San Diego, CA 92122
Tel.: (858) 678-5070
Fax: (858) 678-5099

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL558601784US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit September 21, 2000

Signature 

Derek Norwood
Typed or Printed Name of Person Signing Certificate

COMPOSITIONS AND METHODS FOR INHIBITING G2 CELL CYCLE ARREST AND SENSITIZING CELLS TO DNA DAMAGING AGENTS

TECHNICAL FIELD

This invention generally pertains to the fields of medicine and cancer therapeutics. In particular, this invention provides novel genes and polypeptides and methods for making and using them. Specifically, the compositions and methods of the invention are used to treat disorders of cell growth, such as cancer. In particular, the invention provides methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA damaging agents and treatments. Also provided are methods for screening for compounds able to interact with, e.g., inhibit, enzymes involved in the G2 cell cycle arrest checkpoint, such as Chk1 and/or Chk2/Cds1 kinase.

BACKGROUND

It is a continuing challenge to develop anti-cancer agents that are capable of inhibiting the growth of, or killing, cancer cells, without affecting normal cells. Researchers have focused on genetic mutations in cancer cells to find clues to discover such new anti-cancer drugs.

Many cancer cells have mutations in genes involved in the G1 cell cycle arrest checkpoint. Such genes include impaired tumor suppressor genes, e.g., p53, Rb, p16^{INK4}, and p19^{ARF}. Alternatively, such mutations can cause expression of oncogenes, e.g., MDM-2 and cyclin D. In addition to these, excessive growth factor signaling can be caused by the over expression of growth factors. Together with these gain-of-function mutations, growth factor receptors or downstream signal-transducing molecules can cause cell transformation by overriding the G1 checkpoint. In contrast, few cancers have disrupted G2 cell cycle arrest checkpoints. Thus, the G2 checkpoint is usually retained in cancer cells with the impaired G1 checkpoint.

If the G2 checkpoint could be selectively disrupted, cancer cells with an impaired G1 checkpoint would become more sensitive to DNA-damaging treatment, as compared to normal cells (with intact G1), since progression through G1 and G2 without repairing such damage induces apoptosis.

The mechanism that promotes the cell cycle G2 arrest after DNA damage is conserved among species from yeast to human. In the presence of damaged DNA, Cdc2/Cyclin B kinase is kept inactive because of inhibitory phosphorylation of threonine-14 and tyrosine-15 residues on Cdc2 kinase. At the onset of mitosis, the dual phosphatase 5 Cdc25 kinase removes these inhibitory phosphates and thereby activates Cdc2/Cyclin B kinase.

In fission yeast, the protein kinase Chk1 is required for the cell cycle arrest in response to damaged DNA. Chk1 kinase acts downstream of several rad gene products and is modified by the phosphorylation upon DNA damage. The kinases Rad53 of budding yeast 10 and Cds1 of fission yeast are known to conduct signals from unreplicated DNA. It appears that there is some redundancy between Chk1 and Cds1 because elimination of both Chk1 and Cds1 was culminated in disruption of the G2 arrest induced by damaged DNA. Interestingly, both Chk1 and Cds1 phosphorylate Cdc25 kinase and promote Rad24 binding to Cdc25, which sequesters Cdc25 to cytosol and prevents Cdc2/Cyclin B activation. Therefore Cdc25 15 appears to be a common target of these kinases and presumably an indispensable factor in the G2 checkpoint.

In humans, both hChk1, a human homologue of fission yeast Chk1, and Chk2/HuCds1, a human homologue of the budding yeast Rad53 and fission yeast Cds1, phosphorylate Cdc25C at serine-216, a critical regulatory site, in response to DNA damage. 20 This phosphorylation creates a binding site for small acidic proteins 14-3-3s, human homologues of Rad24 and Rad25 of fission yeast (Lopez-Girona (1999) Nature 397:172-175). The regulatory role of this phosphorylation was clearly indicated by the fact that substitution of serine-216 to alanine on Cdc25C disrupted cell cycle G2 arrest in human cells (Peng (1997) Science 277:1501-1505).

25

SUMMARY

This invention provides nucleic acids and polypeptides which can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanisms, the polypeptides of the invention can function by inhibiting the G2 cell cycle arrest checkpoint. Thus, the

invention also provides compositions and methods for selectively sensitizing a cell with an impaired G1 cell cycle arrest checkpoint, e.g., a cancer cell, to a DNA damaging agent

The invention provides an isolated or recombinant polypeptide comprising the amino acid sequence: X₁ X₂ X₃ X₄ X₅ X₆ X₇ X₈ X₉ X₁₀ X₁₁, wherein X₁ is L, F, W, M, R, I, V, Y, K, or absent, X₂ is Y, F, A, W, S or T, X₃ is any amino acid, X₄ is any amino acid, X₅ is any amino acid, X₆ is S, A, N, H or P, X₇ is any amino acid, X₈ is any amino acid, X₉ is any amino acid or absent, X₁₀ is N, G, L, S, M, P, N, A or absent, and X₁₁ is L or absent, wherein the polypeptide when administered to or expressed in a cell disrupts the G2 cell cycle arrest checkpoint.

In alternative embodiments, for the isolated or recombinant polypeptide of the invention: X₁ is L, F, W, M, R or absent or X₁ is L, F or W; X₂ is Y, F, A; X₃ is R, T, S, H, D, G, A, L, K, A, N, Q or P, or, X₃ is R, T, S, H, D, G, A or L, or, X₃ is R, T, S or H; X₄ is S, T, G, A, L, R, I, M, V, P, or, X₄ is S, T, G, A, L, R, or, X₄ is S; X₅ is P, A, G, S or T, or, X₅ is P; X₆ is S, N, H, P, A, G or T, or, X₆ is S, N or H, or, X₆ is S; X₇ is M, F, Y, D, E, N, Q, H, G, I, L, V, A, P, N or W, or, X₇ is M, F, Y, D, E, N, Q or H, or, X₇ is M, F, Y, Q or H; X₈ is P, F, Y, W, L, G, M, D, E, N, Q, H, I, V, A or P, or, X₈ is P, F, Y or W, or, X₈ is Y; X₉ is E, G, L, S, M, P, N, D, A, T, P or absent; X₁₀ is absent; X₁₁ is absent.

In one embodiment, the invention provides a polypeptide wherein X₂ is Y, X₅ is P, and X₁₀ is N. In one embodiment, the invention provides a polypeptide wherein X₃ is R, X₈ is P, and X₁₁ is L. In one embodiment, the invention provides a polypeptide wherein X₄ is S, X₅ is P, X₆ is S, X₉ is E, X₁₀ is N and X₁₁ is L.

In alternative embodiments, the invention provides an isolated or recombinant polypeptide wherein the amino acid sequence comprises Y G G P G G G G N; R Y S L P P E L S N M; L A R S A S M P E A L; L Y R S P S M P E N L; L Y R S P A M P E N L; W Y R S P S F Y E N L; W Y R S P S Y Y E N L; or, W Y R S P S Y Y.

In alternative embodiments, the invention provides an isolated or recombinant polypeptide wherein the amino acid sequence comprises L Y R S P S Y P E N L, L Y R S P S Y F E N L, L Y R S P S Y Y E N L, or L Y R S P S Y W E N L.

In alternative embodiments, the invention provides an isolated or recombinant polypeptide wherein the amino acid sequence comprises L Y R S P S N P E N L, L Y R S P S N F E N L, L Y R S P S N Y E N L, or L Y R S P S N W E N L.

In alternative embodiments, the invention provides an isolated or recombinant polypeptide wherein the amino acid sequence comprises L Y R S P S H P E N L, L Y R S P S H F E N L, L Y R S P S H Y E N L, L Y R S P S H W E N L, L Y S S P S M P E N L, L Y S S P S M F E N L, L Y S S P S M Y E N L, L Y S S P S M W E N L, L Y S S P S F P E N L, L Y S S P S F P E N L, L Y S S P S F F E N L, L Y S S P S F Y E N L, L Y S S P S F W E N L, L Y S S P S Y P E N L, L Y S S P S Y F E N L, L Y S S P S Y Y E N L, or L Y S S P S Y W E N L.

10 In alternative embodiments, the invention provides an isolated or recombinant polypeptide wherein the amino acid sequence comprises L Y S S P S Q P E N L, L Y S S P S Q W E N L, L Y S S P S H P E N L, L Y S S P S H F E N L, L Y S S P S H Y E N L, L Y S S P S H W E N L, L Y T S P S M P E N L, L Y T S P S M F E N L, L Y T S P S M Y E N L, L Y T S P S M W E N L, L Y T S P S F P E N L, L Y T S P S F F E N L, L Y T S P S F Y E N L, L Y T S P S F W E N L, L Y T S P S Y P E N L, L Y T S P S Y F E N L, L Y T S P S Y Y E N L, or L Y T S P S Y W E N L.

15 In alternative embodiments, the invention provides an isolated or recombinant polypeptide wherein the amino acid sequence comprises L Y T S P S N P E N L, L Y T S P S N F E N L, L Y T S P S N Y E N L or L Y T S P S N W E N L.

20 In alternative embodiments, the invention provides an isolated or recombinant polypeptide wherein the amino acid sequence comprises L Y T S P S H P E N L, L Y T S P S H F E N L, L Y T S P S H Y E N L or L Y T S P S H W E N L.

In alternative embodiments, the invention provides an isolated or recombinant polypeptide wherein the amino acid sequence comprises L Y H S P S Y P E N L, L Y H S P S Y F E N L, L Y H S P S Y Y E N L or L Y H S P S Y W E N L.

25 In alternative embodiments, the invention provides an isolated or recombinant polypeptide wherein the amino acid sequence comprises L F T S P S Y P E N L, L F T S P S Y F E N L, L F T S P S Y Y E N L or L F T S P S Y W E N L.

30 In alternative embodiments, the invention provides an isolated or recombinant polypeptide wherein the amino acid sequence comprises F Y S S P S H P E N L, F Y S S P S H F E N L, F Y S S P S H Y E N L, F Y S S P S H W E N L, F Y T S P S M P E N L, F Y T S P S M F E N L, F Y T S P S M Y E N L, F Y T S P S M W E N L, F Y T S P S F P

ENL, FYTSPSFFENL, FYTSPSFYENL, FYTSPSFWENL, FYTSPSY PENL, FYTSPSYFENL, FYTSPSYYENL or FYTSPSYWENL.

In alternative embodiments, the invention provides an isolated or recombinant polypeptide wherein the amino acid sequence comprises W Y R S P S M P E N L, W Y R S P S M F E N L, W Y R S P S M Y E N L, W Y R S P S M W E N L, W Y R S P S F P E N L, W Y R S P S F F E N L, W Y R S P S F Y E N L, W Y R S P S F W E N L, W Y R S P S Y P E N L, W Y R S P S Y F E N L, W Y R S P S Y Y E N L or W Y R S P S Y W E N L.

In alternative embodiments, the invention provides an isolated or recombinant polypeptide wherein the amino acid sequence comprises W Y T S P S M P E N L, W Y T S P S M F E N L, W Y T S P S M Y E N L, W Y T S P S M W E N L, W Y T S P S F P E N L, W Y T S P S F F E N L, W Y T S P S F Y E N L, W Y T S P S F W E N L, W Y T S P S Y P E N L, W Y T S P S Y F E N L, W Y T S P S Y Y E N L or W Y T S P S Y W E N L.

In alternative embodiments, the invention provides an isolated or recombinant polypeptide wherein the amino acid sequence comprises W Y T S P S H P E N L, W Y T S P S H F E N L, W Y T S P S H Y E N L or W Y T S P S H W E N L.

In alternative embodiments, the invention provides an isolated or recombinant polypeptide wherein the amino acid sequence comprises L K R S P S M P E N L, L Y I S P S M P E N L or L Y R S P S M V E N L.

In one embodiment, the invention provides an isolated or recombinant polypeptide wherein the polypeptide when administered to or expressed in a cell disrupts the G2 cell cycle arrest checkpoint, wherein the cell is a mammalian cell. The cell can be a human cell, a yeast cell, an insect cell, a bacterial cell, a plant cell, and the like.

In one embodiment, the invention provides an isolated or recombinant polypeptide further comprising a cell membrane permeant. The cell membrane permeant can comprise a polypeptide, such as a TAT protein transduction domain, e.g., comprising a sequence Y G R K K R R Q R R R. Alternatively, the cell membrane permeant can comprise a lipid, such as a liposome.

The invention provides a chimeric polypeptide comprising a first domain comprising a polypeptide of the invention and a second domain comprising a cell membrane

permeant, wherein the polypeptide when administered to or expressed in a cell disrupts the G2 cell cycle arrest checkpoint. The chimeric polypeptide can be a recombinant fusion protein.

The invention provides an isolated or recombinant nucleic acid encoding a polypeptide or a chimeric polypeptide of the invention, wherein the polypeptide, when administered to or expressed in a cell, disrupts the G2 cell cycle arrest checkpoint.

The invention provides an expression vector comprising a nucleic acid encoding a polypeptide or a chimeric polypeptide of the invention, wherein the polypeptide, when administered to or expressed in a cell, disrupts the G2 cell cycle arrest checkpoint.

The invention provides a cell comprising a nucleic acid or an expression vector of the invention. The cell can be a bacterial, a yeast, an insect, a plant, or a mammalian cell.

The invention provides a pharmaceutical composition comprising a polypeptide of the invention, a nucleic acid of the invention, an expression vector of the invention, or a cell of the invention; and, a pharmaceutically acceptable excipient. In one embodiment, the pharmaceutical composition can comprise a liposome.

The invention provides a method for inhibiting the activity of a Chk1 kinase or a Chk2 kinase comprising contacting the kinase with a polypeptide of the invention or a pharmaceutical composition of the invention, in an amount sufficient to inhibit the activity of the Chk1 or Chk2 kinase.

The invention provides a method for disrupting a cell G2 cell cycle arrest checkpoint comprising contacting the cell with a polypeptide of the invention or a pharmaceutical composition of the invention in an amount sufficient to disrupt the G2 cell cycle arrest checkpoint. In alternative embodiments the cell is a mammalian cell, a human cell or a cancer cell.

The invention provides a method for sensitizing a cell to a DNA damaging agent comprising contacting the cell with a polypeptide of the invention or a pharmaceutical composition of the invention in an amount sufficient to disrupt the G2 cell cycle arrest checkpoint, thereby sensitizing the cell to the DNA damaging agent. In alternative embodiments the cell is a mammalian cell, a human cell or a cancer cell. The cancer cell can have an impaired G1 cell cycle arrest checkpoint.

The invention provides a method for selectively sensitizing a cell with an impaired G1 cell cycle arrest checkpoint to a DNA damaging agent comprising contacting the cell with a polypeptide of the invention or a pharmaceutical composition of the invention, in an amount sufficient to disrupt the G2 cell cycle arrest checkpoint, thereby sensitizing the cell to the DNA damaging agent. In alternative embodiments the cell is a mammalian cell, a human cell or a cancer cell.

The invention provides a method for inducing apoptosis in a cell in an individual comprising administering a polypeptide of the invention or a pharmaceutical composition of the invention, in an amount sufficient to disrupt the G2 cell cycle arrest checkpoint in the cancer cell, thereby sensitizing the cancer cell to a DNA damaging agent, and administering a DNA damaging agent. In alternative embodiments the cell is a mammalian cell, a human cell or a cancer cell. The cancer cell can have an impaired G1 cell cycle arrest checkpoint. The DNA damaging agent can be 5-fluorouracil (5-FU), rebeccamycin, adriamycin, bleomycin, cisplatin, hyperthermia, UV irradiation or gamma-irradiation.

The invention provides a method for screening for compounds capable of modulating the activity of a Chk1 kinase or a Chk2 kinase comprising the following steps: (a) providing a test compound; (b) providing a Chk1 kinase or a Chk2 kinase; (c) providing a polypeptide of the invention, wherein the polypeptide binds to the Chk1 kinase or the Chk2 kinase; and, (d) contacting the test compound with the kinase and the polypeptide and measuring the ability of the test compound to prevent binding of the polypeptide to the kinase.

The invention provides a method for screening for compounds capable of modulating the activity of a Chk1 kinase or a Chk2 kinase comprising the following steps: (a) providing a test compound; (b) providing a Chk1 kinase or a Chk2 kinase; (c) providing a polypeptide of the invention, wherein the polypeptide is phosphorylated by the Chk1 kinase or the Chk2 kinase; and, (d) contacting the test compound with the kinase and the polypeptide and measuring the ability of the test compound to inhibit or abrogate phosphorylation of the polypeptide by the kinase. The method can further comprising providing a full length human Cdc25C. In one embodiment of the method, the polypeptide of step (c) comprises amino acid residue serine 216 of human Cdc25C, such as comprising

from about amino acid residue 200 to about amino acid residue 250 of human Cdc25C. In one embodiment of the method, the polypeptide of step (c) further comprises glutathione-S-transferase.

5 In one embodiment of the methods of the invention, including the screening methods, the polypeptide of the invention is immobilized.

The invention provides a method for screening for compounds capable of specifically inhibiting the G2 cell cycle checkpoint comprising the following steps: (a) providing a test compound and a polypeptide of the invention; (b) providing a G1 checkpoint impaired cell; (c) contacting the cell of step (b) with the test compound or the polypeptide of step (a) plus a DNA damaging treatment, such as 5-fluorouracil (5-FU), rebeccamycin, adriamycin, bleomycin, cisplatin, hyperthermia, UV irradiation or gamma-irradiation, or, or an M phase checkpoint activator; and, (d) measuring the amount of DNA in the cells after the contacting of step (c) to determine if the test compound has inhibited the G2 cell cycle checkpoint, wherein the polypeptide of step (a) acts as a G2-checkpoint-inhibiting positive control. In alternative embodiments the cell is a mammalian cell, a human cell or a cancer cell. In one embodiment, the amount of DNA is measured using propidium iodide by, e.g., a FACS analysis, or equivalent. In one embodiment, the amount of DNA is measured after about 10 to about 72 hours after the contacting of step (c).

20 In one embodiment, the method comprises contacting the cell of step (b) with an M phase checkpoint activator alone (as a substitute for a DNA damaging agent) and the test compound or the polypeptide of step (a), wherein a test compound that has not inhibited or abrogated the arrest at the M phase checkpoint of the cell cycle after contacting the cell with an M phase activator is a specific inhibitor of the G2 cell cycle checkpoint (because it did not affect M phase checkpoint or it was not a non-specific phenomenon). In one embodiment, the M phase checkpoint activator is colchicine or nocodazole.

25 The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

30 All publications, patents, patent applications, GenBank sequences and ATCC deposits, cited herein are hereby expressly incorporated by reference for all purposes.

DESCRIPTION OF DRAWINGS

Figure 1 shows chimeric peptides used in and results of experiments demonstrating that TAT-S216A and TAT-S216 peptides inhibit hChk1 and Chk2/HuCds1 kinase activity *in vitro*, as described in Example 1, below. Figure 1A shows a schematic diagram of the fusion/chimeric peptides TAT-control, TAT-S216A and TAT-S216. Figure 1B shows SDS-PAGE autoradiograms demonstrating the results of *in vitro* Cdc25C phosphorylation assays using TAT-S216A and TAT-S216 peptides to inhibit purified hChk1 activity; amino acid residues 200 to 256 of Cdc25C (SEQ ID NO:1) were used as a substrate at a concentration of 1 µM. Figure 1C shows SDS-PAGE autoradiograms demonstrating the results of *in vitro* Cdc25C phosphorylation assays using TAT-S216A peptide to inhibit purified hChk1 and Chk2/HuCds1 activity; amino acid residues 211 to 220 of Cdc25C (SEQ ID NO:1) were used as a substrate at a concentration of 10 µM.

Figure 2 the results of experiments demonstrating that TAT-S216A and TAT-S216 peptides can abrogate DNA damage-induced G2 arrest in Jurkat cells. Figure 2A shows the results of a FACS analysis of Jurkat cells treated with bleomycin (10 µg/ml) and TAT-S216A and TAT-S216 peptides (10 µM each). Figure 2B shows the results of an SDS-PAGE of cell lysates from a histone H1 kinase analysis; lysates were prepared from cells treated with the indicated reagent for six hours. Figure 2C shows the results a FACS analysis of colchicines- (5 µg/ml) and peptide- (10 µM each) treated cells; Jurkat cells were treated for 20 hours.

Figure 3 shows the results of experiments demonstrating that TAT-S216A and TAT-S216 peptides can specifically sensitize cancer cells to bleomycin, but not colchicine. Figure 3A shows the results of trypan blue dye exclusion analysis of Jurkat cells treated with bleomycin with or without the TAT-S216A and TAT-S216 peptides. Figure 3B shows the results of trypan blue dye exclusion (survival) analysis of Jurkat cells treated with colchicine with or without the TAT-S216A and TAT-S216 peptides. Figure 3C shows the results of trypan blue dye exclusion (survival) analysis of PHA blasts treated with bleomycin with or without the TAT-S216A and TAT-S216 peptides. Figure 3D shows the results of FACS analysis PHA blasts treated with bleomycin with or without the TAT-S216A and TAT-S216 peptides (vertical axis is DNA content indicated by propidium iodide staining).

Figure 4 shows the results of experiments demonstrating that TAT-S216A and TAT-S216 peptides can sensitize cancer cells to bleomycin. Figure 4A shows the results of X-TT analysis of PANC1 cells treated with bleomycin with or without the TAT-S216A and TAT-S216 peptides. Figure 4B shows the results of X-TT analysis of MIA PaCa2 cells treated with bleomycin with or without the TAT-S216A and TAT-S216 peptides.

5

Figure 5 shows a schematic 3-dimensional structure of human Chk2 interacting with exemplary G2-abrogating peptides of the invention, as described in Example 2, below.

10

Figure 6 shows the results of FACS analysis of the amount of DNA in cells to determine the number of cells in one of the four cell cycle phases after incubating these cells with bleomycin and exemplary peptides of the invention, as described in Example 3, below.

15

Figure 7 shows the results of FACS analysis of the amount of DNA in cells to determine the number of cells in one of the four cell cycle phases after incubating these cells with colchicine and exemplary peptides of the invention, as described in Example 3, below.

Figure 8 shows the sequences of peptides used in experiments described in Example 4, below.

20

Figure 9 shows a summary of results of experiments as described in Example 4, below.

Figure 10 shows the results of experiments demonstrating that a peptide of the invention (as a S216-containing fusion protein) administered to an animal *in vivo* effectively sensitized cancer cells to a DNA damaging agent.

Figure 11 shows the results of experiments demonstrating that a peptide of the invention (as a R-II-containing fusion protein) administered to an animal *in vivo* effectively sensitized cancer cells to a DNA damaging agent.

25

Like reference symbols in the various drawings indicate like elements.

DETAILED DESCRIPTION

30

The genes and polypeptides of the invention provide a novel means to treat cell proliferative disorders, including, e.g., to stop the growth of, or kill, cancer cells. While the invention is not limited by any particular mechanism of action, administration of the polypeptides of the invention will delay or abrogate G2 cell cycle arrest checkpoint in cells.

The genes and polypeptides of the invention can also be used to inhibit Chk1 and/or Chk2/Cds1 kinase activity. Inhibition of Chk1 and/or Chk2/Cds1 kinase may be the mechanism by which the G2 checkpoint is inhibited. The invention also provides methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA damaging agents and treatments. Also provided are methods for screening for compounds able to interact with, e.g., inhibit, enzymes involved in the G2 cell cycle arrest checkpoint, such as Chk1 and/or Chk2/Cds1 kinases. Thus, the invention provides methods to screen for compounds that inhibit or abrogate cell cycle G2 checkpoint.

The invention for the first time describes amino acid peptide motifs in the human Cdc25C (hCdc25C) polypeptide (SEQ ID NO:1) that are the substrate motifs for human Chk1 (hChk1) (SEQ ID NO:3) and human Chk2/ human Cds1 (Chk2/HuCds1) (SEQ ID NO:4) kinase activity. The kinase-inhibitory polypeptides and nucleic acids of the invention are modeled on these hCdc25C peptide motifs. Wild-type hCdc25C is phosphorylated by hChk1 (SEQ ID NO:3) and Chk2/HuCds1 (SEQ ID NO:4).

Phosphorylation of Cdc25C is necessary for the cell's arrest at G2 checkpoint. Thus, the polypeptides and peptides of the invention, by inhibiting the phosphorylation of Cdc25C (by enzymes which probably include Chk1 and Chk2/HuCds1), can inhibit or abrogate the cell's G2 checkpoint capability. The lack of an effective G2 checkpoint after DNA damage becomes fatal to the cell (see, e.g., Maity (1994) Radiother. Oncol. 31:1-13). If a cell progresses through G2 without sufficient repair of DNA damage it becomes apoptotic. Thus, the compositions of the invention can be used to sensitize cells, such as tumor cells, to DNA damaging agents. In fact, as discussed below, the compositions of the invention can sensitize cancer cells to the apoptotic effects of DNA-damaging agents with little or no cytotoxic effect on normal cells.

Example 1, below, describes the synthesis and use of two exemplary polypeptides of the invention. Two peptides corresponding to amino acids 211 to 221 of human Cdc25C (SEQ ID NO:1) fused with a part of HIV-1-TAT (SEQ ID NO:5). These peptides were demonstrated to inhibit hChk1 kinase (SEQ ID NO:3) and Chk2/HuCds1 kinase (SEQ ID NO:4) activity *in vitro* and to specifically abrogate the G2 checkpoint *in vivo*. These peptides sensitized p53-defective cancer cell lines to the apoptotic effects of DNA-damaging agents without obvious cytotoxic effect on normal cells. These results

clearly demonstrate that the polypeptides comprising the motifs of the invention can be used to specifically inhibit or abrogate the cell cycle G2 checkpoint. These results demonstrate that the compositions of the invention can be used to screen for compositions that inhibit Chk1 or Chk2 kinase activity. These results also demonstrate that the compositions of the 5 invention can be used for cancer therapy. While the invention is not limited by any particular mechanism of action, the polypeptides and peptides of the invention can be used to target and inhibit hChk1 (SEQ ID NO:3) and Chk2/HuCds1 (SEQ ID NO:4) kinases.

DEFINITIONS

Unless defined otherwise, all technical and scientific terms used herein have 10 the meaning commonly understood by a person skilled in the art to which this invention belongs. As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

The term “cell membrane permeant” as used herein means any composition which, when associated with a peptide or polypeptide of the invention, or a nucleic acid of 15 the invention, causes, or assists in, the internalization of the composition into a cell. The association can be covalent (e.g., a linking reagent, or, as a fusion protein) or non-covalent (e.g., as with liposomes). For example, in one embodiment, a cell membrane permeant domain is linked to a peptide or polypeptide of the invention as a fusion protein domain, e.g., a TAT protein transduction domain (see, e.g., Vives (1997) J. Biol. Chem. 272:16010- 20 16017). Other cell membrane permeant domains include, e.g., the PreS2- and S-domain of the hepatitis-B virus surface antigens, see, e.g., Oess (2000) Gene Ther. 7:750-758.

The term “human Cdc25C” or “hCdc25C” as used herein means, depending 25 on the context, the human Cdc25C polypeptide (SEQ ID NO:1) or the human Cdc25C polypeptide (SEQ ID NO:1) message (cDNA) (SEQ ID NO:2) or gene (see, e.g., Peng (1997) Science 277:1501-1505) . The term also includes all functional variations of hCdc25C, including, e.g., allelic variations, functional mutations, variations with additions, deletions, substitutions that retain functional activity. A Cdc25C polypeptide that has functional activity has the same activity as wild type Cdc25C, i.e., when appropriately phosphorylated, it can act in concert with other cell cycle control polypeptides to arrest cell growth at G2 under the proper conditions, e.g., under conditions in which sufficient DNA damage has 30 incurred to induce apoptosis if the cell passes through the G2 checkpoint.

The terms "DNA damaging treatment" or "DNA damaging agent" include any treatments or agents that will cause DNA damage to a cell, including a drug, a radiation, an environmental shock, and the like, including, e.g., hyperthermia, UV radiation or gamma-radiation, in addition to the known DNA damaging drugs, e.g., 5-fluorouracil (5-FU),
5 rebeccamycin, adriamycin, bleomycin, cisplatin and the like.

The term "disrupt the cell cycle G2 checkpoint" or "inhibit the cell cycle G2 checkpoint" means the ability of a peptide or polypeptide of the invention to inhibit (including abrogate) a Chk1 kinase and/or Chk2 kinase activity, e.g., a mammalian kinase, such as a human Chk1 (hChk1) kinase (SEQ ID NO:3) (see, e.g., Yin (2000) Mol. Pharmacol. 57:453-459) or a human Chk2/ human Cds1 kinase (Chk2/HuCds1) (SEQ ID NO:4) (see, e.g., Hirao (2000) Science 287:1824-1827), or, to disrupt (including abrogate) the ability of a cell to arrest growth at the G2 checkpoint under appropriate conditions, e.g., where conditions in the cell otherwise would cause G2 cell cycle arrest, such as the accumulation of DNA damage by, e.g., some anti-tumor agents.
10

15 The ability of a peptide or polypeptide of the invention to modulate or inhibit a Chk1 kinase and/or a Chk2 kinase activity can be easily tested *in vitro* or *in vivo* as, for example, in the assays, or variations thereof, described in Example 1, below. A peptide or polypeptide is considered an effective inhibitor if, e.g., it binds the kinase to inhibit or abrogate kinase activity. Alternatively, a peptide or polypeptide is also considered an
20 effective inhibitor of kinase activity if it acts as a phosphorylation substrate and prevents phosphorylation of natural substrate, e.g., wild type Cdc25C, thereby disrupt the ability of a cell to arrest growth at the G2 checkpoint under appropriate conditions.

25 The ability of exemplary peptides or polypeptides of the invention to disrupt the ability of a cell to arrest growth at the G2 checkpoint, i.e., to act in concert with other cell cycle control polypeptides to arrest cell growth at G2 under the proper conditions, e.g., under conditions in which sufficient DNA damage has incurred to induce apoptosis if the cell passes through the G2 checkpoint can be easily tested *in vivo*, e.g., cell culture, is demonstrated in Example 1, below

30 The term "expression cassette" as used herein refers to a nucleotide sequence which is capable of affecting expression of a structural gene (i.e., a protein coding sequence) in a host compatible with such sequences. Expression cassettes include at least a promoter

100-900-0000-0000-0000-0000-0000-0000

operably linked with the polypeptide coding sequence; and, optionally, with other sequences, e.g., transcription termination signals. Additional factors necessary or helpful in effecting expression may also be used, e.g., enhancers. "Operably linked" as used herein refers to linkage of a promoter upstream from a DNA sequence such that the promoter mediates transcription of the DNA sequence. Thus, expression cassettes also include plasmids, expression vectors, recombinant viruses, any form of recombinant "naked DNA" vector, and the like. A "vector" comprises a nucleic acid which can infect, transfect, transiently or permanently transduce a cell. It will be recognized that a vector can be a naked nucleic acid, or a nucleic acid complexed with protein or lipid. The vector optionally comprises viral or bacterial nucleic acids and/or proteins, and/or membranes (e.g., a cell membrane, a viral lipid envelope, etc.). Vectors include, but are not limited to replicons (e.g., RNA replicons, bacteriophages) to which fragments of DNA may be attached and become replicated. Vectors thus include, but are not limited to RNA, autonomous self-replicating circular or linear DNA or RNA (e.g., plasmids, viruses, and the like, see, e.g., U.S. Patent No. 5,217,879), and includes both the expression and nonexpression plasmids. Where a recombinant microorganism or cell culture is described as hosting an "expression vector" this includes both extrachromosomal circular and linear DNA and DNA that has been incorporated into the host chromosome(s). Where a vector is being maintained by a host cell, the vector may either be stably replicated by the cells during mitosis as an autonomous structure, or is incorporated within the host's genome.

The term "chemically linked" refers to any chemical bonding of two moieties, e.g., as in one embodiment of the invention, a polypeptide comprising at least two peptide motifs of the invention. Such chemical linking includes the peptide bonding of a recombinantly or *in vivo* generated fusion protein.

The term "chimeric protein" or "fusion protein" refers to a composition comprising at least one polypeptide or peptide domain or motif which is associated with a second polypeptide or peptide domain or motif. For example, in one embodiment, the invention provides an isolated or recombinant nucleic acid molecule encoding a fusion protein comprising at least two domains, wherein the first domain comprises one kinase-inhibiting or G2-checkpoint inhibiting motif and the second domain comprising a second motif with the same or similar activity (for example, on motif may have a high binding

affinity for the kinase, whilst the second motif has high kinase inhibitory activity). Additional domains can comprise a polypeptide, peptide, polysaccharide, or the like. The “fusion” can be an association generated by a peptide bond, a chemical linking, a charge interaction (e.g., electrostatic attractions, such as salt bridges, H-bonding, etc.) or the like. If 5 the polypeptides are recombinant, the “fusion protein” can be translated from a common message. Alternatively, the compositions of the domains can be linked by any chemical or electrostatic means. The chimeric molecules of the invention can also include additional sequences, e.g., linkers, epitope tags, enzyme cleavage recognition sequences, signal sequences, secretion signals, and the like. Alternatively, a peptide can be linked to a carrier 10 simply to facilitate manipulation or identification/ location of the peptide.

The term “G2 checkpoint inhibitory activity” as used herein means any amount of inhibition of the G2 checkpoint.

The term “isolated” as used herein, when referring to a molecule or composition, such as, e.g., a nucleic acid or polypeptide of the invention, means that the 15 molecule or composition is separated from at least one other compound, such as a protein, other nucleic acids (e.g., RNAs), or other contaminants with which it is associated *in vivo* or in its naturally occurring state. Thus, a nucleic acid or polypeptide is considered isolated when it has been isolated from any other component with which it is naturally associated, e.g., cell membrane, as in a cell extract. An isolated composition can, however, also be 20 substantially pure. An isolated composition can be in a homogeneous state and can be in a dry or an aqueous solution. Purity and homogeneity can be determined, for example, using analytical chemistry techniques such as polyacrylamide gel electrophoresis (SDS-PAGE) or high performance liquid chromatography (HPLC). Thus, the isolated compositions of this invention do not contain materials normally associated with their *in situ* environment. Even 25 where a protein has been isolated to a homogenous or dominant band, there can be trace contaminants which co-purify with the desired protein.

The terms “polypeptide,” “protein,” and “peptide” include compositions of the invention that also include “analogs,” or “conservative variants” and “mimetics” or “peptidomimetics” with structures and activity that substantially correspond to the 30 polypeptide from which the variant was derived, including, e.g., variations of the peptides

and polypeptides of the invention which can either inhibit a mammalian Chk1 and/or Chk2 kinase, or, inhibit a mammalian G2 checkpoint.

The term "pharmaceutical composition" refers to a composition suitable for pharmaceutical use, e.g., as an anti-cancer agent, in a subject. The pharmaceutical compositions of this invention are formulations that comprise a pharmacologically effective amount of a composition comprising, e.g., a peptide, polypeptide, nucleic acid, vector, or cell of the invention, and a pharmaceutically acceptable carrier.

The term "promoter" is an array of nucleic acid control sequences which direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerase II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter which is active under most environmental and developmental conditions. An "inducible" promoter is a promoter which is under environmental or developmental regulation. A "tissue specific" promoter is active in certain tissue types of an organism, but not in other tissue types from the same organism. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

The term "recombinant" refers to a polynucleotide synthesized or otherwise manipulated *in vitro* (e.g., "recombinant polynucleotide"), to methods of using recombinant polynucleotides to produce gene products in cells or other biological systems, or to a polypeptide ("recombinant protein") encoded by a recombinant polynucleotide. For example, recombinant peptides or polypeptides or nucleic acids can be used to practice the methods of the invention. "Recombinant means" also encompass the ligation of nucleic acids having various coding regions or domains or promoter sequences from different sources into an expression cassette or vector for expression of, e.g., inducible or constitutive expression of polypeptide coding sequences in the vectors used to practice this invention.

Nucleic Acids and Expression Vectors

This invention provides novel nucleic acids, including expression vectors, for use in the treatment of uncontrolled cell growth, such as cancer, and means to make and express those nucleic acids. As the genes and vectors of the invention can be made and expressed *in vitro* or *in vivo*, the invention provides for a variety of means of making and expressing these genes and vectors. One of skill will recognize that desired levels of expression of the polypeptides of the invention can be obtained by modulating the expression or activity of the genes and nucleic acids (e.g., promoters) within the vectors of the invention. Any of the known methods described for increasing or decreasing expression or activity, including tissue-specific expression, can be used for this invention. The invention can be practiced in conjunction with any method or protocol known in the art, which are well described in the scientific and patent literature.

General Techniques

The nucleic acid sequences of the invention and other nucleic acids used to practice this invention, whether RNA, cDNA, genomic DNA, vectors, viruses or hybrids thereof, may be isolated from a variety of sources, genetically engineered, amplified, and/or expressed recombinantly. Any recombinant expression system can be used, including, in addition to bacterial cells, e.g., mammalian, yeast, insect or plant cell expression systems.

Alternatively, these nucleic acids can be synthesized *in vitro* by well-known chemical synthesis techniques, as described in, e.g., Carruthers (1982) Cold Spring Harbor Symp. Quant. Biol. 47:411-418; Adams (1983) J. Am. Chem. Soc. 105:661; Belousov (1997) Nucleic Acids Res. 25:3440-3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; Blommers (1994) Biochemistry 33:7886-7896; Narang (1979) Meth. Enzymol. 68:90; Brown (1979) Meth. Enzymol. 68:109; Beaucage (1981) Tetra. Lett. 22:1859; U.S. Patent No. 25 4,458,066. Double stranded DNA fragments may then be obtained either by synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.

Techniques for the manipulation of nucleic acids, such as, e.g., generating mutations in sequences, subcloning, labeling probes, sequencing, hybridization and the like are well described in the scientific and patent literature, see, e.g., Sambrook, ed.,

MOLECULAR CLONING: A LABORATORY MANUAL (2ND ED.), Vols. 1-3, Cold Spring Harbor Laboratory, (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Ausubel, ed. John Wiley & Sons, Inc., New York (1997); LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY: HYBRIDIZATION WITH NUCLEIC ACID PROBES, Part I. Theory and
5 Nucleic Acid Preparation, Tijssen, ed. Elsevier, N.Y. (1993).

Nucleic acids, vectors, capsids, polypeptides, and the like can be analyzed and quantified by any of a number of general means well known to those of skill in the art. These include, e.g., analytical biochemical methods such as NMR, spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC),
10 thin layer chromatography (TLC), and hyperdiffusion chromatography, various immunological methods, e.g. fluid or gel precipitin reactions, immunodiffusion, immuno-electrophoresis, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays (ELISAs), immuno-fluorescent assays, Southern analysis, Northern analysis, dot-blot analysis, gel electrophoresis (e.g., SDS-PAGE), nucleic acid or target or signal amplification
15 methods, radiolabeling, scintillation counting, and affinity chromatography. Amplification methods include, e.g., polymerase chain reaction, PCR (PCR PROTOCOLS, A GUIDE TO METHODS AND APPLICATIONS, ed. Innis, Academic Press, N.Y. (1990) and PCR STRATEGIES (1995), ed. Innis, Academic Press, Inc., N.Y., ligase chain reaction (LCR)
(see, e.g., Wu (1989) Genomics 4:560; Landegren (1988) Science 241:1077; Barringer
20 (1990) Gene 89:117); transcription amplification (see, e.g., Kwoh (1989) Proc. Natl. Acad. Sci. USA 86:1173); and, self-sustained sequence replication (see, e.g., Guatelli (1990) Proc. Natl. Acad. Sci. USA 87:1874); Q Beta replicase amplification (see, e.g., Smith (1997) J. Clin. Microbiol. 35:1477-1491), automated Q-beta replicase amplification assay (see, e.g., Burg (1996) Mol. Cell. Probes 10:257-271) and other RNA polymerase mediated techniques
25 (e.g., NASBA, Cangene, Mississauga, Ontario); see also Berger (1987) Methods Enzymol. 152:307-316; Sambrook; Ausubel; U.S. Patent Nos. 4,683,195 and 4,683,202; Sooknanan (1995) Biotechnology 13:563-564.

Once amplified, the libraries can be cloned, if desired, into any of a variety of vectors using routine molecular biological methods; methods for cloning *in vitro* amplified
30 nucleic acids are described, e.g., U.S. Pat. No. 5,426,039. To facilitate cloning of amplified sequences, restriction enzyme sites can be “built into” the PCR primer pair.

The invention provides libraries of expression vectors encoding polypeptides and peptides of the invention. These nucleic acids may be introduced into a genome or into the cytoplasm or a nucleus of a cell and expressed by a variety of conventional techniques, well described in the scientific and patent literature. See, e.g., Roberts (1987) *Nature* 328:731; Schneider (1995) *Protein Expr. Purif.* 64:35:10; Sambrook, Tijssen or Ausubel. The vectors can be isolated from natural sources, obtained from such sources as ATCC or GenBank libraries, or prepared by synthetic or recombinant methods. For example, the nucleic acids of the invention can be expressed in expression cassettes, vectors or viruses which are stably or transiently expressed in cells (e.g., episomal expression systems).

5 Selection markers can be incorporated into expression cassettes and vectors to confer a selectable phenotype on transformed cells and sequences. For example, selection markers can code for episomal maintenance and replication such that integration into the host genome is not required.

10

In one embodiment, the nucleic acids of the invention are administered *in vivo* for *in situ* expression of the peptides or polypeptides of the invention. The nucleic acids can be administered as “naked DNA” (see, e.g., U.S. Patent No. 5,580,859) or in the form of an expression vector, e.g., a recombinant virus. The nucleic acids can be administered by any route, including peri- or intra-tumorally, as described below. Vectors administered *in vivo* can be derived from viral genomes, including recombinantly modified enveloped or non-enveloped DNA and RNA viruses, preferably selected from baculoviridiae, parvoviridiae, picornoviridiae, herpesveridiae, poxviridae, adenoviridiae, or picornnaviridiae. Chimeric vectors may also be employed which exploit advantageous merits of each of the parent vector properties (See e.g., Feng (1997) *Nature Biotechnology* 15:866-870). Such viral genomes may be modified by recombinant DNA techniques to include the nucleic acids of the invention; and may be further engineered to be replication deficient, conditionally replicating or replication competent. In alternative embodiments, vectors are derived from the adenoviral (e.g., replication incompetent vectors derived from the human adenovirus genome, see, e.g., U.S. Patent Nos. 6,096,718; 6,110,458; 6,113,913; 5,631,236); adeno-associated viral and retroviral genomes. Retroviral vectors can include those based upon murine leukemia virus (MuLV), gibbon ape leukemia virus (GaLV), Simian Immuno deficiency virus (SIV), human immuno deficiency virus (HIV), and combinations thereof;

15

20

25

30

see, e.g., U.S. Patent Nos. 6,117,681; 6,107,478; 5,658,775; 5,449,614; Buchscher (1992) J. Virol. 66:2731-2739; Johann (1992) J. Virol. 66:1635-1640). Adeno-associated virus (AAV)-based vectors can be used to transduce cells with target nucleic acids, e.g., in the *in vitro* production of nucleic acids and peptides, and in *in vivo* and *ex vivo* gene therapy procedures; see, e.g., U.S. Patent Nos. 6,110,456; 5,474,935; Okada (1996) Gene Ther. 3:957-964.

The peptides and polypeptides of the invention are derived from, or, based on, the structure of the kinase Cdc25C. The cDNA nucleic acid sequence for hCdc25C is

1 caggaagact ctgagtcgcg cgtggcccta cccagtcgga aggcagagct gcaatctgt
10 61 taactaccc tcctccctta gattccctt cattctgctc aagtctcgc ctgtgtcccg
121 tccctatcta cttctctcc tcttgttagca agcctcagac tccaggcttg agcttaggtt
181 tggtttctc ctggtgagaa ttcaagagacc atgtctacgg aactctctc atccacaaga
241 gaggaaggaa gctctggctc aggaccaggat tttaggtcta atcaaaggaa aatgttaaac
301 ctgctccctgg agagagacac ttcccttacc gtctgtccag atgtccctag aactccagg
361 gccaaatttc ttgtgtattc tgcaaaccata agcattttg ctggaggaac cccaaaatgt
421 tgccctcgatc ttcaaatct tagcagtggg gagataactg ccactcagct taccactct
481 gcagaccttg atgaaactgg tcacctggat tcctcaggac ttcaaggat gcatttagct
541 gggatgaatc atgaccagca cctaatggaaa tgtagccccag cacagctct ttgttagcact
601 ccgaatggtt tggaccgtgg ccatagaaaag agagatgcaa tggtagttc atctgcaaat
20 661 aaagaaaatg acaatggaaa ctgggtggac agtggaaatga aatattttggg cagtcccatt
721 actactgttc caaaatttggaa taaaaatcca aaccttaggg aagaccaggc agaagagatt
781 tcagatgaat taatggagtt ttccctgaaa gatcaagaag caaagggtgg cagaagtggc
841 ctatatcgct ccccgatcgt gccagagaac ttgaacaggc caagactgaa gcagggtggaa
901 aaattcaagg acaacacaat accagataaa gttaaaaaaaaa agtatttttc tggccaaggaa
961 aagctcagga agggcttatg tttaaagaag acagtctctc tggtagtgc acat tactatcact
25 1021 cagatgctgg aggaagattc taaccagggg cacctgattt gtttttttcaaggtatgt
1081 ggcgtgccaa ccgtgtcagg gaaacaccaa gatcaaggat atgtcaaccc agaaacagg
1141 gctgccttac tgcggggaa gttccagggt ctgattgaga agttttatgt cattgtatgt
1201 cgctatccat atgagtatct gggaggacac atccagggg ccttaaactt atatagtcg
30 1261 gaagaactgt ttaactctt tctgaagaag cccatcgatcc cttggacac ccagaagaga
1321 ataatcatcg tggccactg tgaattctcc tcagagaggg gcccccaat gtggccgtgt
1381 ctgcgtgaag aggacaggc tctgaaccag tatccgtcat tggtagtgc acat
1441 atccctaaag gcccgtacag agactctt ccagaatata tggaaactgtg tgaaccacag
1501 agctactgcc ctatgcata tcaggaccac aagactgagt tggtaggtg tcgaaggccag
35 1561 agcaaagtgc aggaaggggg gcccgtacag cgggacqcaq ttccctctt qgtqaaggaa

1621 atgagccat gataacattc cagccactgg ctgctaaca gtcaccaaaa agacactgca
1681 gaaaccctga gcagaaagag gcctctgga tggccaaacc caagattttt aaaagatgtc
1741 tctgcaaacc aacaggctac caacttgtat ccaggcctgg gaatggatta ggttcagca
1801 gagctgaaag ctggcgcag agtctggag ctggcttat aaggcgcct tgagtgcatt
5 1861 agagatttg attggttcag ggaactctgg cattccttt cccaactctt catgtcttct
1921 cacaagccag ccaactctt ctctctggc ttccggctat gcaagagcgt tgctcacctt
1981 cttctttgt atttccttc ttgtttccc cctctttctt tttaaaaat ggaaaaataa
2041 acactacaga atgag (SEQ ID NO:6)

The amino acid sequence of human hCdc25C is

10 MSTELFSSTREEGSSSGGPSFRSNQRKMLNLLERDTSFTVCPD
VPRTPVGKFLGDSANLSILSGGTPKCCLDLNLSSGEITATQLTSAADLDETGHLDSS
LQEVLHAGMNHDQHLMKCSPAQLLCSTPNGLDRGHRKRDAMCSSSANKENDNGNLVD
SEMKYLGSPITTVPKLDKNPQLGEDQAEEISDELMEFSLKDQEAKVSRSGLYRSPSMP
ENLNRPRLKQVEKFKDNTIPDKVKKKYFSGQQGKLRKGGLCLKTVSLCDITITQMLED
15 SNQGHLIGDFSKVCALPTVSGKHQDLKYVNPEVVAALLSGKFQGLIEKFYIDCRYPY
EYLGGHIQGALNLYSQEELNFFLKKPIVPLDTQKRIVFHCEFSSERGPRMCRCLR
EEDRSLNQYPALYYPELYILKGGYRDFFPEYMECEPQSYPYCPMHQDHKTELLRCRSQ
SKVQEGERQLREQIALLVKDMSP (SEQ ID NO:1)

See also, e.g., GenBank Accession Nos. NP_001781 (protein) and NM

20 001790 (nucleic acid, cDNA) and Sadhu (1990) Proc. Natl. Acad. Sci. U.S.A. 87:5139-5143.

Peptides and Polypeptides

The peptides and polypeptides of the invention can be administered to treat cell proliferative disorders, including, e.g., to stop the growth of, or kill, cancer cells. The peptides and polypeptides of the invention can be used to inhibit (e.g., delay) or abrogate G2 cell cycle arrest checkpoint in cells. The peptides and polypeptides of the invention can also be used to inhibit Chk1 and/or Chk2/Cds1 kinase activity.

While the peptides and polypeptides of the invention can be expressed recombinantly *in vivo* after administration of nucleic acids, as described above, they can also be administered directly, e.g., as a pharmaceutical composition.

30 Polypeptides and peptides of the invention can be isolated from natural sources, be synthetic, or be recombinantly generated polypeptides. Peptides and proteins can be recombinantly expressed *in vitro* or *in vivo*. The peptides and polypeptides of the invention can be made and isolated using any method known in the art. Polypeptide and

peptides of the invention can also be synthesized, whole or in part, using chemical methods well known in the art. See e.g., Caruthers (1980) Nucleic Acids Res. Symp. Ser. 215-223; Horn (1980) Nucleic Acids Res. Symp. Ser. 225-232; Banga, A.K., Therapeutic Peptides and Proteins, Formulation, Processing and Delivery Systems (1995) Technomic Publishing Co., Lancaster, PA. For example, peptide synthesis can be performed using various solid-phase techniques (see e.g., Roberge (1995) Science 269:202; Merrifield (1997) Methods Enzymol. 289:3-13) and automated synthesis may be achieved, e.g., using the ABI 431A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer.

The peptides and polypeptides of the invention, as defined above, include all "mimetic" and "peptidomimetic" forms. The terms "mimetic" and "peptidomimetic" refer to a synthetic chemical compound which has substantially the same structural and/or functional characteristics of the polypeptides of the invention. The mimetic can be either entirely composed of synthetic, non-natural analogues of amino acids, or, is a chimeric molecule of partly natural peptide amino acids and partly non-natural analogs of amino acids. The mimetic can also incorporate any amount of natural amino acid conservative substitutions as long as such substitutions also do not substantially alter the mimetic's structure and/or activity. As with polypeptides of the invention which are conservative variants, routine experimentation will determine whether a mimetic is within the scope of the invention, i.e., that its structure and/or function is not substantially altered. Thus, a mimetic composition is within the scope of the invention if, when administered to or expressed in a cell, it disrupts the G2 cell cycle arrest checkpoint. A mimetic composition can also be within the scope of the invention if it can inhibit Chk1 and/or Chk2/Cds1 kinase activity, or, bind to the active site of either of these enzymes.

Polypeptide mimetic compositions can contain any combination of non-natural structural components, which are typically from three structural groups: a) residue linkage groups other than the natural amide bond ("peptide bond") linkages; b) non-natural residues in place of naturally occurring amino acid residues; or c) residues which induce secondary structural mimicry, i.e., to induce or stabilize a secondary structure, e.g., a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like. For example, a polypeptide can be characterized as a mimetic when all or some of its residues are joined by chemical means other than natural peptide bonds. Individual peptidomimetic residues can be

joined by peptide bonds, other chemical bonds or coupling means, such as, e.g., glutaraldehyde, N-hydroxysuccinimide esters, bifunctional maleimides, N,N'-dicyclohexylcarbodiimide (DCC) or N,N'-diisopropylcarbodiimide (DIC). Linking groups that can be an alternative to the traditional amide bond ("peptide bond") linkages include, 5 e.g., ketomethylene (e.g., -C(=O)-CH₂- for -C(=O)-NH-), aminomethylene (CH₂-NH), ethylene, olefin (CH=CH), ether (CH₂-O), thioether (CH₂-S), tetrazole (CN₄-), thiazole, retroamide, thioamide, or ester (see, e.g., Spatola (1983) in Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Vol. 7, pp 267-357, "Peptide Backbone Modifications," Marcell Dekker, NY).

10 A polypeptide can also be characterized as a mimetic by containing all or some non-natural residues in place of naturally occurring amino acid residues. Non-natural residues are well described in the scientific and patent literature; a few exemplary non-natural compositions useful as mimetics of natural amino acid residues and guidelines are described below. Mimetics of aromatic amino acids can be generated by replacing by, e.g., 15 D- or L- naphylalanine; D- or L- phenylglycine; D- or L-2 thieneylalanine; D- or L-1, -2, 3-, or 4- pyreneylalanine; D- or L-3 thieneylalanine; D- or L-(2-pyridinyl)-alanine; D- or L-(3-pyridinyl)-alanine; D- or L-(2-pyrazinyl)-alanine; D- or L-(4-isopropyl)-phenylglycine; D- (trifluoromethyl)-phenylglycine; D-(trifluoromethyl)-phenylalanine; D-p-fluoro-phenylalanine; D- or L-p-biphenylphenylalanine; K- or L-p-methoxy-biphenylphenylalanine; 20 D- or L-2-indole(alkyl)alanines; and, D- or L-alkylainines, where alkyl can be substituted or unsubstituted methyl, ethyl, propyl, hexyl, butyl, pentyl, isopropyl, iso-butyl, sec-isotyl, iso-pentyl, or a non-acidic amino acids. Aromatic rings of a non-natural amino acid include, e.g., thiazolyl, thiophenyl, pyrazolyl, benzimidazolyl, naphthyl, furanyl, pyrrolyl, and pyridyl aromatic rings.

25 Mimetics of acidic amino acids can be generated by substitution by, e.g., non-carboxylate amino acids while maintaining a negative charge; (phosphono)alanine; sulfated threonine. Carboxyl side groups (e.g., aspartyl or glutamyl) can also be selectively modified by reaction with carbodiimides (R'-N-C-N-R') such as, e.g., 1-cyclohexyl-3(2-morpholinyl-(4-ethyl) carbodiimide or 1-ethyl-3(4-azonia- 4,4- dimethylpentyl) carbodiimide. Aspartyl or 30 glutamyl can also be converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.

Mimetics of basic amino acids can be generated by substitution with, e.g., (in addition to lysine and arginine) the amino acids ornithine, citrulline, or (guanidino)-acetic acid, or (guanidino)alkyl-acetic acid, where alkyl is defined above. Nitrile derivative (e.g., containing the CN-moiety in place of COOH) can be substituted for asparagine or glutamine.

5 Asparaginyl and glutaminyl residues can be deaminated to the corresponding aspartyl or glutamyl residues.

Arginine residue mimetics can be generated by reacting arginyl with, e.g., one or more conventional reagents, including, e.g., phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, or ninhydrin, preferably under alkaline conditions. Tyrosine residue mimetics can be generated by reacting tyrosyl with, e.g., aromatic diazonium compounds or tetranitromethane. N-acetylimidizol and tetranitromethane can be used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively. Cysteine residue mimetics can be generated by reacting cysteinyl residues with, e.g., alpha-haloacetates such as 2-chloroacetic acid or chloroacetamide and corresponding amines; to give carboxymethyl or carboxyamidomethyl derivatives. Cysteine residue mimetics can also be generated by reacting cysteinyl residues with, e.g., bromo-trifluoroacetone, alpha-bromo-beta-(5-imidozoyl) propionic acid; chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide; methyl 2-pyridyl disulfide; p-chloromercuribenzoate; 2-chloromercuri-4-nitrophenol; or, chloro-7-nitrobenzo-oxa-1,3-diazole. Lysine mimetics can be generated (and amino terminal residues can be altered) by reacting lysinyl with, e.g., succinic or other carboxylic acid anhydrides. Lysine and other alpha-amino-containing residue mimetics can also be generated by reaction with imidoesters, such as methyl picolinimidate, pyridoxal phosphate, pyridoxal, chloroborohydride, trinitrobenzenesulfonic acid, O-methylisourea, 2,4-pentanedione, and transamidase-catalyzed reactions with glyoxylate. Mimetics of methionine can be generated by reaction with, e.g., methionine sulfoxide. Mimetics of proline include, e.g., pipecolic acid, thiazolidine carboxylic acid, 3- or 4- hydroxy proline, dehydroproline, 3- or 4-methylproline, or 3,3,-dimethylproline. Histidine residue mimetics can be generated by reacting histidyl with, e.g., diethylprocarbonate or para-bromophenacyl bromide. Other mimetics include, e.g., those generated by hydroxylation of proline and lysine; phosphorylation of the hydroxyl groups of seryl or threonyl residues; methylation of the alpha-amino groups of lysine, arginine and histidine; acetylation of the N-terminal amine;

methylation of main chain amide residues or substitution with N-methyl amino acids; or amidation of C-terminal carboxyl groups.

A component of a polypeptide of the invention can also be replaced by an amino acid (or peptidomimetic residue) of the opposite chirality. Thus, any amino acid naturally occurring in the L-configuration (which can also be referred to as the R or S, depending upon the structure of the chemical entity) can be replaced with the amino acid of the same chemical structural type or a peptidomimetic, but of the opposite chirality, referred to as the D- amino acid, but which can additionally be referred to as the R- or S- form.

The skilled artisan will recognize that individual synthetic residues and polypeptides incorporating these mimetics can be synthesized using a variety of procedures and methodologies, which are well described in the scientific and patent literature, *e.g.*, Organic Syntheses Collective Volumes, Gilman, et al. (Eds) John Wiley & Sons, Inc., NY. Peptides and peptide mimetics of the invention can also be synthesized using combinatorial methodologies. Various techniques for generation of peptide and peptidomimetic libraries are well known, and include, *e.g.*, multipin, tea bag, and split-couple-mix techniques; see, *e.g.*, al-Obeidi (1998) Mol. Biotechnol. 9:205-223; Hruby (1997) Curr. Opin. Chem. Biol. 1:114-119; Ostergaard (1997) Mol. Divers. 3:17-27; Ostresh (1996) Methods Enzymol. 267:220-234. Modified peptides of the invention can be further produced by chemical modification methods, see, *e.g.*, Belousov (1997) Nucleic Acids Res. 25:3440-3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; Blommers (1994) Biochemistry 33:7886-7896.

Peptides and polypeptides of the invention can also be synthesized and expressed as fusion proteins with one or more additional domains linked thereto for, *e.g.*, producing a more immunogenic peptide, to more readily isolate a recombinantly synthesized peptide, to identify and isolate antibodies and antibody-expressing B cells, and the like.

Detection and purification facilitating domains include, *e.g.*, metal chelating peptides such as polyhistidine tracts and histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA). The inclusion of a cleavable linker sequences such as Factor Xa or enterokinase (Invitrogen, San Diego CA) between a purification domain and the motif-comprising peptide or polypeptide to facilitate purification. For example, an expression vector can include an

epitope-encoding nucleic acid sequence linked to six histidine residues followed by a thioredoxin and an enterokinase cleavage site (see e.g., Williams (1995) Biochemistry 34:1787-1797; Dobeli (1998) Protein Expr. Purif. 12:404-14). The histidine residues facilitate detection and purification while the enterokinase cleavage site provides a means for purifying the epitope from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described in the scientific and patent literature, see e.g., Kroll (1993) DNA Cell. Biol., 12:441-53.

The invention provides methods for inhibiting the activity of a Chk1 kinase or a Chk2 kinase. The invention also provides methods for screening for compositions that inhibit the activity of, or bind to (e.g., bind to the active site), Chk1 kinase and/or a Chk2 kinase. The amino acid sequence of human Chk1 kinase is

MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVALKIVDMKR
AVDCPENIKKEICINKMLNHENVVKFYGHRREGNIQYLFLEYCSGGELFDRIEPDGM
PEPDAQRFFHQLMAGVVYLHGIGITHRDIKPENLLLDERDNLKISDFGLATVFRYNNR
ERLLNKMCGTLPYVAPELLKRREFHAEPVDWSCGIVLTAMLAGELPWDQPSDSCQEY
SDWKEKKTYLNPWKKIDSAPALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRP
RVTSGGVSESPSGFSKHIQSNLDFSPVNSASSEENVYSSSQPEPRTGLSLWDTSPSY
IDKLVQGISFSQPTCPDHMLLNSQLLGTGSSQNPWQRLVKRMTRFFTAKLADKSYQC
LKETCEKLGYQWKKSCMNQVTISTTDRRNNKLIFKVNLLEMDDKILVDFRLSKGDGLE
FKRHFLKIKGKLIDIVSSQKVWLPA (SEQ ID NO:3)

See also, Sanchez (1997) Science 277:1497-1501; Genbank Accession Nos. AF 016582; AAC 51736; NP 001265, NM 001274.

The amino acid sequence of human Chk2 kinase is

MSRESDVAAQQSHGSSACSPHGSVTQSQGSSSQGISSSTS
MPNSSQSSHSSGTLSLETVSTQELYSIPEDQEPEPEDQEPPEEPTPAPWARLWALQDG
FANLECVNDNYWFGRDKSCEYCFDEPLLKRTDKYRTYSKKHFRIFREVGPKN SYIAYI
EDHSGNGTFVNTELVGKGKRRPLNNNSEIALSLSRNKVFVFFDLTVDDQSVYPKALRD
EYIMSKTLGSGACGEVKLAERKTCVVKAIIISKRKFAIGSAREADPALNVETEIEI
LKKLNHPCIKKNFFDAEDYYIVLELMEGGELFDKVVGNKRLKEATCKLYFYQMLLA
VQYLHENGIIRDLKPENVLLSSQEEDCLIKITDFGHSKILGETSLMRTLCGPTYLA
PEVLVSGTAGYNRAVDCWSLGVLFICLSGYPPFSEHRTQVSLKDQITSGKYNFIPE
VWAEVSEKALDLVKKLLVVDPKARFTTEEARHPWLQDEDMKRKFQDLLSEENESTAL
PQVLAQPSTS RKRPREGEAEGAETTKRP AVCAAVL (SEQ ID NO:4)

See also Brown (1999) Proc. Natl. Acad. Sci. USA 96:3745-3750; Chaturvedi (1999) Oncogene 18:4047-4054; Genbank Accession Nos. NP 009125; NM 007194.

Antibody Generation

The invention provides antibodies that specifically bind to the peptides and polypeptides of the invention. These antibodies can be used to identify the presence of these peptides and polypeptides. The peptides and polypeptides of the invention can be used as immunogens to generate antibodies specific for a corresponding Cdc25C phosphatase. The anti-peptide antibodies of the invention can be used to generate anti-idiotype antibodies that specifically bind to active sites of Chk1 or Chk2 kinase.

Methods of producing polyclonal and monoclonal antibodies are known to those of skill in the art and described in the scientific and patent literature, see, e.g., Coligan, CURRENT PROTOCOLS IN IMMUNOLOGY, Wiley/Greene, NY (1991); Stites (eds.) BASIC AND CLINICAL IMMUNOLOGY (7th ed.) Lange Medical Publications, Los Altos, CA ("Stites"); Goding, MONOCLOINAL ANTIBODIES: PRINCIPLES AND PRACTICE (2d ed.) Academic Press, New York, NY (1986); Kohler (1975) Nature 256:495; Harlow (1988) ANTIBODIES, A LABORATORY MANUAL, Cold Spring Harbor Publications, New York. Antibodies can be generated *in vitro*, e.g., using recombinant antibody binding site expressing phage display libraries, in addition to the traditional *in vivo* methods using animals. See, e.g., Huse (1989) Science 246:1275; Ward (1989) Nature 341:544; Hoogenboom (1997) Trends Biotechnol. 15:62-70; Katz (1997) Annu. Rev. Biophys. Biomol. Struct. 26:27-45. Human antibodies can be generated in mice engineered to produce only human antibodies, as described by, e.g., U.S. Patent No. 5,877,397; 5,874,299; 5,789,650; and 5,939,598. B-cells from these mice can be immortalized using standard techniques (e.g., by fusing with an immortalizing cell line such as a myeloma or by manipulating such B-cells by other techniques to perpetuate a cell line) to produce a monoclonal human antibody-producing cell. See, e.g., U.S. Patent No. 5,916,771; 5,985,615. For making chimeric, e.g., "humanized," antibodies, see e.g., U.S. Patent Nos. 5,811,522; 5,789,554; 5,861,155. Alternatively, recombinant antibodies can also be expressed by transient or stable expression vectors in mammalian, including human, cells as in Norderhaug (1997) J. Immunol. Methods 204:77-87; Boder (1997) Nat. Biotechnol. 15:553-557; see also U.S. Patent No. 5,976,833

Screening for candidate compounds

The invention provides compositions and methods for screening for potential therapeutic compounds (“candidate compounds”) to inhibit or abrogate Chk1 and/or Chk2/Cds1 kinase activity and/or the G2 cell cycle arrest checkpoint. For example, the screening can involve *in vitro* or *in vivo* assays wherein Chk1 and Chk2/Cds1 kinases phosphorylate peptides and polypeptides comprising the motifs of the invention; see Example 1, below. Inhibitors of peptide phosphorylation are candidate compounds. Alternatively, assays incorporating the experiments, or variations thereof, as set forth in Example 1, below, can be designed to assay for candidate compounds which can inhibit or abrogate Chk1 and/or Chk2/Cds1 kinase activity and/or the G2 cell cycle arrest checkpoint.

In one embodiment, the peptides and polypeptides of the invention can be bound to a solid support. Solid supports can include, e.g., membranes (e.g., nitrocellulose or nylon), a microtiter dish (e.g., PVC, polypropylene, or polystyrene), a test tube (glass or plastic), a dip stick (e.g., glass, PVC, polypropylene, polystyrene, latex and the like), a microfuge tube, or a glass, silica, plastic, metallic or polymer bead or other substrate such as paper. One solid support uses a metal (e.g., cobalt or nickel)-comprising column which binds with specificity to a histidine tag engineered onto a peptide.

Adhesion of peptides to a solid support can be direct (i.e. the protein contacts the solid support) or indirect (a particular compound or compounds are bound to the support and the target protein binds to this compound rather than the solid support). Peptides can be immobilized either covalently (e.g., utilizing single reactive thiol groups of cysteine residues (see, e.g., Colliuod (1993) Bioconjugate Chem. 4:528-536) or non-covalently but specifically (e.g., via immobilized antibodies (see, e.g., Schuhmann (1991) Adv. Mater. 3:388-391; Lu (1995) Anal. Chem. 67:83-87; the biotin/strepavidin system (see, e.g., Iwane (1997) Biophys. Biochem. Res. Comm. 230:76-80); metal chelating, e.g., Langmuir-Blodgett films (see, e.g., Ng (1995) Langmuir 11:4048-55); metal-chelating self-assembled monolayers (see, e.g., Sigal (1996) Anal. Chem. 68:490-497) for binding of polyhistidine fusions.

Indirect binding can be achieved using a variety of linkers which are commercially available. The reactive ends can be any of a variety of functionalities including, but not limited to: amino reacting ends such as N-hydroxysuccinimide (NHS) active esters, imidoesters, aldehydes, epoxides, sulfonyl halides, isocyanate, isothiocyanate,

and nitroaryl halides; and thiol reacting ends such as pyridyl disulfides, maleimides, thiophthalimides, and active halogens. The heterobifunctional crosslinking reagents have two different reactive ends, e.g., an amino-reactive end and a thiol-reactive end, while homobifunctional reagents have two similar reactive ends, e.g., bismaleimidohexane (BMH) which permits the cross-linking of sulfhydryl-containing compounds. The spacer can be of varying length and be aliphatic or aromatic. Examples of commercially available homobifunctional cross-linking reagents include, but are not limited to, the imidoesters such as dimethyl adipimidate dihydrochloride (DMA); dimethyl pimelimidate dihydrochloride (DMP); and dimethyl suberimidate dihydrochloride (DMS). Heterobifunctional reagents include commercially available active halogen-NHS active esters coupling agents such as N-succinimidyl bromoacetate and N-succinimidyl (4-iodoacetyl)aminobenzoate (SIAB) and the sulfosuccinimidyl derivatives such as sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB) (Pierce). Another group of coupling agents is the heterobifunctional and thiol cleavable agents such as N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP) (Pierce Chemicals, Rockford, IL).

Antibodies can be used for binding polypeptides and peptides of the invention to a solid support. This can be done directly by binding peptide-specific antibodies to the column or it can be done by creating fusion protein chimeras comprising motif-containing peptides linked to, e.g., a known epitope (e.g., a tag (e.g., FLAG, myc) or an appropriate immunoglobulin constant domain sequence (an “immunoadhesin,” see, e.g., Capon (1989) Nature 377:525-531 (1989).

There are a variety of assay formats that can be used to screen for “candidate compounds” to inhibit or abrogate Chk1 and/or Chk2/Cds1 kinase activity and/or the G2 cell cycle arrest checkpoint.. For example, as discussed above, compounds that inhibit the phosphorylation of the motif-comprising peptides of the invention can be candidate compounds. Alternatively, compounds that specifically bind to the motifs of the invention can be candidate compounds. For a general description of different formats for binding assays, see, e.g., BASIC AND CLINICAL IMMUNOLOGY, 7th Ed. (D. Stiles and A. Terr, ed.)(1991); ENZYME IMMUNOASSAY, E.T. Maggio, ed., CRC Press, Boca Raton, Florida (1980); and “Practice and Theory of Enzyme Immunoassays” in P. Tijssen, LABORATORY

TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, Elsevier Science Publishers, B.V. Amsterdam (1985).

Combinatorial chemical libraries

Combinatorial chemical libraries are one means to assist in the generation of new chemical compound leads, i.e., compounds that inhibit Chk1 and/or Chk2/Cds1 kinase and/or inhibit or abrogate the G2 cell cycle arrest checkpoint. A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library such as a polypeptide library is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (i.e., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks. For example, the systematic, combinatorial mixing of 100 interchangeable chemical building blocks results in the theoretical synthesis of 100 million tetrameric compounds or 10 billion pentameric compounds (see, e.g., Gallop et al. (1994) 37(9): 1233-1250). Preparation and screening of combinatorial chemical libraries are well known to those of skill in the art, see, e.g., U.S. Patent No. 6,004,617; 5,985,356. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent No. 5,010,175; Furka (1991) Int. J. Pept. Prot. Res., 37: 487-493, Houghton et al. (1991) Nature, 354: 84-88). Other chemistries for generating chemical diversity libraries include, but are not limited to: peptoids (see, e.g., WO 91/19735), encoded peptides (see, e.g., WO 93/20242), random bio-oligomers (see, e.g., WO 92/00091), benzodiazepines (see, e.g., U.S. Patent No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (see, e.g., Hobbs (1993) Proc. Nat. Acad. Sci. USA 90: 6909-6913), vinylogous polypeptides (see, e.g., Hagihara (1992) J. Amer. Chem. Soc. 114: 6568), non-peptidal peptidomimetics with a Beta- D- Glucose scaffolding (see, e.g., Hirschmann (1992) J. Amer. Chem. Soc. 114: 9217-9218), analogous organic syntheses of small compound libraries (see, e.g., Chen (1994) J. Amer. Chem. Soc. 116: 2661), oligocarbamates (see, e.g., Cho (1993) Science 261:1303), and/or peptidyl phosphonates (see, e.g., Campbell (1994) J. Org. Chem. 59: 658). See also Gordon (1994) J. Med. Chem. 37:1385; for nucleic acid libraries, peptide nucleic acid libraries, see, e.g., U.S. Patent No. 5,539,083; for antibody libraries, see, e.g.,

Vaughn (1996) Nature Biotechnology 14:309-314; for carbohydrate libraries, see, e.g., Liang et al. (1996) Science 274: 1520-1522, U.S. Patent No. 5,593,853; for small organic molecule libraries, see, e.g., for isoprenoids U.S. Patent 5,569,588; for thiazolidinones and metathiazanones, U.S. Patent No. 5,549,974; for pyrrolidines, U.S. Patent Nos. 5,525,735 and 5,519,134; for morpholino compounds, U.S. Patent No. 5,506,337; for benzodiazepines U.S. Patent No. 5,288,514.

Devices for the preparation of combinatorial libraries are commercially available (see, e.g., U.S. Patent No. 6,045,755; 5,792,431 ; 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Woburn, MA, 433A Applied Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA). A number of robotic systems have also been developed for solution phase chemistries. These systems include automated workstations, e.g., like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, Mass.; Orca, Hewlett-Packard, Palo Alto, Calif.) which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art. In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J., Asinex, Moscow, Ru, Tripos, Inc., St. Louis, MO, ChemStar, Ltd, Moscow, RU, 3D Pharmaceuticals, Exton, PA, Martek Biosciences, Columbia, MD, etc.).

Formulation and Administration of Pharmaceutical Compositions

In one embodiment, the peptides and polypeptides of the invention are combined with a pharmaceutically acceptable carrier (excipient) to form a pharmacological composition. Pharmaceutically acceptable carriers can contain a physiologically acceptable compound that acts to, e.g., stabilize, or increase or decrease the absorption or clearance rates of the pharmaceutical compositions of the invention. Physiologically acceptable compounds can include, e.g., carbohydrates, such as glucose, sucrose, or dextrans, antioxidants, such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins, compositions that reduce the clearance or hydrolysis of the peptides or polypeptides, or excipients or other stabilizers and/or buffers. Detergents can also be used to stabilize or to increase or decrease the absorption of the pharmaceutical composition, including liposomal carriers. Pharmaceutically acceptable carriers and formulations for peptides and polypeptide are known to the skilled artisan and are described in detail in the scientific and patent literature, see e.g., the latest edition of Remington's Pharmaceutical Science, Mack Publishing Company, Easton, Pennsylvania ("Remington's").

Other physiologically acceptable compounds include wetting agents, emulsifying agents, dispersing agents or preservatives which are particularly useful for preventing the growth or action of microorganisms. Various preservatives are well known and include, e.g., phenol and ascorbic acid. One skilled in the art would appreciate that the choice of a pharmaceutically acceptable carrier including a physiologically acceptable compound depends, for example, on the route of administration of the peptide or polypeptide of the invention and on its particular physio-chemical characteristics.

In one embodiment, a solution of peptide or polypeptide of the invention is dissolved in a pharmaceutically acceptable carrier, e.g., an aqueous carrier if the composition is water-soluble. Examples of aqueous solutions that can be used in formulations for enteral, parenteral or transmucosal drug delivery include, e.g., water, saline, phosphate buffered saline, Hank's solution, Ringer's solution, dextrose/saline, glucose solutions and the like. The formulations can contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as buffering agents, tonicity adjusting agents, wetting agents, detergents and the like. Additives can also include additional active ingredients such as bactericidal agents, or stabilizers. For example, the solution can contain

sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate or triethanolamine oleate. These compositions can be sterilized by conventional, well-known sterilization techniques, or can be sterile filtered. The resulting aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration. The concentration of peptide in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs.

Solid formulations can be used for enteral (oral) administration. They can be formulated as, e.g., pills, tablets, powders or capsules. For solid compositions, conventional nontoxic solid carriers can be used which include, e.g., pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10% to 95% of active ingredient (e.g., peptide). A non-solid formulation can also be used for enteral administration. The carrier can be selected from various oils including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, and the like. Suitable pharmaceutical excipients include e.g., starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol.

Peptides and polypeptides of the invention, when administered orally, can be protected from digestion. This can be accomplished either by complexing the peptide or polypeptide with a composition to render it resistant to acidic and enzymatic hydrolysis or by packaging the peptide or complex in an appropriately resistant carrier such as a liposome. Means of protecting compounds from digestion are well known in the art, see, e.g., Fix (1996) Pharm Res. 13:1760-1764; Samanen (1996) J. Pharm. Pharmacol. 48:119-135; U.S. Patent 5,391,377, describing lipid compositions for oral delivery of therapeutic agents (liposomal delivery is discussed in further detail, infra).

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be

permeated can be used in the formulation. Such penetrants are generally known in the art, and include, e.g., for transmucosal administration, bile salts and fusidic acid derivatives. In addition, detergents can be used to facilitate permeation. Transmucosal administration can be through nasal sprays or using suppositories. See, e.g., Sayani (1996) "Systemic delivery of peptides and proteins across absorptive mucosae" Crit. Rev. Ther. Drug Carrier Syst. 13:85-184. For topical, transdermal administration, the agents are formulated into ointments, creams, salves, powders and gels. Transdermal delivery systems can also include, e.g., patches.

The peptides and polypeptide complexes can also be administered in sustained delivery or sustained release mechanisms, which can deliver the formulation internally. For example, biodegradeable microspheres or capsules or other biodegradeable polymer configurations capable of sustained delivery of a peptide can be included in the formulations of the invention (see, e.g., Putney (1998) Nat. Biotechnol. 16:153-157).

For inhalation, the peptide or polypeptide can be delivered using any system known in the art, including dry powder aerosols, liquids delivery systems, air jet nebulizers, propellant systems, and the like. See, e.g., Patton (1998) Biotechniques 16:141-143; product and inhalation delivery systems for polypeptide macromolecules by, e.g., Dura Pharmaceuticals (San Diego, CA), Aradigm (Hayward, CA), Aerogen (Santa Clara, CA), Inhale Therapeutic Systems (San Carlos, CA), and the like. For example, the pharmaceutical formulation can be administered in the form of an aerosol or mist. For aerosol administration, the formulation can be supplied in finely divided form along with a surfactant and propellant. In another embodiment, the device for delivering the formulation to respiratory tissue is an inhaler in which the formulation vaporizes. Other liquid delivery systems include, e.g., air jet nebulizers.

In preparing pharmaceuticals of the present invention, a variety of formulation modifications can be used and manipulated to alter pharmacokinetics and biodistribution. A number of methods for altering pharmacokinetics and biodistribution are known to one of ordinary skill in the art. Examples of such methods include protection of the complexes in vesicles composed of substances such as proteins, lipids (for example, liposomes, see below), carbohydrates, or synthetic polymers (discussed above). For a general discussion of pharmacokinetics, see, e.g., Remington's, Chapters 37-39.

The peptide and polypeptide complexes used in the methods of the invention can be delivered alone or as pharmaceutical compositions by any means known in the art, e.g., systemically, regionally, or locally (e.g., directly into, or directed to, a tumor); by intraarterial, intrathecal (IT), intravenous (IV), parenteral, intra-pleural cavity, topical, oral, or local administration, as subcutaneous, intra-tracheal (e.g., by aerosol) or transmucosal (e.g., buccal, bladder, vaginal, uterine, rectal, nasal mucosa). Actual methods for preparing administrable compositions will be known or apparent to those skilled in the art and are described in detail in the scientific and patent literature, see e.g., Remington's. For a "regional effect," e.g., to focus on a specific organ, one mode of administration includes intra-arterial or intrathecal (IT) injections, e.g., to focus on a specific organ, e.g., brain and CNS (see e.g., Gurun (1997) Anesth Analg. 85:317-323). For example, intra-carotid artery injection if preferred where it is desired to deliver a peptide or polypeptide complex of the invention directly to the brain. Parenteral administration is a preferred route of delivery if a high systemic dosage is needed. Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in detail, in e.g., Remington's,. See also, Bai (1997) J. Neuroimmunol. 80:65-75; Warren (1997) J. Neurol. Sci. 152:31-38; Tonegawa (1997) J. Exp. Med. 186:507-515.

In one embodiment, the pharmaceutical formulations comprising peptides or polypeptides of the invention are incorporated in lipid monolayers or bilayers, e.g., liposomes, see, e.g., U.S. Patent No. 6,110,490; 6,096,716; 5,283,185; 5,279,833. The invention also provides formulations in which water soluble peptides or complexes have been attached to the surface of the monolayer or bilayer. For example, peptides can be attached to hydrazide- PEG- (distearoylphosphatidyl) ethanolamine- containing liposomes (see, e.g., Zalipsky (1995) Bioconjug. Chem. 6:705-708). Liposomes or any form of lipid membrane, such as planar lipid membranes or the cell membrane of an intact cell, e.g., a red blood cell, can be used. Liposomal formulations can be by any means, including administration intravenously, transdermally (see, e.g., Vutla (1996) J. Pharm. Sci. 85:5-8), transmucosally, or orally. The invention also provides pharmaceutical preparations in which the peptides and/or complexes of the invention are incorporated within micelles and/or liposomes (see, e.g., Suntres (1994) J. Pharm. Pharmacol. 46:23-28; Woodle (1992) Pharm. Res. 9:260-265). Liposomes and liposomal formulations can be prepared according to standard methods and

are also well known in the art, see, e.g., Remington's; Akimaru (1995) Cytokines Mol. Ther. 1:197-210; Alving (1995) Immunol. Rev. 145:5-31; Szoka (1980) Ann. Rev. Biophys. Bioeng. 9:467, U.S. Pat. Nos. 4, 235,871, 4,501,728 and 4,837,028.

Treatment Regimens: Pharmacokinetics

5 The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. Dosages for typical peptide and polypeptide pharmaceutical compositions are well known to those of skill in the art. Such dosages are typically advisory in nature and are adjusted depending on the particular therapeutic context, patient tolerance, etc. The amount of peptide or polypeptide adequate to
10 accomplish this is defined as a "therapeutically effective dose." The dosage schedule and amounts effective for this use, i.e., the "dosing regimen," will depend upon a variety of factors, including the stage of the disease or condition, the severity of the disease or condition, the general state of the patient's health, the patient's physical status, age, pharmaceutical formulation and concentration of active agent, and the like. In calculating the
15 dosage regimen for a patient, the mode of administration also is taken into consideration. The dosage regimen must also take into consideration the pharmacokinetics, i.e., the pharmaceutical composition's rate of absorption, bioavailability, metabolism, clearance, and the like. See, e.g., the latest Remington's; Egleton (1997) "Bioavailability and transport of peptides and peptide drugs into the brain" Peptides 18:1431-1439; Langer (1990) Science
20 249:1527-1533.

In therapeutic applications, compositions are administered to a patient suffering from a cancer in an amount sufficient to at least partially arrest the disease and/or its complications. For example, in one embodiment, a soluble peptide pharmaceutical composition dosage for intravenous (IV) administration would be about 0.01 mg/hr to about
25 1.0 mg/hr administered over several hours (typically 1, 3, or 6 hours), which can be repeated for weeks with intermittent cycles. Considerably higher dosages (e.g., ranging up to about 10 mg/ml) can be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ, e.g., the cerebrospinal fluid (CSF).

EXAMPLES

The following examples are offered to illustrate, but not to limit the claimed invention.

Example 1: Administration of peptides of the invention to selectively sensitize cancer cells to DNA damaging agents

The invention provides compositions and methods for sensitizing cells, particularly cells with an impaired G1 cell cycle arrest checkpoint, such as cancer cells, to DNA damaging agents. The following example describes studies which demonstrate that the compositions and methods of the invention are effective for selectively killing cancer cells (versus normal cells, which have an unimpaired G1 checkpoint). Specifically, these experiments describes the synthesis and use of two exemplary polypeptides of the invention. Two peptides corresponding to amino acids 211 to 221 of human Cdc25C (SEQ ID NO:1) fused with a part of HIV-1-TAT (SEQ ID NO:5). These peptides were demonstrated to inhibit hChk1 kinase (SEQ ID NO:3) and Chk2/HuCds1 (SEQ ID NO:4) kinase activity *in vitro* and to specifically abrogate the G2 checkpoint *in vivo*.

Chemicals and reagents. Bleomycin and colchicine were purchased from Wako Pure Chemical Co. (Osaka, Japan). Hydroxyurea was purchased from Sigma Chemical Co. (St. Louis, MO). These chemicals were dissolved in distilled H₂O to 10, 5 and 50 mg/ml, respectively, and stored at 4°C. Antibodies against 14-3-3β were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and anti-rabbit IgG horseradish peroxidase-conjugated secondary antibodies were purchased from Amersham Life Sciences (Arlington Heights, IL). Antibodies against HA and c-myc, and protein G-Sepharose were purchased from Santa Cruz Biotechnology and Amersham Pharmacia Biotech (Uppsala, Sweden), respectively.

Cell culture and plasmids. A human T-cell leukemia-derived cell line, Jurkat, was cultured in RPMI 1640 (Sigma) supplemented with 10% fetal calf serum (IBL: Immuno-Biological Laboratories, Gunma, Japan) at 37°C/5% CO₂. Human pancreatic epitheloid carcinoma-derived cell lines, MIA PaCa2 and PANC1, were cultured in Eagle's MEM (IWAKI, Chiba, Japan) and Dulbecco's modified Eagle's medium with 4 mM l-glucose (Sigma) and 1.0 mM sodium pyruvate (Life Technologies, Inc., Grand Island, NY), respectively, and supplemented with 10% fetal calf serum at 37°C/5% CO₂. Normal human

5 peripheral blood lymphocytes were collected by Ficoll-Paque (Amersham Pharmacia Biotech) density gradient. Two million cells/ml were cultured in RPMI 1640 supplemented with 10% fetal calf serum at 37°C/5% CO₂ in the presence of 5 µg/ml PHA (Life Technologies, Inc.) for a week. Baculovirus lysates that include HA-tagged hChk1 (SEQ ID NO:3) or c-myc-tagged Chk2/HuCds1 (SEQ ID NO:4) and plasmid for GST-Cdc25C (amino acid 200-256) were made as described in Matsuoka (1998) Science 282:1893-1897, and provided by Dr. Makoto Nakanishi (Department of Biochemistry, Nagoya City University).

10 *Peptides.* TAT-S216 peptide was synthesized so that it contained an NH₂-terminal 11 amino acid TAT protein transduction domain (YGRKKRRQRRR (SEQ ID NO:5); see, e.g., Nagahara (1998) Nature Med. 4:1449-1452) followed by a corresponding amino acid 211 to 221 derived from the human Cdc25C amino acid sequence (SEQ ID NO:1) (S216; LYRSPASMPENL). Serine-216 residue was changed to alanine in TAT-S216A (S216A; LYRSPSMPENL) (SEQ ID NO:6). The Cdc25C portion was partially deleted and substituted with glycine in TAT-Control (GGRSPAMPE) (SEQ ID NO:7). All 15 peptides were synthesized by Sawady Technology Co. (Tokyo, Japan).

20 *Purification of recombinant GST-Cdc25C proteins.* *Escherichia coli* DH5α cells were transformed by GST-Cdc25C (200-256) plasmid. The cells were incubated with 0.1 mM isopropyl β-D-thiogalactoside for 2 hr, harvested, and lysed with a buffer containing 50 mM Tris HCl (pH8.0), 100 mM NaCl, 0.5% NP-40, 5 µg/ml aprotinin, 5 µg/ml pepstatin A and 5 µg/ml leupeptin. The lysate was sonicated, centrifuged for clarification and incubated with glutathione-Sepharose 4B™ beads for 1 hr at 4°C and washed five times.

25 *Kinase assay.* HA-tagged hChk1 (SEQ ID NO:3) and c-myc-tagged Chk2/HuCds1 (SEQ ID NO:4) expressed in insect cells using recombinant baculovirus (see, e.g., Kaneko (1999) Oncogene 18:3673-3681) were purified by immunoprecipitation using anti-HA or anti-c-myc antibodies and protein G-Sepharose. Immune complex kinase reaction was done in PBS with 1 mM DTT, 1 mM MgCl₂ and 100 µCi of [γ-³²P] ATP (Amersham; 6000Ci/mmol) plus purified 1 µM GST-Cdc25C or 10 µM Cdc25C peptide (amino acid 211 to 221 of Cdc25C (SEQ ID NO:1); LYRSPSMPENL, Sawady Technology Co.) substrates at 30°C for 15 min in the presence of 10 µM TAT-S216, TAT-S216A or 30 TAT-Control. After the reaction, samples were separated in 12% or 15% SDS-PAGE and autoradiographed to detect GST-Cdc25C or peptide phosphorylation.

Cell-cycle analysis. The cell cycle status of the cells treated with peptides and/or bleomycin or colchicine was analyzed by FACS, as described by Kawabe (1997) Nature 385:454-458. In brief, two million Jurkat cells were re-suspended and incubated in 300 µl Krishan's solution (0.1% Sodium citrate, 50 µg/ml PI, 20 µg/ml RNase A and 0.5% NP-40; see supra) for 1 hr at 4°C and analyzed by FACScan™ (Beckton Dickinson, Mountain View, CA) with the program CELLQuest™ (Beckton Dickinson).

Histone H1 kinase assay. Ten million Jurkat cells were treated with hydroxyurea (100 µg/ml), bleomycin (10 µg/ml), or colchicine (5 µg/ml) with or without addition of TAT-S216A, TAT-S216 or TAT-Control (10 µM) for 6 hr. The cells were washed in cold PBS and lysed at 4°C in 1 ml of buffer A (50 mM Tris pH 8, 2 mM DTT, 5 mM EDTA, 100 mM NaCl, 0.5% NP40, 20 mM Na₃V0₄, 50 mM NaF, 4 µM Okadaic acid, 5 µg/ml aprotinin, 5 µg/ml pepstatin A and 5 µg/ml leupeptin.). Twenty microliter of p13^{suc1} agarose beads (Upstate Biotechnology., Saranac, NY) were added to the cleared lysates, incubated for 4 hr at 4°C, and washed five times with buffer A without 5 mM EDTA, 20 mM Na₃V0₄, 50 mM NaF, 4 µM Okadaic acid. Histone H1 kinase activity on the beads were analyzed by using Cdc2 kinase assay kit (Upstate Biotechnology) with [γ -³²P] ATP followed by 12% SDS-PAGE electrophoresis, and autoradiographed to detect the phosphorylated Histone H1.

Cell cytotoxicity assay. MIA PaCa2 and PANC1 cells (3x10³/well) were plated in 96-well microtiter plates. After an overnight adherence, cells were treated with bleomycin (10 µg/ml) with or without the indicated TAT-peptides at various time points up to 96 hr. Cytotoxicity and cell survival were determined by the 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT) assay (Cell Proliferation Kit II™: Boehringer Mannheim, Germany), which was done according to company's protocol and Scudiero (1988) Cancer Res. 48.4827-4833.

TAT-S216 and TAT-S216A peptides inhibit hChk1 and Chk2/HuCds1 kinase activities

To inhibit hChk1 (SEQ ID NO:3) and Chk2/HuCds1 (SEQ ID NO:4) kinase activities and to abrogate DNA damage-induced-G2 arrest, synthetic peptides comprising amino acid residues 211 to 221 of Cdc25C (SEQ ID NO:1) and a variation of the TAT protein transduction domain (YGRKKRRQRRR (SEQ ID NO:5) (TAT-S216) were generated.

The results are shown in Figure 1: TAT-S216A and TAT-S216 peptides inhibit hChk1 and Chk2/HuCds1 kinase activities *in vitro*. Figure 1A. sequences of the peptides. Figure 1B, *in vitro* phosphorylation analysis using GST-Cdc25C and purified hChk1. GST-Cdc25C (amino acid 200-256) that was produced in E. coli (DH5 α) was used as substrate (1 μ M). Immune complex kinase reaction was done in the presence of TAT-S216A (10 μ M) or TAT-S216 (10 μ M). Figure 1C, *in vitro* phosphorylation analysis of hChk1 and Chk2/HuCds1 using synthesized Cdc25C peptide corresponding amino acid 211-221 of Cdc25C (LYRSPSMPENL) as a substrate (10 μ M).

A TAT-S216A peptide (S216A; LYRSPSMPENL, (SEQ ID NO:6)), in which serine residue 216 was substituted by alanine was devised to stabilize the transient status of its interaction with hChk1 (SEQ ID NO:3) and Chk2/HuCds1 (SEQ ID NO:4) (Fig. 1A). This TAT peptide was included to efficiently transduce these peptides into cells (see, e.g., Nagahara (1998) *supra*). This sequence is known to facilitate the uptake of heterologous proteins across the cell membrane. As a control peptide, part of the Cdc25C portion of this peptide was deleted (TAT-Control).

As shown in Fig. 1B, hChk1 (SEQ ID NO:3) was capable of phosphorylating a Cdc25C protein (residues 200-256) (SEQ ID NO:1) fused to GST. Serine-216 on Cdc25C (SEQ ID NO:1) is the major phosphorylation site of this fusion protein *in vivo* (see, e.g., Furnari (1997) *Science* 277:1495-1497; Sanchez (1997) *Science* 277:1497-1501; Peng (1997) *Science* 277:1501-1505).

In Fig. 1B, both TAT-S216 and TAT-S216A inhibited the phosphorylation of Cdc25C by baculovirus-produced hChk1 (SEQ ID NO:3). TAT-S216 but not TAT-S216A was efficiently phosphorylated by hChk1, suggesting that serine-216 on TAT-S216 was phosphorylated by hChk1 and TAT-S216 would competitively inhibit substrate

phosphorylation at excess molar ratio if present in great enough quantity. TAT-Control peptide did not inhibit hChk1 kinase activity.

As shown in Fig. 1C, TAT-S216A significantly inhibited phosphorylation of Cdc25C peptide (residues 200-256) (SEQ ID NO:1) mediated by hChk1 (SEQ ID NO:3) and Chk2/HuCds1 (SEQ ID NO:4) even at a low stoichiometry (at four times more molar excess of TAT-S216A peptide against substrate Cdc25C peptide).

Abrogation of DNA damage-induced G2 checkpoint by TAT-S216 and TAT-S216A peptides

The cell cycle status of the cells treated with TAT-S216A or TAT-S216 upon the DNA damage-induced G2 arrest was analyzed by FACS analysis. Histone H1 kinase activities of these cells were simultaneously monitored. Jurkat cells arrested exclusively at G2 by bleomycin (10 µg/ml) treatment, because it does not have functional p53. Results are shown in Figure 2: abrogation of DNA damage-induced G2 arrest by TAT-S216A and TAT-S216 peptides. Figure 2A, FACS analysis of Jurkat cells treated with bleomycin and peptides. Cells were treated with bleomycin (10 µg/ml) with or without peptides (10 µM) for 20 hr. B, histone H1 kinase analysis. Cell lysates were prepared from the cells treated with the indicated reagent for 6 hr. Concentrations used were: hydroxyurea (HU), 100 µg/ml; bleomycin (Bleo), 10 µg/ml; colchicine, 5 µg/ml; TAT-S216A and TAT-S216, 10 µM. C, FACS analysis of colchicine -and peptide-treated cells. Jurkat cells were treated with colchicine (5 µg/ml) with or without peptide (10 µM) for 20 hr.

As shown in Fig. 2A, G2 arrest was completely abrogated by the addition of TAT-S216A or TAT-S216 in response to bleomycin. G2 arrest was abrogated at any time point between 12 and 48 hr by the treatment with TAT-S216A or TAT-S216. Jurkat cells treated with bleomycin together with TAT-Control arrested at G2 similarly to the cells treated with bleomycin alone.

We also observed that either TAT-S216A or TAT-S216 also abrogated G2 arrest induced by gamma-irradiation and cisplatin (gamma-irradiation, 5 Gy; cisplatin, 1 µg/ml for 1 hr treatment). To further analyze the effect of these peptides on G2/M transition, histone H1 kinase activity was monitored. Consistent with the above findings, although histone H1 kinase activity was decreased by the treatment with bleomycin or hydroxyurea, it was unchanged or rather increased by the treatment with bleomycin in the presence of TAT-

S216A or TAT-S216 (Fig. 2B). In the presence of TAT-Control peptide, the bleomycin treatment did not affect with H1 kinase activity.

As shown in Fig. 2C, The M-phase arrest of Jurkat cells induced by colchicine was not affected by the addition of TAT-S216 or TAT-S216A. These results demonstrate that TAT-S216A and TAT-S216 specifically abrogated the DNA damage-activated cell cycle G2 checkpoint by inhibiting hChk1 (SEQ ID NO:3) and/or Chk2/HuCds1 (SEQ ID NO:4) kinase activities.

Sensitization of Jurkat cells to the bleomycin-induced cell death by TAT-S216A and TAT-S216 peptides

The effect of TAT-S216A and TAT-S216 on the cell death induced by bleomycin was examined. The results are shown in Figure 3; Trypan blue dye exclusion analysis of Jurkat cells treated with bleomycin (A) or colchicine (B) with or without indicated peptides. Bars, SD Vertical axis, % viability of the cells; Bleo 5, bleomycin 5 μ g/ml; Bleo 10, bleomycin 10 μ g/ml; colchicine, 5 μ g/ml; TAT-S216 or TAT-S216A, 10 μ M of indicated peptide. Note that TAT-S216A and TAT-S216 peptides did not increase the cytotoxicity of bleomycin to normal cells. C, survival analysis of PHA blasts treated with bleomycin and peptides. Vertical axis, % viability of the cells determined by trypan blue dye exclusion analysis; horizontal axis, time in hours. Bleo 5, bleomycin 5 μ g/ml; Bleo 10, bleomycin 10 μ g/ml; TAT-S216 or TAT-S216A, 10 μ M of indicated peptide. D, FACS analysis of the cells treated with bleomycin and peptides. PHA- blasts were treated with bleomycin with or without peptides for 20 hr. Vertical axis, cell number; horizontal axis, DNA content indicated by propidium iodide staining.

As shown in Fig. 3A, the addition of TAT-S216A and TAT-S216 efficiently sensitized Jurkat cells to the bleomycin-induced cell death. Whereas bleomycin treatment at 5 or 10μ g/ml killed Jurkat cells by only 27-30%, the addition of 10 μ M TAT-216A or TAT-S216 killed Jurkat cells by nearly 80%. In contrast, these peptide by themselves did not show any significant cytotoxicity. In addition, a control peptide TAT-Control did not affect the viability of bleomycin-treated Jurkat cells. Moreover, as expected from the result in Fig. 2C, either TAT-S216A or TAT-S216 did not affect the cytotoxicity by colchicine (Fig. 3B). This observation indicates that the cell death induced by these peptides in the presence of bleomycin was not attributable to a nonspecific cytotoxic effect.

TAT-S216 and TAT-S216A peptides did not affect the viability of normal cells

In order to confirm the specificity of the effect of these peptides on cancer cells in which the G1 checkpoint is abrogated, the effect of these peptides on normal human cells was investigated. Mitogen-activated normal human T lymphocytes (PHA blasts) were prepared by stimulating peripheral blood mononuclear cells obtained from a healthy donor with PHA for 1 week. These cells were treated with bleomycin (5 and 10 µg/ml) in the presence or absence of either TAT-S216A or TAT-S216.

As shown in Fig. 3C, these peptides did not augment the cytotoxic effect of bleomycin, although these cells replicated as fast as Jurkat cells. As shown in Fig. 3D, PHA blasts treated with bleomycin (5 µg/ml) arrested at G1 and S phase but not G2, presumably because of the activity of wild-type p53. When these cells were treated with TAT-S216 or TAT-S216A in addition to bleomycin, no further alteration of cell cycle pattern was observed.

Sensitization of pancreatic cancer cells to the bleomycin-induced cell death by TAT-S216A and TAT-S216 peptides

The effect of these peptides on two other p53-defective pancreatic cancer cell lines, MIA PaCa2 and PANC1 cells, was examined. Figure 4 shows the results of survival analysis of PANC1 (A) and MIA PaCa2 (B) cells treated with bleomycin and peptides. PANC1 and MIA PaCa2 cells were treated with bleomycin with or without the indicated peptide. The cell viability was determined by the 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate assay at the indicated times after addition of bleomycin and peptide. Bleo 60, bleomycin 60 µg/ml; TAT-S216 or TAT-S216A, 10 µM of indicated peptide. Bars, SD.

Although these pancreatic cancer cells are known to be resistant to various anti-cancer reagents, these cells could also be sensitized to the bleomycin-induced cell death by TAT-S216A and TAT-S216 (Fig. 4). Similarly, these peptides could sensitize these cells to the cell death induced by other DNA-damaging agents including cisplatin and gamma-irradiation.

In summary, these experiments demonstrated for the first time that short peptides that inhibit both hChk1 and Chk2/HuCds1 kinase activities can specifically abrogate the DNA damage-induced G2 cell growth arrest checkpoint. These data also demonstrated

that the specific abrogation of the G2 checkpoint sensitized cancer cells to bleomycin, a DNA-damaging agent, without obvious effect on normal cell cycle and its viability. These observations indicate that these kinases involved in G2 cell cycle checkpoint are ideal targets for the specific abrogation of G2 checkpoint and that the peptides and polypeptides of the invention and their derivatives can be used in novel cancer therapy.

5

Example 2: Optimization of sequences for G2 abrogating peptides of the invention

10

The following example describes studies which identified exemplary G2 checkpoint-abrogating peptides of the invention. This was accomplished by using a computer analysis of the structure of human Chk2 kinase (SEQ ID NO:4) and the peptides of the invention.

15

20

The 3-dimensional structure of human Chk2 was predicted by comparing the primary and 3-D structure of another serine threonine kinase, PKA (PDB protein data base, Research Collaboratory for Structural Bioinformatics (RCSB), The National Science Foundation, Arlington, VA) (1CDK), using a computer program, MODELER™ (IMMD, Tokyo, Japan). The alignment of the peptides of the invention and hChk2 were predicted by comparing an alignment of hChk1 and various Cdc25C peptides as described by Chen (2000) "The 1.7 Å crystal structure of human cell cycle checkpoint kinase Chk1: implications for Chk1 regulation," Cell 100:681-92. By comparing the predicted structure of hChk2 with the peptides of the invention, it was predicted that there are four pockets on hChk2 that are important for the interaction with peptides, as shown in Figure 5, P1, P2, P3 and P4. The structure of these pockets was used to design and confirm the sequences of exemplary peptides of the invention

25

The ability of these peptides to abrogate the activity of Chk2 kinase, thereby imbuing the ability to abrogate the G2 cell cycle checkpoint, was demonstrated by their ability to act as a phosphorylation substrate for human Chk2 kinase. Exemplary peptides were directly synthesized (immobilized) on a membrane and contacted with human Chk2 kinase. Specifically, oligo-peptides with all sequences predicted by the 3-dimensional model were directly synthesized on a membrane by using an auto-spot-peptide-synthesizer, Model ASP-22 2 (ABiMED, Germany). The amount of peptide was about 0.1 micro-mol/cm².

30

The membrane was incubated with 2% Gly-Gly in PBS for 2 hours (hr) at room temperature (RT). Then, they were washed three times with 0.1% Tween-P BS™. The

“kination,” or “phosphorylation,” reaction was performed with a recombinant fusion protein Gst-Chk2 at a concentration of about 5 µg in 4 ml reaction buffer, 1 mM MgCl₂, 2% Gly-Gly and γ -³³P-ATP in PBS at RT for 1 hr. After the reaction, the membrane was washed 5 times with RIPA (1% SDS, 1% NP-40, 100 mM NaCl) and analyzed with a Bass 2500™ image analyzer (Fuji, Japan). The signal was graded to “-,” a “+,” a “++,” or a “+++.” Table 1 shows the peptide sequences that gave signals stronger than “++.” The peptides RYSLPPELSNM and LYRSPSAMPENL gave “+” signals by this analysis.

All of the following peptides were phosphorylated by human Chk2 kinase; in position “X” (corresponding to position X₈), wherein X = P, F, Y, or W, the signal was strongest (a “+++”) when X = the amino acid tyrosine (Y):

10	37-40	L Y R S P S H X E N L
	52-53	L Y S S P S Y X E N L
	92-95	L Y T S P S Y X E N L
	117-121	L Y T S P S H X E N L
15	132-135	L Y H S P S Y X E N L
	1127-1130	W Y R S P S F X E N L
	1237-1240	W Y T S P S H X E N L
	372-375	L F T S P S Y X E N L
	637-640	F Y S S P S H X E N L
20	642-645	F Y T S P S M X E N L
	648-651	F Y T S P S F X E N L
	652-655	F Y T S P S Y X E N L
	1202-1205	W Y T S P S M X E N L
	1207-1210	W Y T S P S F X E N L
25	1212-1215	W Y T S P S Y X E N L

The best phosphorylation substrates were the peptides L Y R S P S Y Y E N L and W Y T S P S Y F E N L.

The following Table 1 is a complete list of tested peptides and results of the *in vitro* phosphorylation by human Chk2 kinase assay. Results are presented to the right of the peptide, below: a “+++” indicates the peptide was relatively highly phosphorylated; a “++” indicates the peptide was relatively less phosphorylated, a “+” indicates the peptide was

detectably significantly phosphorylated over negative control, and no indication indicates that a peptide was not significantly phosphorylated over negative control (note: the number immediately to the right of the peptide is the MW of the peptide).

Table 1

1 R Y S L P P E L S N M 1308.6	+	1 R Y S L P P E L S N M 1308.6
2 L Y R S P S M P E N L 1308.6	+	2 L Y R S P S M P E N L 1308.6
3 L Y R S P S M F E N L 1358.6	-	
4 L Y R S P S M Y E N L 1374.6	-	
5 L Y R S P S M W E N L 1397.7	-	
7 L Y R S P S F P E N L 1324.5	-	
8 L Y R S P S F F E N L 1374.5	-	
9 L Y R S P S F Y E N L 1390.5	-	
10 L Y R S P S F W E N L 1413.6	-	
12 L Y R S P S Y P E N L 1340.5	+	
13 L Y R S P S Y F E N L 1390.5	+	
14 L Y R S P S Y Y E N L 1406.5	+	
15 L Y R S P S Y W E N L 1429.6	+	
17 L Y R S P S D P E N L 1292.4	-	
18 L Y R S P S D F E N L 1342.4	-	
19 L Y R S P S D Y E N L 1358.4	-	
20 L Y R S P S D W E N L 1381.5	-	
22 L Y R S P S E P E N L 1306.4	-	
23 L Y R S P S E F E N L 1356.4	-	
24 L Y R S P S E Y E N L 1372.4	-	
25 L Y R S P S E W E N L 1395.5	-	
27 L Y R S P S N P E N L 1291.5	+	
28 L Y R S P S N P E N L 1341.5	+	
29 L Y R S P S N Y E N L 1357.5	+	
30 L Y R S P S N W E N L 1380.6	+	
32 L Y R S P S Q P E N L 1305.5	-	
33 L Y R S P S Q F E N L 1355.5	-	
34 L Y R S P S Q Y E N L 1371.5	-	
35 L Y R S P S Q W E N L 1394.6	-	
37 L Y R S P S H P E N L 1314.5	+	

38 LYRSPSHFENL 1364.5	+	
39 LYRSPSHYENL 1380.5	+	
40 LYRSPSHWENL 1403.6	+	
42 LYSSPSMPENL 1240.3	+	
43 LYSSPSMFENL 1290.3	+	
44 LYSSPSMYENL 1306.3	+	
45 LYSSPSMWENL 1329.4	+	
47 LYSSPSFPENL 1256.2	+	
48 LYSSPSFFENL 1306.2	+	
49 LYSSPSFYENL 1322.2	+	
50 LYSSPSFWENL 1345.3	+	
52 LYSSPSYPENL 1272.2	+	
53 LYSSPSYFENL 1322.2	+	
54 LYSSPSYYENL 1338.2	+	
55 LYSSPSYWENL 1361.3	+	
57 LYSSPSDPENL 1224.1	-	
58 LYSSPSDFENL 1274.1	-	
59 LYSSPSDYENL 1290.1	-	
60 LYSSPSDWENL 1313.2	-	
62 LYSSPSEOPENL 1238.1	-	
63 LYSSPSEFENL 1288.1	-	
64 LYSSPSEYENL 1304.1	-	
65 LYSSPSEWENL 1327.2	-	
67 LYSSPSNPENL 1223.2	-	
68 LYSSPSNFENL 1273.2	-	
69 LYSSPSNYENL 1289.2	-	
70 LYSSPSNWENL 1312.3	-	
72 LYSSPSQOPENL 1237.2	+	
73 LYSSPSQFENL 1287.2	-	
74 LYSSPSQYENL 1303.2	-	
75 LYSSPSQWENL 1326.3	+	
77 LYSSPSHPENL 1246.2	++	
78 LYSSPSHFENL 1296.2	++	
79 LYSSPSHYENL 1312.2	++	
80 LYSSPSHWENL 1335.3	++	
82 LYTSPSMPENL 1253.5	++	
		37 LYRSPSHPENL 1314.5
		38 LYRSPSHFENL 1364.5
		39 LYRSPSHYENL 1380.5
		40 LYRSPSHWENL 1403.6
		52 LYSSPSYPENL 1272.2
		53 LYSSPSYFENL 1322.2
		54 LYSSPSYYENL 1338.2
		55 LYSSPSYWENL 1361.3
		72 LYSSPSQOPENL 1237.2
		75 LYSSPSQWENL 1326.3
		92 LYTSPSYOPENL 1285.4
		93 LYTSPSYFENL 1335.4
		94 LYTSPSYYENL 1361.4
		95 LYTSPSYWENL 1374.5
		117 LYTSPSHPENL 1259.4
		118 LYTSPSHFENL 1309.4
		119 LYTSPSHYENL 1325.4
		120 LYTSPSHWENL 1348.5
		132 LYHSPSYOPENL 1321.5
		133 LYHSPSYFENL 1371.5
		134 LYHSPSYYENL 1387.5
		135 LYHSPSYWENL 1410.6
		1127 WYRSPSFOPENL 1397.6
		1128 WYRSPSFFENL 1447.6
		1129 WYRSPSFYENL 1463.6
		1130 WYRSPSFWENL 1486.7
		1237 WYTSPSHOPENL 1332.5
		1238 WYTSPSHFENL 1382.5
		1239 WYTSPSHYENL 1398.5

83 LY TSPSMFENL 1303.5	++ 1240 W YTSPSHWENL 1421.6
84 LY TSPSMYENL 1319.5	++ 372 LFTSPSY PENL 1269.4
85 LY TSPSMWENL 1342.6	++ 373 LFTSPSYFENL 1319.4
87 LY TSPSF PENL 1269.4	++ 374 LFTSPSY YENL 1335.4
88 LY TSPSFFENL 1319.4	++ 375 LFTSPSYWENL 1358.5
89 LY TSPSFYENL 1335.4	++ 637 FYSSPSH PENL 1280.2
90 LY TSPSF WENL 1358.5	++ 638 FYSSPSHFENL 1330.2
92 LY TSPSY PENL 1285.4	++ 639 FYSSPSHYENL 1346.2
93 LY TSPSYFENL 1335.4	++ 640 FYSSPSHWENL 1369.3
94 LY TSPSY YENL 1351.4	+++ 642 FYTSPSM PENL 1287.5
95 LY TSPSYWENL 1374.5	++ 643 FYTSPSMFENL 1337.5
97 LY TSPSD PENL 1237.3	- 644 FYTSPSMYENL 1353.5
98 LY TSPSDFENL 1287.3	- 645 FYTSPSMWENL 1376.6
99 LY TSPSDYENL 1303.3	- 647 FYTSPSF PENL 1303.4
100 LY TSPSDWENL 1326.4	- 648 FYTSPSF FENL 1353.4
102 LY TSPSE PENL 1251.3	- 649 FYTSPSFYENL 1369.4
103 LY TSPSEFENL 1301.3	- 650 FYTSPSF WENL 1392.5
104 LY TSPSEYENL 1317.3	- 652 FYTSPSY PENL 1319.4
105 LY TSPSEWENL 1340.4	- 653 FYTSPSYFENL 1369.4
107 LY TSPSN PENL 1236.4	+ 654 FYTSPSY YENL 1385.4
108 LY TSPSNFENL 1286.4	+ 655 FYTSPSYWENL 1408.5
109 LY TSPSNYENL 1302.4	+ 1202 W YTSPSM P ENL 1326.6
110 LY TSPSNWENL 1325.5	+ 1203 W YTSPSMFENL 1376.6
112 LY TSPSQ PENL 1250.4	- 1204 W YTSPSMYENL 1392.6
113 LY TSPSQFENL 1300.4	- 1205 W YTSPSMWENL 1415.7
114 LY TSPSQYENL 1316.4	- 1207 W YTSPSF PENL 1342.5
115 LY TSPSQWENL 1339.5	- 1208 W YTSPSFFENL 1392.5
117 LY TSPSH PENL 1259.4	+ 1209 W YTSPSFYENL 1408.5
118 LY TSPSHFENL 1309.4	+ 1210 W YTSPSF WENL 1431.6
119 LY TSPSHYENL 1325.4	+ 1212 W YTSPSY PENL 1358.5
120 LY TSPSHWENL 1348.5	+ 1213 W YTSPSYFENL 1408.5
122 LY HSPSM PENL 1289.6	- 1214 W YTSPSY YENL 1424.5
123 LY HSPSMFENL 1339.6	- 1215 W YTSPSYWENL 1447.6
124 LY HSPSMYENL 1355.6	-
125 LY HSPSMWENL 1378.7	-
127 LY HSPSF PENL 1305.5	-
	1 RYSLPPELSNM 1308.6
	2 LYRSPSM PENL 1308.6

128 LYHSPSFFENL	1355.5	-	2274 LKRSPSMPENL	1273.6
129 LYHSPSFYENL	1371.5	-	2342 LYRSPSMVENL	1310.6
130 LYHSPSFWENL	1394.6	-	2292 LYISPSMPENL	1265.6
132 LYHSPSYOPENL	1321.5	+	2254 KYRSPSMPENL	1323.6
133 LYHSPSYEENL	1371.5	+		
134 LYHSPSYEENL	1337.5	+++		
135 LYHSPSYWENL	1410.6	+		
137 LYHSPSDPENL	1273.4	-		
138 LYHSPSDFENL	1323.4	-		
139 LYHSPSDYENL	1339.4	-		
140 LYHSPSDWENL	1362.5	-		
142 LYHSPSEOPENL	1287.4	-		
143 LYHSPSEFENL	1337.4	-		
144 LYHSPSEYENL	1353.4	-		
145 LYHSPSEWENL	1376.5	-		
147 LYHSPSNPENL	1272.5	-		
148 LYHSPSNFENL	1322.5	-		
149 LYHSPSNYENL	1338.5	-		
150 LYHSPSNWENL	1361.6	-		
152 LYHSPSQOPENL	1286.5	-		
153 LYHSPSQFENL	1336.5	-		
154 LYHSPSQYENL	1352.5	-		
155 LYHSPSQWENL	1375.6	-		
157 LYHSPSHPENL	1295.5	-		
158 LYHSPSHFENL	1345.5	-		
159 LYHSPSHYENL	1361.5	-		
160 LYHSPSHWENL	1384.6	-		
162 LYNSPSPMPENL	1266.6	-		
163 LYNSPSPMFENL	1316.6	-		
164 LYNSPSPMYENL	1332.6	-		
165 LYNSPSPMWENL	1355.7	-		
167 LYNSPSFPENL	1282.5	-		
168 LYNSPSFFENL	1332.5	-		
169 LYNSPSFYENL	1348.5	-		
170 LYNSPSFWENL	1371.6	-		
172 LYNSPSYPENL	1298.5	-		

173	LYN S P S Y F E N L	1348.5	-
174	LYN S P S Y Y E N L	1364.5	-
175	LYN S P S Y W E N L	1387.6	-
177	LYN S P S D P E N L	1250.4	-
178	LYN S P S D F E N L	1300.4	-
179	LYN S P S D Y E N L	1316.4	-
180	LYN S P S D W E N L	1339.5	-
182	LYN S P S E P E N L	1264.4	-
183	LYN S P S E F E N L	1314.4	-
184	LYN S P S E Y E N L	1330.4	-
185	LYN S P S E W E N L	1353.5	-
187	LYN S P S N P E N L	1249.5	-
188	LYN S P S N F E N L	1299.5	-
189	LYN S P S N Y E N L	1315.5	-
190	LYN S P S N W E N L	1338.6	-
192	LYN S P S Q P E N L	1263.5	-
193	LYN S P S Q F E N L	1313.5	-
194	LYN S P S Q Y E N L	1329.5	-
195	LYN S P S Q W E N L	1352.6	-
197	LYN S P S H P E N L	1272.5	-
198	LYN S P S H F E N L	1322.5	-
199	LYN S P S H Y E N L	1338.5	-
200	LYN S P S H W E N L	1361.6	-
202	LYG S P S M P E N L	1209.5	-
203	LYG S P S M F E N L	1259.5	-
204	LYG S P S M Y E N L	1275.5	-
205	LYG S P S M W E N L	1298.6	-
207	LYG S P S F P E N L	1225.4	-
208	LYG S P S F F E N L	1275.4	-
209	LYG S P S F Y E N L	1291.4	-
210	LYG S P S F W E N L	1314.5	-
212	LYG S P S Y P E N L	1241.4	-
213	LYG S P S Y F E N L	1291.4	-
214	LYG S P S Y Y E N L	1307.4	-
215	LYG S P S Y W E N L	1330.5	-
217	LYG S P S D P E N L	1193.3	-

218 LY G S P S D F E N L 1243.3
219 LY G S P S D Y E N L 1259.3
220 LY G S P S D W E N L 1282.4
222 LY G S P S E P E N L 1207.3
223 LY G S P S E F E N L 1257.3
224 LY G S P S E Y E N L 1273.3
225 LY G S P S E W E N L 1296.4
227 LY G S P S N P E N L 1192.4
228 LY G S P S N F E N L 1242.4
229 LY G S P S N Y E N L 1258.4
230 LY G S P S N W E N L 1281.5
232 LY G S P S Q P E N L 1206.4
233 LY G S P S Q F E N L 1256.4
234 LY G S P S Q Y E N L 1272.4
235 LY G S P S Q W E N L 1295.5
237 LY G S P S H P E N L 1215.4
238 LY G S P S H F E N L 1265.4
239 LY G S P S H Y E N L 1281.4
240 LY G S P S H W E N L 1304.5
242 LY A P S M P E N L 1223.5
243 LY A P S M F E N L 1273.5
244 LY A P S M Y E N L 1289.5
245 LY A P S M W E N L 1312.6
247 LY A P S F P E N L 1239.4
248 LY A P S F F E N L 1289.4
249 LY A P S F Y E N L 1305.4
250 LY A P S F W E N L 1328.5
252 LY A P S Y P E N L 1255.4
253 LY A P S Y F E N L 1305.4
254 LY A P S Y Y E N L 1321.4
255 LY A P S Y W E N L 1344.5
257 LY A P S D P E N L 1207.3
258 LY A P S D F E N L 1257.3
259 LY A P S D Y E N L 1273.3
260 LY A P S D W E N L 1296.4
262 LY A P S E P E N L 1221.3

263 LY ASPSEFENL 1271.3
264 LY ASPSEYENL 1287.3
265 LY ASPSEWENL 1310.4
267 LY ASPSNPENL 1206.4
268 LY ASPSNFENL 1256.4
269 LY ASPSNYENL 1272.4
270 LY ASPSNWENL 1295.5
272 LY ASPSQOPENL 1220.4
273 LY ASPSQFENL 1270.4
274 LY ASPSQYENL 1286.4
275 LY ASPSQWENL 1309.5
277 LY ASPSHPENL 1229.4
278 LY ASPSHFENL 1279.4
279 LY ASPSHYENL 1295.4
280 LY ASPSHWENL 1318.5
282 LFRSPSMPENL 1292.6
283 LFRSPSMFENL 1342.6
284 LFRSPSMYENL 1358.6
285 LFRSPSMWENL 1381.7
287 LFRSPSFOPENL 1308.5
288 LFRSPSFFENL 1358.5
289 LFRSPSFYENL 1374.5
290 LFRSPSFWENL 1397.6
292 LFRSPSYOPENL 1324.5
293 LFRSPSYFENL 1374.5
294 LFRSPSYYENL 1390.5
295 LFRSPSYWENL 1413.6
297 LFRSPSDOPENL 1276.4
298 LFRSPSDFENL 1326.4
299 LFRSPSDYENL 1342.4
300 LFRSPSDWENL 1365.5
302 LFRSPSEOPENL 1290.4
303 LFRSPSEFENL 1340.4
304 LFRSPSEYENL 1356.4
305 LFRSPSEWENL 1379.5
307 LFRSPSNPENL 1275.5

308 LFRSPSNFENL 1325.5 -
309 LFRSPSNYENL 1341.5 -
310 LFRSPSNWENL 1364.6 -
312 LFRSPSQPENL 1289.5 -
313 LFRSPSQFENL 1339.5 -
314 LFRSPSQYENL 1355.5 -
315 LFRSPSQWENL 1378.6 -
317 LFRSPSHPENL 1298.5 -
318 LFRSPSHFENL 1348.5 -
319 LFRSPSHYENL 1364.5 -
320 LFRSPSHWENL 1387.6 -
322 LFSSPSMPENL 1224.3 -
323 LFSSPSMFENL 1274.3 -
324 LFSSPSMYENL 1290.3 -
325 LFSSPSMWENL 1313.4 -
327 LFSSPSFPENL 1240.2 -
328 LFSSPSFFENL 1290.2 -
329 LFSSPSFYENL 1306.2 -
330 LFSSPSFWENL 1329.3 -
332 LFSSPSYPENL 1256.2 -
333 LFSSPSYFENL 1306.2 -
334 LFSSPSYYENL 1322.2 -
335 LFSSPSYWENL 1345.3 -
337 LFSSPSDPENL 1208.1 -
338 LFSSPSDFENL 1258.1 -
339 LFSSPSDYENL 1274.1 -
340 LFSSPSDWENL 1297.2 -
342 LFSSPSEPENL 1222.1 -
343 LFSSPSEFENL 1272.1 -
344 LFSSPSEYENL 1288.1 -
345 LFSSPSEWENL 1311.2 -
347 LFSSPSNPENL 1207.2 -
348 LFSSPSNFENL 1257.2 -
349 LFSSPSNYENL 1273.2 -
350 LFSSPSNWENL 1296.3 -
352 LFSSPSQPENL 1221.2 -

353	L F S S P S Q F E N L	1271.2	-
354	L F S S P S Q Y E N L	1287.2	-
355	L F S S P S Q W E N L	1310.3	-
357	L F S S P S H P E N L	1230.2	-
358	L F S S P S H F E N L	1280.2	-
359	L F S S P S H Y E N L	1296.2	-
360	L F S S P S H W E N L	1319.3	-
362	L F T S P S M P E N L	1237.5	-
363	L F T S P S M F E N L	1287.5	-
364	L F T S P S M Y E N L	1303.5	-
365	L F T S P S M W E N L	1326.6	-
367	L F T S P S F P E N L	1253.4	-
368	L F T S P S F F E N L	1303.4	-
369	L F T S P S F Y E N L	1319.4	-
370	L F T S P S F W E N L	1342.5	-
372	L F T S P S Y P E N L	1269.4	+
373	L F T S P S Y F E N L	1319.4	+
374	L F T S P S Y Y E N L	1335.4	+++
375	L F T S P S Y W E N L	1358.5	+
377	L F T S P S D P E N L	1221.3	-
378	L F T S P S D F E N L	1271.3	-
379	L F T S P S D Y E N L	1287.3	-
380	L F T S P S D W E N L	1310.4	-
382	L F T S P S E P E N L	1235.3	-
383	L F T S P S E F E N L	1285.3	-
384	L F T S P S E Y E N L	1301.3	-
385	L F T S P S E W E N L	1324.4	-
387	L F T S P S N P E N L	1220.4	-
388	L F T S P S N F E N L	1270.4	-
389	L F T S P S N Y E N L	1286.4	-
390	L F T S P S N W E N L	1309.5	-
392	L F T S P S Q P E N L	1234.4	-
393	L F T S P S Q F E N L	1284.4	-
394	L F T S P S Q Y E N L	1300.4	-
395	L F T S P S Q W E N L	1323.5	-
397	L F T S P S H P E N L	1243.4	-

398	LFTSPSHFENL	1293.4	-
399	LFTSPSHYENL	1309.4	-
400	LFTSPSHWENL	1332.5	-
402	LFHSPSMPENL	1273.6	-
403	LFHSPSMFENL	1323.6	-
404	LFHSPSMYENL	1339.6	-
405	LFHSPSMWENL	1362.7	-
407	LFHSPSFOPENL	1289.5	-
408	LFHSPSFFENL	1339.5	-
409	LFHSPSFYENL	1355.5	-
410	LFHSPSFOPENL	1378.6	-
412	LFHSPSYOPENL	1305.5	-
413	LFHSPSYFENL	1355.5	-
414	LFHSPSYYENL	1371.5	-
415	LFHSPSYWENL	1394.6	-
417	LFHSPSDOPENL	1257.4	-
418	LFHSPSDFENL	1307.4	-
419	LFHSPSDYENL	1323.4	-
420	LFHSPSDWENL	1346.5	-
422	LFHSPSEOPENL	1271.4	-
423	LFHSPSEFENL	1321.4	-
424	LFHSPSEYENL	1337.4	-
425	LFHSPSEWENL	1360.5	-
427	LFHSPSNPENL	1256.5	-
428	LFHSPSNFENL	1306.5	-
429	LFHSPSNYENL	1322.5	-
430	LFHSPSNWENL	1345.6	-
432	LFHSPSQOPENL	1270.5	-
433	LFHSPSQFENL	1320.5	-
434	LFHSPSQYENL	1336.5	-
435	LFHSPSQWENL	1359.6	-
437	LFHSPSHOPENL	1279.5	-
438	LFHSPSHFENL	1329.5	-
439	LFHSPSHYENL	1345.5	-
440	LFHSPSHWENL	1368.6	-
442	LFNSPSPMPENL	1250.6	-

443 L F N S P S M F E N L 1300.6 -
444 L F N S P S M Y E N L 1316.6 -
445 L F N S P S M W E N L 1339.7 -
447 L F N S P S F P E N L 1266.5 -
448 L F N S P S F F E N L 1316.5 -
449 L F N S P S F Y E N L 1332.5 -
450 L F N S P S F W E N L 1355.6 -
452 L F N S P S Y P E N L 1282.5 -
453 L F N S P S Y F E N L 1332.5 -
454 L F N S P S Y Y E N L 1348.5 -
455 L F N S P S Y W E N L 1371.6 -
457 L F N S P S D P E N L 1234.4 -
458 L F N S P S D F E N L 1284.4 -
459 L F N S P S D Y E N L 1300.4 -
460 L F N S P S D W E N L 1323.5 -
462 L F N S P S E P E N L 1248.4 -
463 L F N S P S E F E N L 1298.4 -
464 L F N S P S E Y E N L 1314.4 -
465 L F N S P S E W E N L 1337.5 -
467 L F N S P S N P E N L 1233.5 -
468 L F N S P S N F E N L 1283.5 -
469 L F N S P S N Y E N L 1299.5 -
470 L F N S P S N W E N L 1322.6 -
472 L F N S P S Q P E N L 1247.5 -
473 L F N S P S Q F E N L 1297.5 -
474 L F N S P S Q Y E N L 1313.5 -
475 L F N S P S Q W E N L 1336.6 -
477 L F N S P S H P E N L 1256.5 -
478 L F N S P S H F E N L 1306.5 -
479 L F N S P S H Y E N L 1322.5 -
480 L F N S P S H W E N L 1345.6 -
482 L F G S P S M P E N L 1193.5 -
483 L F G S P S M F E N L 1243.5 -
484 L F G S P S M Y E N L 1259.5 -
485 L F G S P S M W E N L 1282.6 -
487 L F G S P S F P E N L 1209.4 -

488 LFGSPSFFENL 1259.4 -
489 LFGSPSFYENL 1275.4 -
490 LFGSPSFWENL 1298.5 -
492 LFGSPSYOPENL 1225.4 -
493 LFGSPSYFENL 1275.4 -
494 LFGSPSYYENL 1291.4 -
495 LFGSPSYWENL 1314.5 -
497 LFGSPSDPENL 1177.3 -
498 LFGSPSDFENL 1227.3 -
499 LFGSPSDYENL 1243.3 -
500 LFGSPSDWENL 1266.4 -
502 LFGSPSEOPENL 1191.3 -
503 LFGSPSEFENL 1241.3 -
504 LFGSPSEYENL 1257.3 -
505 LFGSPSEWENL 1280.4 -
507 LFGSPSNOPENL 1176.4 -
508 LFGSPSNFENL 1226.4 -
509 LFGSPSNYENL 1242.4 -
510 LFGSPSNWENL 1265.5 -
512 LFGSPSQOPENL 1190.4 -
513 LFGSPSQFENL 1240.4 -
514 LFGSPSQYENL 1256.4 -
515 LFGSPSQWENL 1279.5 -
517 LFGSPSHOPENL 1199.4 -
518 LFGSPSHFENL 1249.4 -
519 LFGSPSHYENL 1265.4 -
520 LFGSPSHWENL 1288.5 -
522 LFASPSMPENL 1207.5 -
523 LFASPSMFENL 1257.5 -
524 LFASPSMYENL 1273.5 -
525 LFASPSMWENL 1296.6 -
527 LFASPSFPENL 1223.4 -
528 LFASPSFFENL 1273.4 -
529 LFASPSFYENL 1289.4 -
530 LFASPSFWENL 1312.5 -
532 LFASPSYPENL 1239.4 -

533 LFASPSYFENL 1289.4 -
534 LFASPSYYENL 1305.4 -
535 LFASPSYWENL 1328.5 -
537 LFASPSDPENL 1191.3 -
538 LFASPSDFENL 1241.3 -
539 LFASPSDYENL 1257.3 -
540 LFASPSDWENL 1280.4 -
542 LFASPSEOPENL 1205.3 -
543 LFASPSEFENL 1255.3 -
544 LFASPSEYENL 1271.3 -
545 LFASPSEWENL 1294.4 -
547 LFASPSNPENL 1190.4 -
548 LFASPSNFENL 1240.4 -
549 LFASPSNYENL 1256.4 -
550 LFASPSNWENL 1279.5 -
552 LFASPSQOPENL 1204.4 -
553 LFASPSQFENL 1254.4 -
554 LFASPSQYENL 1270.4 -
555 LFASPSQWENL 1293.5 -
557 LFASPSHPENL 1213.4 -
558 LFASPSHFENL 1263.4 -
559 LFASPSHYENL 1279.4 -
560 LFASPSHWENL 1302.5 -
562 FYRSPSMOPENL 1342.6 -
563 FYRSPSMFENL 1392.6 -
564 FYRSPSMYENL 1408.6 -
565 FYRSPSMWENL 1431.7 -
567 FYRSPSFOPENL 1358.5 -
568 FYRSPSFFENL 1408.5 -
569 FYRSPSFYENL 1424.5 -
570 FYRSPSFWENL 1447.6 -
572 FYRSPSYOPENL 1374.5 -
573 FYRSPSYFENL 1424.5 -
574 FYRSPSYYENL 1440.5 -
575 FYRSPSYWENL 1463.6 -
577 FYRSPSDPENL 1326.4 -

578 F Y R S P S D F E N L 1376.4
579 F Y R S P S D Y E N L 1392.4
580 F Y R S P S D W E N L 1415.5
582 F Y R S P S E P E N L 1340.4
583 F Y R S P S E F E N L 1390.4
584 F Y R S P S E Y E N L 1406.4
585 F Y R S P S E W E N L 1429.5
587 F Y R S P S N P E N L 1325.5
588 F Y R S P S N F E N L 1375.5
589 F Y R S P S N Y E N L 1391.5
590 F Y R S P S N W E N L 1414.6
592 F Y R S P S Q P E N L 1339.5
593 F Y R S P S Q F E N L 1389.5
594 F Y R S P S Q Y E N L 1405.5
595 F Y R S P S Q W E N L 1428.6
597 F Y R S P S H P E N L 1348.5
598 F Y R S P S H F E N L 1398.5
599 F Y R S P S H Y E N L 1414.5
600 F Y R S P S H W E N L 1437.6
602 F Y S S P S M P E N L 1274.3
603 F Y S S P S M F E N L 1324.3
604 F Y S S P S M Y E N L 1340.3
605 F Y S S P S M W E N L 1363.4
607 F Y S S P S F P E N L 1290.2
608 F Y S S P S F F E N L 1340.2
609 F Y S S P S F Y E N L 1356.2
610 F Y S S P S F W E N L 1379.3
612 F Y S S P S Y P E N L 1306.2
613 F Y S S P S Y F E N L 1356.2
614 F Y S S P S Y Y E N L 1372.2
615 F Y S S P S Y W E N L 1395.3
617 F Y S S P S D P E N L 1258.1
618 F Y S S P S D F E N L 1308.1
619 F Y S S P S D Y E N L 1324.1
620 F Y S S P S D W E N L 1347.2
622 F Y S S P S E P E N L 1272.1

623 F Y S S P S E F E N L	1322.1	-
624 F Y S S P S E Y E N L	1338.1	-
625 F Y S S P S E W E N L	1361.2	-
627 F Y S S P S N P E N L	1257.2	-
628 F Y S S P S N F E N L	1307.2	-
629 F Y S S P S N Y E N L	1323.2	-
630 F Y S S P S N W E N L	1346.3	-
632 F Y S S P S Q P E N L	1271.2	-
633 F Y S S P S Q F E N L	1321.2	-
634 F Y S S P S Q Y E N L	1337.2	-
635 F Y S S P S Q W E N L	1360.3	-
637 F Y S S P S H P E N L	1280.2	+
638 F Y S S P S H F E N L	1330.2	+
639 F Y S S P S H Y E N L	1346.2	+
640 F Y S S P S H W E N L	1369.3	+
642 F Y T S P S M P E N L	1287.5	+
643 F Y T S P S M F E N L	1337.5	+
644 F Y T S P S M Y E N L	1353.5	+
645 F Y T S P S M W E N L	1376.6	+
647 F Y T S P S F P E N L	1303.4	+
648 F Y T S P S F F E N L	1353.4	+
649 F Y T S P S F Y E N L	1369.4	+
650 F Y T S P S F W E N L	1392.5	+
652 F Y T S P S Y P E N L	1319.4	+
653 F Y T S P S Y F E N L	1369.4	+
654 F Y T S P S Y Y E N L	1385.4	+
655 F Y T S P S Y W E N L	1408.5	+
657 F Y T S P S D P E N L	1271.3	-
658 F Y T S P S D F E N L	1321.3	-
659 F Y T S P S D Y E N L	1337.3	-
660 F Y T S P S D W E N L	1360.4	-
662 F Y T S P S E P E N L	1285.3	-
663 F Y T S P S E F E N L	1335.3	-
664 F Y T S P S E Y E N L	1351.3	-
665 F Y T S P S E W E N L	1374.4	-
667 F Y T S P S N P E N L	1270.4	-

668 F Y T S P S N F E N L 1320.4 -
669 F Y T S P S N Y E N L 1336.4 -
670 F Y T S P S N W E N L 1359.5 -
672 F Y T S P S Q P E N L 1284.4 -
673 F Y T S P S Q F E N L 1334.4 -
674 F Y T S P S Q Y E N L 1350.4 -
675 F Y T S P S Q W E N L 1373.5 -
677 F Y T S P S H P E N L 1293.4 -
678 F Y T S P S H F E N L 1343.4 -
679 F Y T S P S H Y E N L 1359.4 -
680 F Y T S P S H W E N L 1382.5 -
682 F Y H S P S M P E N L 1323.6 -
683 F Y H S P S M F E N L 1373.6 -
684 F Y H S P S M Y E N L 1389.6 -
685 F Y H S P S M W E N L 1412.7 -
687 F Y H S P S F P E N L 1339.5 -
688 F Y H S P S F F E N L 1389.5 -
689 F Y H S P S F Y E N L 1405.5 -
690 F Y H S P S F W E N L 1428.6 -
692 F Y H S P S Y P E N L 1355.5 -
693 F Y H S P S Y F E N L 1405.5 -
694 F Y H S P S Y Y E N L 1421.5 -
695 F Y H S P S Y W E N L 1444.6 -
697 F Y H S P S D P E N L 1307.4 -
698 F Y H S P S D F E N L 1357.4 -
699 F Y H S P S D Y E N L 1373.4 -
700 F Y H S P S D W E N L 1396.5 -
702 F Y H S P S E P E N L 1321.4 -
703 F Y H S P S E F E N L 1371.4 -
704 F Y H S P S E Y E N L 1387.4 -
705 F Y H S P S E W E N L 1410.5 -
707 F Y H S P S N P E N L 1306.5 -
708 F Y H S P S N F E N L 1356.5 -
709 F Y H S P S N Y E N L 1372.5 -
710 F Y H S P S N W E N L 1395.6 -
712 F Y H S P S Q P E N L 1320.5 -

713 F Y H S P S Q F E N L	1370.5	-
714 F Y H S P S Q Y E N L	1386.5	-
715 F Y H S P S Q W E N L	1409.6	-
717 F Y H S P S H P E N L	1329.5	-
718 F Y H S P S H F E N L	1379.5	-
719 F Y H S P S H Y E N L	1395.5	-
720 F Y H S P S H W E N L	1418.6	-
722 F Y N S P S M P E N L	1300.6	-
723 F Y N S P S M F E N L	1350.6	-
724 F Y N S P S M Y E N L	1366.6	-
725 F Y N S P S M W E N L	1389.7	-
727 F Y N S P S F P E N L	1316.5	-
728 F Y N S P S F F E N L	1366.5	-
729 F Y N S P S F Y E N L	1382.5	-
730 F Y N S P S F W E N L	1405.6	-
732 F Y N S P S Y P E N L	1332.5	-
733 F Y N S P S Y F E N L	1382.5	-
734 F Y N S P S Y Y E N L	1398.5	-
735 F Y N S P S Y W E N L	1421.6	-
737 F Y N S P S D P E N L	1284.4	-
738 F Y N S P S D F E N L	1334.4	-
739 F Y N S P S D Y E N L	1350.4	-
740 F Y N S P S D W E N L	1373.5	-
742 F Y N S P S E P E N L	1298.4	-
743 F Y N S P S E F E N L	1348.4	-
744 F Y N S P S E Y E N L	1364.4	-
745 F Y N S P S E W E N L	1387.5	-
747 F Y N S P S N P E N L	1283.5	-
748 F Y N S P S N F E N L	1333.5	-
749 F Y N S P S N Y E N L	1349.5	-
750 F Y N S P S N W E N L	1372.6	-
752 F Y N S P S Q P E N L	1297.5	-
753 F Y N S P S Q F E N L	1347.5	-
754 F Y N S P S Q Y E N L	1363.5	-
755 F Y N S P S Q W E N L	1386.6	-
757 F Y N S P S H P E N L	1306.5	-

758 F Y N S P S H F E N L 1356.5 -
759 F Y N S P S H Y E N L 1372.5 -
760 F Y N S P S H W E N L 1395.6 -
762 F Y G S P S M P E N L 1243.5 -
763 F Y G S P S M F E N L 1293.5 -
764 F Y G S P S M Y E N L 1309.5 -
765 F Y G S P S M W E N L 1332.6 -
767 F Y G S P S F P E N L 1259.4 -
768 F Y G S P S F F E N L 1309.4 -
769 F Y G S P S F Y E N L 1325.4 -
770 F Y G S P S F W E N L 1348.5 -
772 F Y G S P S Y P E N L 1275.4 -
773 F Y G S P S Y F E N L 1325.4 -
774 F Y G S P S Y Y E N L 1341.4 -
775 F Y G S P S Y W E N L 1364.5 -
777 F Y G S P S D P E N L 1227.3 -
778 F Y G S P S D F E N L 1277.3 -
779 F Y G S P S D Y E N L 1293.3 -
780 F Y G S P S D W E N L 1316.4 -
782 F Y G S P S E P E N L 1241.3 -
783 F Y G S P S E F E N L 1291.3 -
784 F Y G S P S E Y E N L 1307.3 -
785 F Y G S P S E W E N L 1330.4 -
787 F Y G S P S N P E N L 1226.4 -
788 F Y G S P S N F E N L 1276.4 -
789 F Y G S P S N Y E N L 1292.4 -
790 F Y G S P S N W E N L 1315.5 -
792 F Y G S P S Q P E N L 1240.4 -
793 F Y G S P S Q F E N L 1290.4 -
794 F Y G S P S Q Y E N L 1306.4 -
795 F Y G S P S Q W E N L 1329.5 -
797 F Y G S P S H P E N L 1249.4 -
798 F Y G S P S H F E N L 1299.4 -
799 F Y G S P S H Y E N L 1315.4 -
800 F Y G S P S H W E N L 1338.5 -
802 F Y A S P S M P E N L 1257.5 -

803 F Y A S P S M F E N L 1307.5 -
804 F Y A S P S M Y E N L 1323.5 -
805 F Y A S P S M W E N L 1346.6 -
807 F Y A S P S F P E N L 1273.4 -
808 F Y A S P S F F E N L 1323.4 -
809 F Y A S P S F Y E N L 1339.4 -
810 F Y A S P S F W E N L 1362.5 -
812 F Y A S P S Y P E N L 1289.4 -
813 F Y A S P S Y F E N L 1339.4 -
814 F Y A S P S Y Y E N L 1355.4 -
815 F Y A S P S Y W E N L 1378.5 -
817 F Y A S P S D P E N L 1241.3 -
818 F Y A S P S D F E N L 1291.3 -
819 F Y A S P S D Y E N L 1307.3 -
820 F Y A S P S D W E N L 1330.4 -
822 F Y A S P S E P E N L 1255.3 -
823 F Y A S P S E F E N L 1305.3 -
824 F Y A S P S E Y E N L 1321.3 -
825 F Y A S P S E W E N L 1344.4 -
827 F Y A S P S N P E N L 1240.4 -
828 F Y A S P S N F E N L 1290.4 -
829 F Y A S P S N Y E N L 1306.4 -
830 F Y A S P S N W E N L 1329.5 -
832 F Y A S P S Q P E N L 1254.4 -
833 F Y A S P S Q F E N L 1304.4 -
834 F Y A S P S Q Y E N L 1320.4 -
835 F Y A S P S Q W E N L 1343.5 -
837 F Y A S P S H P E N L 1263.4 -
838 F Y A S P S H F E N L 1313.4 -
839 F Y A S P S H Y E N L 1329.4 -
840 F Y A S P S H W E N L 1352.5 -
842 F F R S P S M P E N L 1326.6 -
843 F F R S P S M F E N L 1376.6 -
844 F F R S P S M Y E N L 1392.6 -
845 F F R S P S M W E N L 1415.7 -
847 F F R S P S F P E N L 1342.5 -

848 FFRSPSFFENL 1392.5 -
849 FFRSPSFYENL 1408.5 -
850 FFRSPSFWENL 1431.6 -
852 FFRSPSYOPENL 1358.5 -
853 FFRSPSYFENL 1408.5 -
854 FFRSPSYYYENL 1424.5 -
855 FFRSPSYWENL 1447.6 -
857 FFRSPSDPENL 1310.4 -
858 FFRSPSDFENL 1360.4 -
859 FFRSPSDYENL 1376.4 -
860 FFRSPSDWENL 1399.5 -
862 FFRSPSEOPENL 1324.4 -
863 FFRSPSEFENL 1374.4 -
864 FFRSPSEYENL 1390.4 -
865 FFRSPSEWENL 1413.5 -
867 FFRSPSNPENL 1309.5 -
868 FFRSPSNFENL 1359.5 -
869 FFRSPSNYENL 1375.5 -
870 FFRSPSNWENL 1398.6 -
872 FFRSPSQOPENL 1323.5 -
873 FFRSPSQFENL 1373.5 -
874 FFRSPSQYENL 1389.5 -
875 FFRSPSQWENL 1412.6 -
877 FFRSPSHPENL 1332.5 -
878 FFRSPSHFENL 1382.5 -
879 FFRSPSHYENL 1398.5 -
880 FFRSPSHWENL 1421.6 -
882 FFSSPSMPENL 1258.3 -
883 FFSSPSMFENL 1308.3 -
884 FFSSPSMYENL 1324.3 -
885 FFSSPSMWEENL 1347.4 -
887 FFSSPSFPENL 1274.2 -
888 FFSSPSFFENL 1324.2 -
889 FFSSPSFYENL 1340.2 -
890 FFSSPSFWENL 1363.3 -
892 FFSSPSYPENL 1290.2 -

893 FFSSPSYFENL 1340.2
894 FFSSPSYYENL 1356.2
895 FFSSPSYWENL 1379.3
897 FFSSPSDOPENL 1242.1
898 FFSSPSDFENL 1292.1
899 FFSSPSDYENL 1308.1
900 FFSSPSDWENL 1331.2
902 FFSSPSEOPENL 1256.1
903 FFSSPSEFENL 1306.1
904 FFSSPSEYENL 1322.1
905 FFSSPSEWENL 1345.2
907 FFSSPSNPENL 1241.2
908 FFSSPSNFENL 1291.2
909 FFSSPSNYENL 1307.2
910 FFSSPSNWENL 1330.3
912 FFSSPSQOPENL 1255.2
913 FFSSPSQFENL 1305.2
914 FFSSPSQYENL 1321.2
915 FFSSPSQWENL 1344.3
917 FFSSPSHOPENL 1264.2
918 FFSSPSHFENL 1314.2
919 FFSSPSHYENL 1330.2
920 FFSSPSHWENL 1353.3
922 FFTSPSMOPENL 1271.5
923 FFTSPSMFENL 1321.5
924 FFTSPSMYENL 1337.5
925 FFTSPSMWENL 1360.6
927 FFTSPSFOPENL 1287.4
928 FFTSPSFFENL 1337.4
929 FFTSPSFYENL 1353.4
930 FFTSPSFWENL 1376.5
932 FFTSPSYOPENL 1303.4
933 FFTSPSYFENL 1353.4
934 FFTSPSYYYENL 1369.4
935 FFTSPSYWENL 1392.5
937 FFTSPSDOPENL 1255.3

938 F F T S P S D F E N L	1305.3	-
939 F F T S P S D Y E N L	1321.3	-
940 F F T S P S D W E N L	1344.4	-
942 F F T S P S E P E N L	1269.3	-
943 F F T S P S E F E N L	1319.3	-
944 F F T S P S E Y E N L	1335.3	-
945 F F T S P S E W E N L	1358.4	-
947 F F T S P S N P E N L	1254.4	-
948 F F T S P S N F E N L	1304.4	-
949 F F T S P S N Y E N L	1320.4	-
950 F F T S P S N W E N L	1343.5	-
952 F F T S P S Q P E N L	1268.4	-
953 F F T S P S Q F E N L	1318.4	-
954 F F T S P S Q Y E N L	1334.4	-
955 F F T S P S Q W E N L	1357.5	-
957 F F T S P S H P E N L	1277.4	-
958 F F T S P S H F E N L	1327.4	-
959 F F T S P S H Y E N L	1343.4	-
960 F F T S P S H W E N L	1366.5	-
962 F F H S P S M P E N L	1307.6	-
963 F F H S P S M F E N L	1357.6	-
964 F F H S P S M Y E N L	1373.6	-
965 F F H S P S M W E N L	1396.7	-
967 F F H S P S F P E N L	1323.5	-
968 F F H S P S F F E N L	1373.5	-
969 F F H S P S F Y E N L	1389.5	-
970 F F H S P S F W E N L	1412.6	-
972 F F H S P S Y P E N L	1339.5	-
973 F F H S P S Y F E N L	1389.5	-
974 F F H S P S Y Y E N L	1405.5	-
975 F F H S P S Y W E N L	1428.6	-
977 F F H S P S D P E N L	1291.4	-
978 F F H S P S D F E N L	1341.4	-
979 F F H S P S D Y E N L	1357.4	-
980 F F H S P S D W E N L	1380.5	-
982 F F H S P S E P E N L	1305.4	-

983 F F H S P S E F E N L 1355.4 -
984 F F H S P S E Y E N L 1371.4 -
985 F F H S P S E W E N L 1394.5 -
987 F F H S P S N P E N L 1290.5 -
988 F F H S P S N F E N L 1340.5 -
989 F F H S P S N Y E N L 1356.5 -
990 F F H S P S N W E N L 1379.6 -
992 F F H S P S Q P E N L 1304.5 -
993 F F H S P S Q F E N L 1354.5 -
994 F F H S P S Q Y E N L 1370.5 -
995 F F H S P S Q W E N L 1393.6 -
997 F F H S P S H P E N L 1313.5 -
998 F F H S P S H F E N L 1363.5 -
999 F F H S P S H Y E N L 1379.5 -
1000 F F H S P S H W E N L 1402.6 -
1002 F F N S P S M P E N L 1284.6 -
1003 F F N S P S M F E N L 1334.6 -
1004 F F N S P S M Y E N L 1350.6 -
1005 F F N S P S M W E N L 1373.7 -
1007 F F N S P S F P E N L 1300.5 -
1008 F F N S P S F F E N L 1350.5 -
1009 F F N S P S F Y E N L 1366.5 -
1010 F F N S P S F W E N L 1389.6 -
1012 F F N S P S Y P E N L 1316.5 -
1013 F F N S P S Y F E N L 1366.5 -
1014 F F N S P S Y Y E N L 1382.5 -
1015 F F N S P S Y W E N L 1405.6 -
1017 F F N S P S D P E N L 1268.4 -
1018 F F N S P S D F E N L 1318.4 -
1019 F F N S P S D Y E N L 1334.4 -
1020 F F N S P S D W E N L 1357.5 -
1022 F F N S P S E P E N L 1282.4 -
1023 F F N S P S E F E N L 1332.4 -
1024 F F N S P S E Y E N L 1348.4 -
1025 F F N S P S E W E N L 1371.5 -
1027 F F N S P S N P E N L 1267.5 -

1028 F F N S P S N F E N L	1317.5	-
1029 F F N S P S N Y E N L	1333.5	-
1030 F F N S P S N W E N L	1356.6	-
1032 F F N S P S Q P E N L	1281.5	-
1033 F F N S P S Q F E N L	1331.5	-
1034 F F N S P S Q Y E N L	1347.5	-
1035 F F N S P S Q W E N L	1370.6	-
1037 F F N S P S H P E N L	1290.5	-
1038 F F N S P S H F E N L	1340.5	-
1039 F F N S P S H Y E N L	1356.5	-
1040 F F N S P S H W E N L	1379.6	-
1042 F F G S P S M P E N L	1227.5	-
1043 F F G S P S M F E N L	1277.5	-
1044 F F G S P S M Y E N L	1293.5	-
1045 F F G S P S M W E N L	1316.6	-
1047 F F G S P S F P E N L	1243.4	-
1048 F F G S P S F F E N L	1293.4	-
1049 F F G S P S F Y E N L	1309.4	-
1050 F F G S P S F W E N L	1332.5	-
1052 F F G S P S Y P E N L	1259.4	-
1053 F F G S P S Y F E N L	1309.4	-
1054 F F G S P S Y Y E N L	1325.4	-
1055 F F G S P S Y W E N L	1348.5	-
1057 F F G S P S D P E N L	1211.3	-
1058 F F G S P S D F E N L	1261.3	-
1059 F F G S P S D Y E N L	1277.3	-
1060 F F G S P S D W E N L	1300.4	-
1062 F F G S P S E P E N L	1225.3	-
1063 F F G S P S E F E N L	1275.3	-
1064 F F G S P S E Y E N L	1291.3	-
1065 F F G S P S E W E N L	1314.4	-
1067 F F G S P S N P E N L	1210.4	-
1068 F F G S P S N F E N L	1260.4	-
1069 F F G S P S N Y E N L	1276.4	-
1070 F F G S P S N W E N L	1299.5	-
1072 F F G S P S Q P E N L	1224.4	-

1073 F F G S P S Q F E N L 1274.4 -
1074 F F G S P S Q Y E N L 1290.4 -
1075 F F G S P S Q W E N L 1313.5 -
1077 F F G S P S H P E N L 1233.4 -
1078 F F G S P S H F E N L 1283.4 -
1079 F F G S P S H Y E N L 1299.4 -
1080 F F G S P S H W E N L 1322.5 -
1082 F F A S P S M P E N L 1241.5 -
1083 F F A S P S M F E N L 1291.5 -
1084 F F A S P S M Y E N L 1307.5 -
1085 F F A S P S M W E N L 1330.6 -
1087 F F A S P S F P E N L 1257.4 -
1088 F F A S P S F F E N L 1307.4 -
1089 F F A S P S F Y E N L 1323.4 -
1090 F F A S P S F W E N L 1346.5 -
1092 F F A S P S Y P E N L 1273.4 -
1093 F F A S P S Y F E N L 1323.4 -
1094 F F A S P S Y Y E N L 1339.4 -
1095 F F A S P S Y W E N L 1362.5 -
1097 F F A S P S D P E N L 1225.3 -
1098 F F A S P S D F E N L 1275.3 -
1099 F F A S P S D Y E N L 1291.3 -
1100 F F A S P S D W E N L 1314.4 -
1102 F F A S P S E P E N L 1239.3 -
1103 F F A S P S E F E N L 1289.3 -
1104 F F A S P S E Y E N L 1305.3 -
1105 F F A S P S E W E N L 1328.4 -
1107 F F A S P S N P E N L 1224.4 -
1108 F F A S P S N F E N L 1274.4 -
1109 F F A S P S N Y E N L 1290.4 -
1110 F F A S P S N W E N L 1313.5 -
1112 F F A S P S Q P E N L 1238.4 -
1113 F F A S P S Q F E N L 1288.4 -
1114 F F A S P S Q Y E N L 1304.4 -
1115 F F A S P S Q W E N L 1327.5 -
1117 F F A S P S H P E N L 1247.4 -

1118 F F A S P S H F E N L	1297.4	-
1119 F F A S P S H Y E N L	1313.4	-
1120 F F A S P S H W E N L	1336.5	-
1122 W Y R S P S M P E N L	1381.7	+
1123 W Y R S P S M F E N L	1431.7	+
1124 W Y R S P S M Y E N L	1447.7	++
1125 W Y R S P S M W E N L	1470.8	++
1127 W Y R S P S F P E N L	1397.6	++
1128 W Y R S P S F F E N L	1447.6	++
1129 W Y R S P S F Y E N L	1463.6	+++
1130 W Y R S P S F W E N L	1486.7	++
1132 W Y R S P S Y P E N L	1413.6	++
1133 W Y R S P S Y F E N L	1463.6	+
1134 W Y R S P S Y Y E N L	1479.6	++
1135 W Y R S P S Y W E N L	1502.7	+
1137 W Y R S P S D P E N L	1365.5	-
1138 W Y R S P S D F E N L	1415.5	-
1139 W Y R S P S D Y E N L	1431.5	-
1140 W Y R S P S D W E N L	1454.6	-
1142 W Y R S P S E P E N L	1379.5	-
1143 W Y R S P S E F E N L	1429.5	-
1144 W Y R S P S E Y E N L	1445.5	-
1145 W Y R S P S E W E N L	1468.6	-
1147 W Y R S P S N P E N L	1364.6	-
1148 W Y R S P S N F E N L	1414.6	-
1149 W Y R S P S N Y E N L	1430.6	-
1150 W Y R S P S N W E N L	1453.7	-
1152 W Y R S P S Q P E N L	1378.6	-
1153 W Y R S P S Q F E N L	1428.6	-
1154 W Y R S P S Q Y E N L	1444.6	-
1155 W Y R S P S Q W E N L	1467.7	-
1157 W Y R S P S H P E N L	1387.6	-
1158 W Y R S P S H F E N L	1437.6	-
1159 W Y R S P S H Y E N L	1453.6	-
1160 W Y R S P S H W E N L	1476.7	-
1162 W Y S S P S M P E N L	1313.4	-

1163	W Y S S P S M F E N L	1363.4	-
1164	W Y S S P S M Y E N L	1379.4	-
1165	W Y S S P S M W E N L	1402.5	-
1167	W Y S S P S F P E N L	1329.3	-
1168	W Y S S P S F F E N L	1379.3	-
1169	W Y S S P S F Y E N L	1395.3	-
1170	W Y S S P S F W E N L	1418.4	-
1172	W Y S S P S Y P E N L	1345.3	-
1173	W Y S S P S Y F E N L	1395.3	-
1174	W Y S S P S Y Y E N L	1411.3	-
1175	W Y S S P S Y W E N L	1434.4	-
1177	W Y S S P S D P E N L	1297.2	-
1178	W Y S S P S D F E N L	1347.2	-
1179	W Y S S P S D Y E N L	1363.2	-
1180	W Y S S P S D W E N L	1386.3	-
1182	W Y S S P S E P E N L	1311.2	-
1183	W Y S S P S E F E N L	1361.2	-
1184	W Y S S P S E Y E N L	1377.2	-
1185	W Y S S P S E W E N L	1400.3	-
1187	W Y S S P S N P E N L	1296.3	-
1188	W Y S S P S N F E N L	1346.3	-
1189	W Y S S P S N Y E N L	1362.3	-
1190	W Y S S P S N W E N L	1385.4	-
1192	W Y S S P S Q P E N L	1310.3	-
1193	W Y S S P S Q F E N L	1360.3	-
1194	W Y S S P S Q Y E N L	1376.3	-
1195	W Y S S P S Q W E N L	1399.4	-
1197	W Y S S P S H P E N L	1319.3	-
1198	W Y S S P S H F E N L	1369.3	-
1199	W Y S S P S H Y E N L	1385.3	-
1200	W Y S S P S H W E N L	1408.4	-
1202	W Y T S P S M P E N L	1326.6	+
1203	W Y T S P S M F E N L	1376.6	+
1204	W Y T S P S M Y E N L	1392.6	+
1205	W Y T S P S M W E N L	1415.7	+
1207	W Y T S P S F P E N L	1342.5	+

1208 W Y T S P S F F E N L	1392.5	+
1209 W Y T S P S F Y E N L	1408.5	+
1210 W Y T S P S F W E N L	1431.6	+
1212 W Y T S P S Y P E N L	1358.5	++
1213 W Y T S P S Y F E N L	1408.5	+
1214 W Y T S P S Y Y E N L	1424.5	+
1215 W Y T S P S Y W E N L	1447.6	+
1217 W Y T S P S D P E N L	1310.4	-
1218 W Y T S P S D F E N L	1360.4	-
1219 W Y T S P S D Y E N L	1376.4	-
1220 W Y T S P S D W E N L	1399.5	-
1222 W Y T S P S E P E N L	1324.4	-
1223 W Y T S P S E F E N L	1374.4	-
1224 W Y T S P S E Y E N L	1390.4	-
1225 W Y T S P S E W E N L	1413.5	-
1227 W Y T S P S N P E N L	1309.5	-
1228 W Y T S P S N F E N L	1359.5	-
1229 W Y T S P S N Y E N L	1375.5	-
1230 W Y T S P S N W E N L	1398.6	-
1232 W Y T S P S Q P E N L	1323.5	-
1233 W Y T S P S Q F E N L	1373.5	-
1234 W Y T S P S Q Y E N L	1389.5	-
1235 W Y T S P S Q W E N L	1412.6	-
1237 W Y T S P S H P E N L	1332.5	+
1238 W Y T S P S H F E N L	1382.5	+
1239 W Y T S P S H Y E N L	1398.5	+
1240 W Y T S P S H W E N L	1421.6	+
1242 W Y H S P S M P E N L	1362.7	-
1243 W Y H S P S M F E N L	1412.7	-
1244 W Y H S P S M Y E N L	1428.7	-
1245 W Y H S P S M W E N L	1451.8	-
1247 W Y H S P S F P E N L	1378.6	-
1248 W Y H S P S F F E N L	1428.6	-
1249 W Y H S P S F Y E N L	1444.6	-
1250 W Y H S P S F W E N L	1467.7	-
1252 W Y H S P S Y P E N L	1394.6	-

1253	W Y H S P S Y F E N L	1444.6	-
1254	W Y H S P S Y Y E N L	1460.6	-
1255	W Y H S P S Y W E N L	1483.7	-
1257	W Y H S P S D P E N L	1346.5	-
1258	W Y H S P S D F E N L	1396.5	-
1259	W Y H S P S D Y E N L	1412.5	-
1260	W Y H S P S D W E N L	1435.6	-
1262	W Y H S P S E P E N L	1360.5	-
1263	W Y H S P S E F E N L	1410.5	-
1264	W Y H S P S E Y E N L	1426.5	-
1265	W Y H S P S E W E N L	1449.6	-
1267	W Y H S P S N P E N L	1345.6	-
1268	W Y H S P S N F E N L	1395.6	-
1269	W Y H S P S N Y E N L	1411.6	-
1270	W Y H S P S N W E N L	1434.7	-
1272	W Y H S P S Q P E N L	1359.6	-
1273	W Y H S P S Q F E N L	1409.6	-
1274	W Y H S P S Q Y E N L	1425.6	-
1275	W Y H S P S Q W E N L	1448.7	-
1277	W Y H S P S H P E N L	1368.6	-
1278	W Y H S P S H F E N L	1418.6	-
1279	W Y H S P S H Y E N L	1434.6	-
1280	W Y H S P S H W E N L	1457.7	-
1282	W Y N S P S M P E N L	1339.7	-
1283	W Y N S P S M F E N L	1389.7	-
1284	W Y N S P S M Y E N L	1405.7	-
1285	W Y N S P S M W E N L	1428.8	-
1287	W Y N S P S F P E N L	1355.6	-
1288	W Y N S P S F F E N L	1405.6	-
1289	W Y N S P S F Y E N L	1421.6	-
1290	W Y N S P S F W E N L	1444.7	-
1292	W Y N S P S Y P E N L	1371.6	-
1293	W Y N S P S Y F E N L	1421.6	-
1294	W Y N S P S Y Y E N L	1437.6	-
1295	W Y N S P S Y W E N L	1460.7	-
1297	W Y N S P S D P E N L	1323.5	-

1298	W Y N S P S D F E N L	1373.5	-
1299	W Y N S P S D Y E N L	1389.5	-
1300	W Y N S P S D W E N L	1412.6	-
1302	W Y N S P S E P E N L	1337.5	-
1303	W Y N S P S E F E N L	1387.5	-
1304	W Y N S P S E Y E N L	1403.5	-
1305	W Y N S P S E W E N L	1426.6	-
1307	W Y N S P S N P E N L	1322.6	-
1308	W Y N S P S N F E N L	1372.6	-
1309	W Y N S P S N Y E N L	1388.6	-
1310	W Y N S P S N W E N L	1411.7	-
1312	W Y N S P S Q P E N L	1336.6	-
1313	W Y N S P S Q F E N L	1386.6	-
1314	W Y N S P S Q Y E N L	1402.6	-
1315	W Y N S P S Q W E N L	1425.7	-
1317	W Y N S P S H P E N L	1345.6	-
1318	W Y N S P S H F E N L	1395.6	-
1319	W Y N S P S H Y E N L	1411.6	-
1320	W Y N S P S H W E N L	1434.7	-
1322	W Y G S P S M P E N L	1282.6	-
1323	W Y G S P S M F E N L	1332.6	-
1324	W Y G S P S M Y E N L	1348.6	-
1325	W Y G S P S M W E N L	1371.7	-
1327	W Y G S P S F P E N L	1298.5	-
1328	W Y G S P S F F E N L	1348.5	-
1329	W Y G S P S F Y E N L	1364.5	-
1330	W Y G S P S F W E N L	1387.6	-
1332	W Y G S P S Y P E N L	1314.5	-
1333	W Y G S P S Y F E N L	1364.5	-
1334	W Y G S P S Y Y E N L	1380.5	-
1335	W Y G S P S Y W E N L	1403.6	-
1337	W Y G S P S D P E N L	1266.4	-
1338	W Y G S P S D F E N L	1316.4	-
1339	W Y G S P S D Y E N L	1332.4	-
1340	W Y G S P S D W E N L	1355.5	-
1342	W Y G S P S E P E N L	1280.4	-

1343 W Y G S P S E F E N L 1330.4 -
1344 W Y G S P S E Y E N L 1346.4 -
1345 W Y G S P S E W E N L 1369.5 -
1347 W Y G S P S N P E N L 1265.5 -
1348 W Y G S P S N F E N L 1315.5 -
1349 W Y G S P S N Y E N L 1331.5 -
1350 W Y G S P S N W E N L 1354.6 -
1352 W Y G S P S Q P E N L 1279.5 -
1353 W Y G S P S Q F E N L 1329.5 -
1354 W Y G S P S Q Y E N L 1345.5 -
1355 W Y G S P S Q W E N L 1368.6 -
1357 W Y G S P S H P E N L 1288.5 -
1358 W Y G S P S H F E N L 1338.5 -
1359 W Y G S P S H Y E N L 1354.5 -
1360 W Y G S P S H W E N L 1377.6 -
1362 W Y A S P S M P E N L 1296.6 -
1363 W Y A S P S M F E N L 1346.6 -
1364 W Y A S P S M Y E N L 1362.6 -
1365 W Y A S P S M W E N L 1385.7 -
1367 W Y A S P S F P E N L 1312.5 -
1368 W Y A S P S F F E N L 1362.5 -
1369 W Y A S P S F Y E N L 1378.5 -
1370 W Y A S P S F W E N L 1401.6 -
1372 W Y A S P S Y P E N L 1328.5 -
1373 W Y A S P S Y F E N L 1378.5 -
1374 W Y A S P S Y Y E N L 1394.5 -
1375 W Y A S P S Y W E N L 1417.6 -
1377 W Y A S P S D P E N L 1280.4 -
1378 W Y A S P S D F E N L 1330.4 -
1379 W Y A S P S D Y E N L 1346.4 -
1380 W Y A S P S D W E N L 1369.5 -
1382 W Y A S P S E P E N L 1294.4 -
1383 W Y A S P S E F E N L 1344.4 -
1384 W Y A S P S E Y E N L 1360.4 -
1385 W Y A S P S E W E N L 1383.5 -
1387 W Y A S P S N P E N L 1279.5 -

1388	W Y A S P S N F E N L	1329.5
1389	W Y A S P S N Y E N L	1345.5
1390	W Y A S P S N W E N L	1368.6
1392	W Y A S P S Q P E N L	1293.5
1393	W Y A S P S Q F E N L	1343.5
1394	W Y A S P S Q Y E N L	1359.5
1395	W Y A S P S Q W E N L	1382.6
1397	W Y A S P S H P E N L	1302.5
1398	W Y A S P S H F E N L	1352.5
1399	W Y A S P S H Y E N L	1368.5
1400	W Y A S P S H W E N L	1391.6
1402	W F R S P S M P E N L	1365.7
1403	W F R S P S M F E N L	1415.7
1404	W F R S P S M Y E N L	1431.7
1405	W F R S P S M W E N L	1454.8
1407	W F R S P S F P E N L	1381.6
1408	W F R S P S F F E N L	1431.6
1409	W F R S P S F Y E N L	1447.6
1410	W F R S P S F W E N L	1470.7
1412	W F R S P S Y P E N L	1397.6
1413	W F R S P S Y F E N L	1447.6
1414	W F R S P S Y Y E N L	1463.6
1415	W F R S P S Y W E N L	1486.7
1417	W F R S P S D P E N L	1349.5
1418	W F R S P S D F E N L	1399.5
1419	W F R S P S D Y E N L	1415.5
1420	W F R S P S D W E N L	1438.6
1422	W F R S P S E P E N L	1363.5
1423	W F R S P S E F E N L	1413.5
1424	W F R S P S E Y E N L	1429.5
1425	W F R S P S E W E N L	1452.6
1427	W F R S P S N P E N L	1348.6
1428	W F R S P S N F E N L	1398.6
1429	W F R S P S N Y E N L	1414.6
1430	W F R S P S N W E N L	1437.7
1432	W F R S P S O P E N L	1362.6

1433 WFRSPSQFENL	1412.6	-
1434 WFRSPSQYENL	1428.6	-
1435 WFRSPSQWENL	1451.7	-
1437 WFRSPSHPENL	1371.6	-
1438 WFRSPSHFENL	1421.6	-
1439 WFRSPSHYENL	1437.6	-
1440 WFRSPSHWENL	1460.7	-
1442 WFSSPSMPENL	1297.4	-
1443 WFSSPSMFENL	1347.4	-
1444 WFSSPSMYENL	1363.4	-
1445 WFSSPSMWENL	1386.5	-
1447 WFSSPSFPENL	1313.3	-
1448 WFSSPSFFENL	1363.3	-
1449 WFSSPSFYENL	1379.3	-
1450 WFSSPSFWENL	1402.4	-
1452 WFSSPSYPENL	1329.3	-
1453 WFSSPSYFENL	1379.3	-
1454 WFSSPSYYENL	1395.3	-
1455 WFSSPSYWENL	1418.4	-
1457 WFSSPSDOPENL	1281.2	-
1458 WFSSPSDFENL	1331.2	-
1459 WFSSPSDYENL	1347.2	-
1460 WFSSPSDWENL	1370.3	-
1462 WFSSPSEOPENL	1295.2	-
1463 WFSSPSEFENL	1345.2	-
1464 WFSSPSEYENL	1361.2	-
1465 WFSSPSEWENL	1384.3	-
1467 WFSSPSNPENL	1280.3	-
1468 WFSSPSNFENL	1330.3	-
1469 WFSSPSNYENL	1346.3	-
1470 WFSSPSNWENL	1369.4	-
1472 WFSSPSQOPENL	1294.3	-
1473 WFSSPSQFENL	1344.3	-
1474 WFSSPSQYENL	1360.3	-
1475 WFSSPSQWENL	1383.4	-
1477 WFSSPSHPENL	1303.3	-

1478	W F S S P S H F E N L	1353.3	-
1479	W F S S P S H Y E N L	1369.3	-
1480	W F S S P S H W E N L	1392.4	-
1482	W F T S P S M P E N L	1310.6	-
1483	W F T S P S M F E N L	1360.6	-
1484	W F T S P S M Y E N L	1376.6	-
1485	W F T S P S M W E N L	1399.7	-
1487	W F T S P S F P E N L	1326.5	-
1488	W F T S P S F F E N L	1376.5	-
1489	W F T S P S F Y E N L	1392.5	-
1490	W F T S P S F W E N L	1415.6	-
1492	W F T S P S Y P E N L	1342.5	-
1493	W F T S P S Y F E N L	1392.5	-
1494	W F T S P S Y Y E N L	1408.5	-
1495	W F T S P S Y W E N L	1431.6	-
1497	W F T S P S D P E N L	1294.4	-
1498	W F T S P S D F E N L	1344.4	-
1499	W F T S P S D Y E N L	1360.4	-
1500	W F T S P S D W E N L	1383.5	-
1502	W F T S P S E P E N L	1308.4	-
1503	W F T S P S E F E N L	1358.4	-
1504	W F T S P S E Y E N L	1374.4	-
1505	W F T S P S E W E N L	1397.5	-
1507	W F T S P S N P E N L	1293.5	-
1508	W F T S P S N F E N L	1343.5	-
1509	W F T S P S N Y E N L	1359.5	-
1510	W F T S P S N W E N L	1382.6	-
1512	W F T S P S Q P E N L	1307.5	-
1513	W F T S P S Q F E N L	1357.5	-
1514	W F T S P S Q Y E N L	1373.5	-
1515	W F T S P S Q W E N L	1396.6	-
1517	W F T S P S H P E N L	1316.5	-
1518	W F T S P S H F E N L	1366.5	-
1519	W F T S P S H Y E N L	1382.5	-
1520	W F T S P S H W E N L	1405.6	-
1522	W F H S P S M P E N L	1346.7	-

1523	WFHSPSMFENL	1396.7	-
1524	WFHSPSMYENL	1412.7	-
1525	WFHSPSMWENL	1435.8	-
1527	WFHSPSFOPENL	1362.6	-
1528	WFHSPSFFENL	1412.6	-
1529	WFHSPSFYENL	1428.6	-
1530	WFHSPSFWENL	1451.7	-
1532	WFHSPSYOPENL	1378.6	-
1533	WFHSPSYFENL	1428.6	-
1534	WFHSPSYYENL	1444.6	-
1535	WFHSPSYWENL	1467.7	-
1537	WFHSPSDPENL	1330.5	-
1538	WFHSPSDFENL	1380.5	-
1539	WFHSPSDYENL	1396.5	-
1540	WFHSPSDWENL	1419.6	-
1542	WFHSPSEOPENL	1344.5	-
1543	WFHSPSEFENL	1394.5	-
1544	WFHSPSEYENL	1410.5	-
1545	WFHSPSEWENL	1433.6	-
1547	WFHSPSNPENL	1329.6	-
1548	WFHSPSNFENL	1379.6	-
1549	WFHSPSNYENL	1395.6	-
1550	WFHSPSNWENL	1418.7	-
1552	WFHSPSQOPENL	1343.6	-
1553	WFHSPSQFENL	1393.6	-
1554	WFHSPSQYENL	1409.6	-
1555	WFHSPSQWENL	1432.7	-
1557	WFHSPSHOPENL	1352.6	-
1558	WFHSPSHFENL	1402.6	-
1559	WFHSPSHYENL	1418.6	-
1560	WFHSPSHWENL	1441.7	-
1562	WFNSPSMPENL	1323.7	-
1563	WFNSPSMFENL	1373.7	-
1564	WFNSPSMYENL	1389.7	-
1565	WFNSPSMWENL	1412.8	-
1567	WFNSPSFPENL	1339.6	-

1568	WFNSPSFFENL	1389.6	-
1569	WFNSPSFYENL	1405.6	-
1570	WFNSPSFWENL	1428.7	-
1572	WFNSPSYPENL	1355.6	-
1573	WFNSPSYFENL	1405.6	-
1574	WFNSPSYYENL	1421.6	-
1575	WFNSPSYWENL	1444.7	-
1577	WFNSPSDOPENL	1307.5	-
1578	WFNSPSDFENL	1357.5	-
1579	WFNSPSDYENL	1373.5	-
1580	WFNSPSDWENL	1396.6	-
1582	WFNSPSEOPENL	1321.5	-
1583	WFNSPSEFENL	1371.5	-
1584	WFNSPSEYENL	1387.5	-
1585	WFNSPSEWENL	1410.6	-
1587	WFNSPSNPENL	1306.6	-
1588	WFNSPSNFENL	1356.6	-
1589	WFNSPSNYENL	1372.6	-
1590	WFNSPSNWENL	1395.7	-
1592	WFNSPSQOPENL	1320.6	-
1593	WFNSPSQFENL	1370.6	-
1594	WFNSPSQYENL	1386.6	-
1595	WFNSPSQWENL	1409.7	-
1597	WFNSPSHPENL	1329.6	-
1598	WFNSPSHFENL	1379.6	-
1599	WFNSPSHYENL	1395.6	-
1600	WFNSPSHWENL	1418.7	-
1602	WFGSPSMOPENL	1266.6	-
1603	WFGSPSMFENL	1316.6	-
1604	WFGSPSMYENL	1332.6	-
1605	WFGSPSMWENL	1355.7	-
1607	WFGSPSFPENL	1282.5	-
1608	WFGSPSFFENL	1332.5	-
1609	WFGSPSFYENL	1348.5	-
1610	WFGSPSFWENL	1371.6	-
1612	WFGSPSYOPENL	1298.5	-

1613	WFGSPSYFENL	1348.5	-
1614	WFGSPSYYENL	1364.5	-
1615	WFGSPSYWENL	1387.6	-
1617	WFGSPSDPENL	1250.4	-
1618	WFGSPSDFENL	1300.4	-
1619	WFGSPSDYENL	1316.4	-
1620	WFGSPSDWENL	1339.5	-
1622	WFGSPSEOPENL	1264.4	-
1623	WFGSPSEFENL	1314.4	-
1624	WFGSPSEYENL	1330.4	-
1625	WFGSPSEWENL	1353.5	-
1627	WFGSPSNPENL	1249.5	-
1628	WFGSPSNFENL	1299.5	-
1629	WFGSPSNYENL	1315.5	-
1630	WFGSPSNWENL	1338.6	-
1632	WFGSPSQPENL	1263.5	-
1633	WFGSPSQFENL	1313.5	-
1634	WFGSPSQYENL	1329.5	-
1635	WFGSPSQWENL	1352.6	-
1637	WFGSPSHPENL	1272.5	-
1638	WFGSPSHFENL	1322.5	-
1639	WFGSPSHYENL	1338.5	-
1640	WFGSPSHWENL	1361.6	-
1642	WFASPSMPENL	1280.6	-
1643	WFASPSMFENL	1330.6	-
1644	WFASPSMYENL	1346.6	-
1645	WFASPSMWENL	1369.7	-
1647	WFASPSFPENL	1296.5	-
1648	WFASPSFFENL	1346.5	-
1649	WFASPSFYENL	1362.5	-
1650	WFASPSFWENL	1385.6	-
1652	WFASPSYPENL	1312.5	-
1653	WFASPSYFENL	1362.5	-
1654	WFASPSYYENL	1378.5	-
1655	WFASPSYWENL	1401.6	-
1657	WFASPSDPENL	1264.4	-

1658	WFASPSDFENL	1314.4	-
1659	WFASPSDYENL	1330.4	-
1660	WFASPSDWENL	1353.5	-
1662	WFASPSEOPENL	1278.4	-
1663	WFASPSEFENL	1328.4	-
1664	WFASPSEYENL	1344.4	-
1665	WFASPSEWENL	1367.5	-
1667	WFASPSNPENL	1263.5	-
1668	WFASPSNFENL	1313.5	-
1669	WFASPSNYENL	1329.5	-
1670	WFASPSNWENL	1352.6	-
1672	WFASPSQOPENL	1277.5	-
1673	WFASPSQFENL	1327.5	-
1674	WFASPSQYENL	1343.5	-
1675	WFASPSQWENL	1366.6	-
1677	WFASPSHPENL	1286.5	-
1678	WFASPSHFENL	1336.5	-
1679	WFASPSHYENL	1352.5	-
1680	WFASPSHWENL	1375.6	-
1682	MYRSPSMOPENL	1326.7	-
1683	MYRSPSMFENL	1376.7	-
1684	MYRSPSMYENL	1392.7	-
1685	MYRSPSMWENL	1415.8	-
1687	MYRSPSFOPENL	1342.6	-
1688	MYRSPSFFENL	1392.6	-
1689	MYRSPSFYENL	1408.6	-
1690	MYRSPSFWENL	1431.7	-
1692	MYRSPSYOPENL	1358.6	-
1693	MYRSPSYFENL	1408.6	-
1694	MYRSPSYYENL	1424.6	-
1695	MYRSPSYWENL	1447.7	-
1697	MYRSPSDOPENL	1310.5	-
1698	MYRSPSDFENL	1360.5	-
1699	MYRSPSDYENL	1376.5	-
1700	MYRSPSDWENL	1399.6	-
1702	MYRSPSEOPENL	1324.5	-

1703	M Y R S P S E F E N L	1374.5	-
1704	M Y R S P S E Y E N L	1390.5	-
1705	M Y R S P S E W E N L	1413.6	-
1707	M Y R S P S N P E N L	1309.6	-
1708	M Y R S P S N F E N L	1359.6	-
1709	M Y R S P S N Y E N L	1375.6	-
1710	M Y R S P S N W E N L	1398.7	-
1712	M Y R S P S Q P E N L	1323.6	-
1713	M Y R S P S Q F E N L	1373.6	-
1714	M Y R S P S Q Y E N L	1389.6	-
1715	M Y R S P S Q W E N L	1412.7	-
1717	M Y R S P S H P E N L	1332.6	-
1718	M Y R S P S H F E N L	1382.6	-
1719	M Y R S P S H Y E N L	1398.6	-
1720	M Y R S P S H W E N L	1421.7	-
1722	M Y S S P S M P E N L	1258.4	-
1723	M Y S S P S M F E N L	1308.4	-
1724	M Y S S P S M Y E N L	1324.4	-
1725	M Y S S P S M W E N L	1347.5	-
1727	M Y S S P S F P E N L	1274.3	-
1728	M Y S S P S F F E N L	1324.3	-
1729	M Y S S P S F Y E N L	1340.3	-
1730	M Y S S P S F W E N L	1363.4	-
1732	M Y S S P S Y P E N L	1290.3	-
1733	M Y S S P S Y F E N L	1340.3	-
1734	M Y S S P S Y Y E N L	1356.3	-
1735	M Y S S P S Y W E N L	1379.4	-
1737	M Y S S P S D P E N L	1242.2	-
1738	M Y S S P S D F E N L	1292.2	-
1739	M Y S S P S D Y E N L	1308.2	-
1740	M Y S S P S D W E N L	1331.3	-
1742	M Y S S P S E P E N L	1256.2	-
1743	M Y S S P S E F E N L	1306.2	-
1744	M Y S S P S E Y E N L	1322.2	-
1745	M Y S S P S E W E N L	1345.3	-
1747	M Y S S P S N P E N L	1241.3	-

1748	MYSSPSNFENL	1291.3	-
1749	MYSSPSNYENL	1307.3	-
1750	MYSSPSNWENL	1330.4	-
1752	MYSSPSQFENL	1255.3	-
1753	MYSSPSQFENL	1305.3	-
1754	MYSSPSQYENL	1321.3	-
1755	MYSSPSQWENL	1344.4	-
1757	MYSSPSHPENL	1264.3	-
1758	MYSSPSHFENL	1314.3	-
1759	MYSSPSHYENL	1330.3	-
1760	MYSSPSHWENL	1353.4	-
1762	MYTSPSMFENL	1271.6	-
1763	MYTSPSMFENL	1321.6	-
1764	MYTSPSMYENL	1337.6	-
1765	MYTSPSMWENL	1360.7	-
1767	MYTSPSFPENL	1287.5	-
1768	MYTSPSFFENL	1337.5	-
1769	MYTSPSFYENL	1353.5	-
1770	MYTSPSFWENL	1376.6	-
1772	MYTSPSYFENL	1303.5	-
1773	MYTSPSYFENL	1353.5	-
1774	MYTSPSYYENL	1369.5	-
1775	MYTSPSYWENL	1392.6	-
1777	MYTSPSDPENL	1255.4	-
1778	MYTSPSDFENL	1305.4	-
1779	MYTSPSDYENL	1321.4	-
1780	MYTSPSDWENL	1344.5	-
1782	MYTSPSEFENL	1269.4	-
1783	MYTSPSEFENL	1319.4	-
1784	MYTSPSEYENL	1335.4	-
1785	MYTSPSEWENL	1358.5	-
1787	MYTSPSNPENL	1254.5	-
1788	MYTSPSNFENL	1304.5	-
1789	MYTSPSNYENL	1320.5	-
1790	MYTSPSNWENL	1343.6	-
1792	MYTSPSQFENL	1268.5	-

1793	MYTSPSQFENL	1318.5	-
1794	MYTSPSQYENL	1334.5	-
1795	MYTSPSQWENL	1357.6	-
1797	MYTSPSHPENL	1277.5	-
1798	MYTSPSHFENL	1327.5	-
1799	MYTSPSHYENL	1343.5	-
1800	MYTSPSHWENL	1366.6	-
1802	MYHSPSMPENL	1307.7	-
1803	MYHSPSMFENL	1357.7	-
1804	MYHSPSMYENL	1373.7	-
1805	MYHSPSMWENL	1396.8	-
1807	MYHSPSFPENL	1323.6	-
1808	MYHSPSFFENL	1373.6	-
1809	MYHSPSFYENL	1389.6	-
1810	MYHSPSFWENL	1412.7	-
1812	MYHSPSYPENL	1339.6	-
1813	MYHSPSYFENL	1389.6	-
1814	MYHSPSYYENL	1405.6	-
1815	MYHSPSYWENL	1428.7	-
1817	MYHSPSDPENL	1291.5	-
1818	MYHSPSDFENL	1341.5	-
1819	MYHSPSDYENL	1357.5	-
1820	MYHSPSDWENL	1380.6	-
1822	MYHSPSEPENL	1305.5	-
1823	MYHSPSEFENL	1355.5	-
1824	MYHSPSEYENL	1371.5	-
1825	MYHSPSEWENL	1394.6	-
1827	MYHSPSNPENL	1290.6	-
1828	MYHSPSNFENL	1340.6	-
1829	MYHSPSNYENL	1356.6	-
1830	MYHSPSNWENL	1379.7	-
1832	MYHSPSQPENL	1304.6	-
1833	MYHSPSQFENL	1354.6	-
1834	MYHSPSQYENL	1370.6	-
1835	MYHSPSQWENL	1393.7	-
1837	MYHSPSHPENL	1313.6	-

1838	M Y H S P S H F E N L	1363.6	-
1839	M Y H S P S H Y E N L	1379.6	-
1840	M Y H S P S H W E N L	1402.7	-
1842	M Y N S P S M P E N L	1284.7	-
1843	M Y N S P S M F E N L	1334.7	-
1844	M Y N S P S M Y E N L	1350.7	-
1845	M Y N S P S M W E N L	1373.8	-
1847	M Y N S P S F P E N L	1300.6	-
1848	M Y N S P S F F E N L	1350.6	-
1849	M Y N S P S F Y E N L	1366.6	-
1850	M Y N S P S F W E N L	1389.7	-
1852	M Y N S P S Y P E N L	1316.6	-
1853	M Y N S P S Y F E N L	1366.6	-
1854	M Y N S P S Y Y E N L	1382.6	-
1855	M Y N S P S Y W E N L	1405.7	-
1857	M Y N S P S D P E N L	1268.5	-
1858	M Y N S P S D F E N L	1318.5	-
1859	M Y N S P S D Y E N L	1334.5	-
1860	M Y N S P S D W E N L	1357.6	-
1862	M Y N S P S E P E N L	1282.5	-
1863	M Y N S P S E F E N L	1332.5	-
1864	M Y N S P S E Y E N L	1348.5	-
1865	M Y N S P S E W E N L	1371.6	-
1867	M Y N S P S N P E N L	1267.6	-
1868	M Y N S P S N F E N L	1317.6	-
1869	M Y N S P S N Y E N L	1333.6	-
1870	M Y N S P S N W E N L	1356.7	-
1872	M Y N S P S Q P E N L	1281.6	-
1873	M Y N S P S Q F E N L	1331.6	-
1874	M Y N S P S Q Y E N L	1347.6	-
1875	M Y N S P S Q W E N L	1370.7	-
1877	M Y N S P S H P E N L	1290.6	-
1878	M Y N S P S H F E N L	1340.6	-
1879	M Y N S P S H Y E N L	1356.6	-
1880	M Y N S P S H W E N L	1379.7	-
1882	M Y G S P S M P E N L	1227.6	-

1883	M Y G S P S M F E N L	1277.6	-
1884	M Y G S P S M Y E N L	1293.6	-
1885	M Y G S P S M W E N L	1316.7	-
1887	M Y G S P S F P E N L	1243.5	-
1888	M Y G S P S F F E N L	1293.5	-
1889	M Y G S P S F Y E N L	1309.5	-
1890	M Y G S P S F W E N L	1332.6	-
1892	M Y G S P S Y P E N L	1259.5	-
1893	M Y G S P S Y F E N L	1309.5	-
1894	M Y G S P S Y Y E N L	1325.5	-
1895	M Y G S P S Y W E N L	1348.6	-
1897	M Y G S P S D P E N L	1211.4	-
1898	M Y G S P S D F E N L	1261.4	-
1899	M Y G S P S D Y E N L	1277.4	-
1900	M Y G S P S D W E N L	1300.5	-
1902	M Y G S P S E P E N L	1225.4	-
1903	M Y G S P S E F E N L	1275.4	-
1904	M Y G S P S E Y E N L	1291.4	-
1905	M Y G S P S E W E N L	1314.5	-
1907	M Y G S P S N P E N L	1210.5	-
1908	M Y G S P S N F E N L	1260.5	-
1909	M Y G S P S N Y E N L	1276.5	-
1910	M Y G S P S N W E N L	1299.6	-
1912	M Y G S P S Q P E N L	1224.5	-
1913	M Y G S P S Q F E N L	1274.5	-
1914	M Y G S P S Q Y E N L	1290.5	-
1915	M Y G S P S Q W E N L	1313.6	-
1917	M Y G S P S H P E N L	1233.5	-
1918	M Y G S P S H F E N L	1283.5	-
1919	M Y G S P S H Y E N L	1299.5	-
1920	M Y G S P S H W E N L	1322.6	-
1922	M Y A S P S M P E N L	1241.6	-
1923	M Y A S P S M F E N L	1291.6	-
1924	M Y A S P S M Y E N L	1307.6	-
1925	M Y A S P S M W E N L	1330.7	-
1927	M Y A S P S F P E N L	1257.5	-

1928	M Y A S P S F F E N L	1307.5	-
1929	M Y A S P S F Y E N L	1323.5	-
1930	M Y A S P S F W E N L	1346.6	-
1932	M Y A S P S Y P E N L	1273.5	-
1933	M Y A S P S Y F E N L	1323.5	-
1934	M Y A S P S Y Y E N L	1339.5	-
1935	M Y A S P S Y W E N L	1362.6	-
1937	M Y A S P S D P E N L	1225.4	-
1938	M Y A S P S D F E N L	1275.4	-
1939	M Y A S P S D Y E N L	1291.4	-
1940	M Y A S P S D W E N L	1314.5	-
1942	M Y A S P S E P E N L	1239.4	-
1943	M Y A S P S E F E N L	1289.4	-
1944	M Y A S P S E Y E N L	1305.4	-
1945	M Y A S P S E W E N L	1328.5	-
1947	M Y A S P S N P E N L	1224.5	-
1948	M Y A S P S N F E N L	1274.5	-
1949	M Y A S P S N Y E N L	1290.5	-
1950	M Y A S P S N W E N L	1313.6	-
1952	M Y A S P S Q P E N L	1238.5	-
1953	M Y A S P S Q F E N L	1288.5	-
1954	M Y A S P S Q Y E N L	1304.5	-
1955	M Y A S P S Q W E N L	1327.6	-
1957	M Y A S P S H P E N L	1247.5	-
1958	M Y A S P S H F E N L	1297.5	-
1959	M Y A S P S H Y E N L	1313.5	-
1960	M Y A S P S H W E N L	1336.6	-
1962	M F R S P S M P E N L	1310.7	-
1963	M F R S P S M F E N L	1360.7	-
1964	M F R S P S M Y E N L	1376.7	-
1965	M F R S P S M W E N L	1399.8	-
1967	M F R S P S F P E N L	1326.6	-
1968	M F R S P S F F E N L	1376.6	-
1969	M F R S P S F Y E N L	1392.6	-
1970	M F R S P S F W E N L	1415.7	-
1972	M F R S P S Y P E N L	1342.6	-

1973 MFRSPSYFENL	1392.6	-
1974 MFRSPSYYENL	1408.6	-
1975 MFRSPSYWENL	1431.7	-
1977 MFRSPSDPENL	1294.5	-
1978 MFRSPSDFENL	1344.5	-
1979 MFRSPSDYENL	1360.5	-
1980 MFRSPSDWENL	1383.6	-
1982 MFRSPSEOPENL	1308.5	-
1983 MFRSPSEFENL	1358.5	-
1984 MFRSPSEYENL	1374.5	-
1985 MFRSPSEWENL	1397.6	-
1987 MFRSPSNPENL	1293.6	-
1988 MFRSPSNFENL	1343.6	-
1989 MFRSPSNYENL	1359.6	-
1990 MFRSPSNWENL	1382.7	-
1992 MFRSPSQPENL	1307.6	-
1993 MFRSPSQFENL	1357.6	-
1994 MFRSPSQYENL	1373.6	-
1995 MFRSPSQWENL	1396.7	-
1997 MFRSPSHPENL	1316.6	-
1998 MFRSPSHFENL	1366.6	-
1999 MFRSPSHYENL	1382.6	-
2000 MFRSPSHWENL	1405.7	-
2002 MFSSPSMPENL	1242.4	-
2003 MFSSPSMFENL	1292.4	-
2004 MFSSPSMYENL	1308.4	-
2005 MFSSPSMWENL	1331.5	-
2007 MFSSPSFPENL	1258.3	-
2008 MFSSPSFFENL	1308.3	-
2009 MFSSPSFYENL	1324.3	-
2010 MFSSPSFWENL	1347.4	-
2012 MFSSPSYPENL	1274.3	-
2013 MFSSPSYFENL	1324.3	-
2014 MFSSPSYYENL	1340.3	-
2015 MFSSPSYWENL	1363.4	-
2017 MFSSPSDPENL	1226.2	-

2018 MFSSPSDFENL	1276.2	-
2019 MFSSPSDYENL	1292.2	-
2020 MFSSPSDWENL	1315.3	-
2022 MFSSPSEOPENL	1240.2	-
2023 MFSSPSEFENL	1290.2	-
2024 MFSSPSEYENL	1306.2	-
2025 MFSSPSEWENL	1329.3	-
2027 MFSSPSNPENL	1225.3	-
2028 MFSSPSNFENL	1275.3	-
2029 MFSSPSNYENL	1291.3	-
2030 MFSSPSNWENL	1314.4	-
2032 MFSSPSQOPENL	1239.3	-
2033 MFSSPSQFENL	1289.3	-
2034 MFSSPSQYENL	1305.3	-
2035 MFSSPSQWENL	1328.4	-
2037 MFSSPSHOPENL	1248.3	-
2038 MFSSPSHFENL	1298.3	-
2039 MFSSPSHYENL	1314.3	-
2040 MFSSPSHWENL	1337.4	-
2042 MFTSPSMPENL	1255.6	-
2043 MFTSPSMFENL	1305.6	-
2044 MFTSPSMYENL	1321.6	-
2045 MFTSPSMWENL	1344.7	-
2047 MFTSPSFOPENL	1271.5	-
2048 MFTSPSFFENL	1321.5	-
2049 MFTSPSFYENL	1337.5	-
2050 MFTSPSFWENL	1360.6	-
2052 MFTSPSYOPENL	1287.5	-
2053 MFTSPSYFENL	1337.5	-
2054 MFTSPSYYENL	1353.5	-
2055 MFTSPSYWENL	1376.6	-
2057 MFTSPSDOPENL	1239.4	-
2058 MFTSPSDFENL	1289.4	-
2059 MFTSPSDYENL	1305.4	-
2060 MFTSPSDWENL	1328.5	-
2062 MFTSPSEOPENL	1253.4	-

2063 MFTSPSEFENL	1303.4	-
2064 MFTSPSEYENL	1319.4	-
2065 MFTSPSEWENL	1342.5	-
2067 MFTSPSNPENL	1238.5	-
2068 MFTSPSNFENL	1288.5	-
2069 MFTSPSNYENL	1304.5	-
2070 MFTSPSNWENL	1327.6	-
2072 MFTSPSQOPENL	1252.5	-
2073 MFTSPSQFENL	1302.5	-
2074 MFTSPSQYENL	1318.5	-
2075 MFTSPSQWENL	1341.6	-
2077 MFTSPSHPENL	1261.5	-
2078 MFTSPSHFENL	1311.5	-
2079 MFTSPSHYENL	1327.5	-
2080 MFTSPSHWENL	1350.6	-
2082 MFHSPSMOPENL	1291.7	-
2083 MFHSPSMFENL	1341.7	-
2084 MFHSPSMYENL	1357.7	-
2085 MFHSPSMWENL	1380.8	-
2087 MFHSPSFPENL	1307.6	-
2088 MFHSPSFFENL	1357.6	-
2089 MFHSPSFYENL	1373.6	-
2090 MFHSPSFWENL	1396.7	-
2092 MFHSPSYOPENL	1323.6	-
2093 MFHSPSYFENL	1373.6	-
2094 MFHSPSYYYENL	1389.6	-
2095 MFHSPSYWENL	1412.7	-
2097 MFHSPSDOPENL	1275.5	-
2098 MFHSPSDFENL	1325.5	-
2099 MFHSPSDYENL	1341.5	-
2100 MFHSPSDWENL	1364.6	-
2102 MFHSPSEOPENL	1289.5	-
2103 MFHSPSEFENL	1339.5	-
2104 MFHSPSEYENL	1355.5	-
2105 MFHSPSEWENL	1378.6	-
2107 MFHSPSNPENL	1274.6	-

2108 MFHSPSNFENL 1324.6 -
2109 MFHSPSNYENL 1340.6 -
2110 MFHSPSNWENL 1363.7 -
2112 MFHSPSQPENL 1288.6 -
2113 MFHSPSQFENL 1338.6 -
2114 MFHSPSQYENL 1354.6 -
2115 MFHSPSQWENL 1377.7 -
2117 MFHSPSHPENL 1297.6 -
2118 MFHSPSHFENL 1347.6 -
2119 MFHSPSHYENL 1363.6 -
2120 MFHSPSHWENL 1386.7 -
2122 MFNSPSMPENL 1268.7 -
2123 MFNSPSMFENL 1318.7 -
2124 MFNSPSMYENL 1334.7 -
2125 MFNSPSMWENL 1357.8 -
2127 MFNSPSFPENL 1284.6 -
2128 MFNSPSFFENL 1334.6 -
2129 MFNSPSFYENL 1350.6 -
2130 MFNSPSFWENL 1373.7 -
2132 MFNSPSYPENL 1300.6 -
2133 MFNSPSYFENL 1350.6 -
2134 MFNSPSYYENL 1366.6 -
2135 MFNSPSYWENL 1389.7 -
2137 MFNSPSDPENL 1252.5 -
2138 MFNSPSDFENL 1302.5 -
2139 MFNSPSDYENL 1318.5 -
2140 MFNSPSDWENL 1341.6 -
2142 MFNSPSEPENL 1266.5 -
2143 MFNSPSEFENL 1316.5 -
2144 MFNSPSEYENL 1332.5 -
2145 MFNSPSEWENL 1355.6 -
2147 MFNSPSNPENL 1251.6 -
2148 MFNSPSNFENL 1301.6 -
2149 MFNSPSNYENL 1317.6 -
2150 MFNSPSNWENL 1340.7 -
2152 MFNSPSQPENL 1265.6 -

2153 M F N S P S Q F E N L 1315.6 -
2154 M F N S P S Q Y E N L 1331.6 -
2155 M F N S P S Q W E N L 1354.7 -
2157 M F N S P S H P E N L 1274.6 -
2158 M F N S P S H F E N L 1324.6 -
2159 M F N S P S H Y E N L 1340.6 -
2160 M F N S P S H W E N L 1363.7 -
2162 M F G S P S M P E N L 1211.6 -
2163 M F G S P S M F E N L 1261.6 -
2164 M F G S P S M Y E N L 1277.6 -
2165 M F G S P S M W E N L 1300.7 -
2167 M F G S P S F P E N L 1227.5 -
2168 M F G S P S F F E N L 1277.5 -
2169 M F G S P S F Y E N L 1293.5 -
2170 M F G S P S F W E N L 1316.6 -
2172 M F G S P S Y P E N L 1243.5 -
2173 M F G S P S Y F E N L 1293.5 -
2174 M F G S P S Y Y E N L 1309.5 -
2175 M F G S P S Y W E N L 1332.6 -
2177 M F G S P S D P E N L 1195.4 -
2178 M F G S P S D F E N L 1245.4 -
2179 M F G S P S D Y E N L 1261.4 -
2180 M F G S P S D W E N L 1284.5 -
2182 M F G S P S E P E N L 1209.4 -
2183 M F G S P S E F E N L 1259.4 -
2184 M F G S P S E Y E N L 1275.4 -
2185 M F G S P S E W E N L 1298.5 -
2187 M F G S P S N P E N L 1194.5 -
2188 M F G S P S N F E N L 1244.5 -
2189 M F G S P S N Y E N L 1260.5 -
2190 M F G S P S N W E N L 1283.6 -
2192 M F G S P S Q P E N L 1208.5 -
2193 M F G S P S Q F E N L 1258.5 -
2194 M F G S P S Q Y E N L 1274.5 -
2195 M F G S P S Q W E N L 1297.6 -
2197 M F G S P S H P E N L 1217.5 -

2198 M F G S P S H F E N L	1267.5	-
2199 M F G S P S H Y E N L	1283.5	-
2200 M F G S P S H W E N L	1306.6	-
2202 M F A S P S M P E N L	1225.6	-
2203 M F A S P S M F E N L	1275.6	-
2204 M F A S P S M Y E N L	1291.6	-
2205 M F A S P S M W E N L	1314.7	-
2207 M F A S P S F P E N L	1241.5	-
2208 M F A S P S F F E N L	1291.5	-
2209 M F A S P S F Y E N L	1307.5	-
2210 M F A S P S F W E N L	1330.6	-
2212 M F A S P S Y P E N L	1257.5	-
2213 M F A S P S Y F E N L	1307.5	-
2214 M F A S P S Y Y E N L	1323.5	-
2215 M F A S P S Y W E N L	1346.6	-
2217 M F A S P S D P E N L	1209.4	-
2218 M F A S P S D F E N L	1259.4	-
2219 M F A S P S D Y E N L	1275.4	-
2220 M F A S P S D W E N L	1298.5	-
2222 M F A S P S E P E N L	1223.4	-
2223 M F A S P S E F E N L	1273.4	-
2224 M F A S P S E Y E N L	1289.4	-
2225 M F A S P S E W E N L	1312.5	-
2227 M F A S P S N P E N L	1208.5	-
2228 M F A S P S N F E N L	1258.5	-
2229 M F A S P S N Y E N L	1274.5	-
2230 M F A S P S N W E N L	1297.6	-
2232 M F A S P S Q P E N L	1222.5	-
2233 M F A S P S Q F E N L	1272.5	-
2234 M F A S P S Q Y E N L	1288.5	-
2235 M F A S P S Q W E N L	1311.6	-
2237 M F A S P S H P E N L	1231.5	-
2238 M F A S P S H F E N L	1281.5	-
2239 M F A S P S H Y E N L	1297.5	-
2240 M F A S P S H W E N L	1320.6	-
2242 R Y S L P P E L S N M	1308.6	-

2243 A Y R S P S M P E N L	1266.5	-
2244 R Y R S P S M P E N L	1351.6	-
2245 N Y R S P S M P E N L	1309.6	-
2246 D Y R S P S M P E N L	1310.5	-
2247 C Y R S P S M P E N L	1298.6	-
2248 Q Y R S P S M P E N L	1323.6	-
2249 E Y R S P S M P E N L	1324.5	-
2250 G Y R S P S M P E N L	1252.5	-
2251 H Y R S P S M P E N L	1332.6	-
2252 I Y R S P S M P E N L	1308.6	-
2253 L Y R S P S M P E N L	1308.6	-
2254 K Y R S P S M P E N L	1323.6	-
2255 M Y R S P S M P E N L	1326.7	-
2256 F Y R S P S M P E N L	1342.6	-
2257 P Y R S P S M P E N L	1292.6	-
2258 S Y R S P S M P E N L	1283.3	-
2259 T Y R S P S M P E N L	1296.5	-
2260 W Y R S P S M P E N L	1381.7	-
2261 Y Y R S P S M P E N L	1358.6	-
2262 V Y R S P S M P E N L	1294.6	-
2263 L A R S P S M P E N L	1216.5	-
2264 L R R S P S M P E N L	1301.6	-
2265 L N R S P S M P E N L	1259.6	-
2266 L D R S P S M P E N L	1260.5	-
2267 L C R S P S M P E N L	1248.6	-
2268 L Q R S P S M P E N L	1273.6	-
2269 L E R S P S M P E N L	1274.5	-
2270 L G R S P S M P E N L	1202.5	-
2271 L H R S P S M P E N L	1282.6	-
2272 L I R S P S M P E N L	1258.6	-
2273 L L R S P S M P E N L	1258.6	-
2274 L K R S P S M P E N L	1273.6	+
2275 L M R S P S M P E N L	1276.7	-
2276 L F R S P S M P E N L	1292.6	-
2277 L P R S P S M P E N L	1242.6	-
2278 L S R S P S M P E N L	1233.3	-

2279	L T R S P S M P E N L	1246.5	-
2280	L W R S P S M P E N L	1331.7	-
2281	L Y R S P S M P E N L	1308.6	-
2282	L V R S P S M P E N L	1244.6	-
2283	L Y A S P S M P E N L	1223.5	-
2284	L Y R S P S M P E N L	1308.6	-
2285	L Y N S P S M P E N L	1266.6	-
2286	L Y D S P S M P E N L	1267.5	-
2287	L Y C S P S M P E N L	1255.6	-
2288	L Y Q S P S M P E N L	1280.6	-
2289	L Y E S P S M P E N L	1281.5	-
2290	L Y G S P S M P E N L	1209.5	-
2291	L Y H S P S M P E N L	1289.6	-
2292	L Y I S P S M P E N L	1265.6	+
2293	L Y L S P S M P E N L	1265.6	-
2294	L Y K S P S M P E N L	1280.6	-
2295	L Y M S P S M P E N L	1283.7	-
2296	L Y F S P S M P E N L	1299.6	-
2297	L Y P S P S M P E N L	1249.6	-
2298	L Y S S P S M P E N L	1240.3	-
2299	L Y T S P S M P E N L	1253.5	-
2300	L Y W S P S M P E N L	1338.7	-
2301	L Y Y S P S M P E N L	1315.6	-
2302	L Y V S P S M P E N L	1251.6	-
2303	L Y R S P S A P E N L	1248.4	-
2304	L Y R S P S R P E N L	1333.5	-
2305	L Y R S P S N P E N L	1291.5	-
2306	L Y R S P S D P E N L	1292.4	-
2307	L Y R S P S C P E N L	1280.5	-
2308	L Y R S P S Q P E N L	1305.5	-
2309	L Y R S P S E P E N L	1306.4	-
2310	L Y R S P S G P E N L	1234.4	-
2311	L Y R S P S H P E N L	1314.5	-
2312	L Y R S P S I P E N L	1290.5	-
2313	L Y R S P S L P E N L	1290.5	-
2314	L Y R S P S K P E N L	1305.5	-

2315	L Y R S P S M P E N L	1308.6	-
2316	L Y R S P S F P E N L	1324.5	-
2317	L Y R S P S P P E N L	1274.5	-
2318	L Y R S P S S P E N L	1265.2	-
2319	L Y R S P S T P E N L	1278.4	-
2320	L Y R S P S W P E N L	1363.6	-
2321	L Y R S P S Y P E N L	1340.5	-
2322	L Y R S P S V P E N L	1276.5	-
2323	L Y R S P S M A E N L	1282.5	-
2324	L Y R S P S M R E N L	1367.6	-
2325	L Y R S P S M N E N L	1325.6	-
2326	L Y R S P S M D E N L	1326.5	-
2327	L Y R S P S M C E N L	1314.6	-
2328	L Y R S P S M Q E N L	1339.6	-
2329	L Y R S P S M E E N L	1340.5	-
2330	L Y R S P S M G E N L	1268.5	-
2331	L Y R S P S M H E N L	1348.6	-
2332	L Y R S P S M I E N L	1324.6	-
2333	L Y R S P S M L E N L	1324.6	-
2334	L Y R S P S M K E N L	1339.6	-
2335	L Y R S P S M M E N L	1342.7	-
2336	L Y R S P S M F E N L	1358.6	-
2337	L Y R S P S M P E N L	1308.6	-
2338	L Y R S P S M S E N L	1299.3	-
2339	L Y R S P S M T E N L	1312.5	-
2340	L Y R S P S M W E N L	1397.7	-
2341	L Y R S P S M Y E N L	1374.6	-
2342	L Y R S P S M V E N L	1310.6	+

Example 3: G2 abrogating peptides of the invention

The following example describes studies which identified exemplary G2 checkpoint-abrogating peptides of the invention. The following peptides of the invention were synthesized directly on membranes and tested in *in vitro* phosphorylation (“kination” assays, as described above.

Table 2

PEPTIDE	X ₁	X ₂	X ₃	X ₄	X ₅	X ₆	X ₇	X ₈	X ₉	X ₁₀	X ₁₁
AAA	L	A	R	S	A	S	M	P	E	A	L
RANDOMII	R	Y	S	L	P	P	E	L	S	N	M
S216A	L	Y	R	S	P	A	M	P	E	N	L
S216P	L	Y	R	S	P	S	M	P	E	N	L
YPN		Y	G	G	P	G	G	G	G		N
YG7N		Y	G	G	G	G	G	G	G		N
YG6N		Y	G	G	G	G	G	G			N
YG5N		Y	G	G	G	G	G				N
YPN		Y			P						N
RPL			R					P			L
YGN			Y			G					N

These peptides were tested in *in vitro* kination reactions. The oligopeptides were used as phosphorylation substrates; added kinases are involved in the cell cycle G2 checkpoint. Thus, a substance that inhibits the kination reaction can be a cell cycle G2 5 checkpoint abrogator. For the detection of the phosphorylation status of substrates in this screening method, isotope-labeled ATP and anti-phospho-peptides antibody can be used.

hChk1; hChk1 fusion proteins (MBP-peptide, GST-peptide), HuCds1/Chk2; HuCds1/Chk2 fusion proteins (MBP-peptide, GST-peptide); or, the cell extract from DNA damaged cells, can be used as the kinases in the screening assay.

The oligopeptides tested as substrates are Y X₂ X₃ P S X₆ X₇ X₈ N (X₂ through X₉, respectively; the first position (X₁) "Y" in this abbreviated nine residue motif corresponds to position X₂ in the eleven residue motif, described above) and variations thereof wherein amino acid residues at positions 2 (X₂) and position 3 (X₃) are Gly, Leu, Ser, or Arg; and the amino acid residue at position 6 through 8 are Gly, Leu, Ser, Met, Pro or Glu. Other tested oligopeptides sequence variations have amino acid residues at position 2 as Gly, Leu, Ser, or Arg; amino acid residues at position 3 as Gly, Leu or Ser; amino acid residues at position 6 as Gly, Met, Pro or Glu; amino acid residues at position 7 as Gly, Leu, or Pro; and, amino acid residues at position 8 as Gly, Met, Ser or Glu. In another variation the residue at

position 2 was Arg; position 3 was Ser; position 6 was Met; position 7 was Pro; and, position 8 was Glu.

The cells with the deficient cell cycle G1 checkpoint (such as a human leukemia-derived cell line Jurkat) were treated with a DNA damaging treatment. As the 5 DNA damaging treatment, the cells were treated with bleomycin or other anti-cancer drugs. These drugs were added to the cell culture medium. Alternatively, the cells were irradiated with gamma irradiation. Peptides were added to these cells and the amount of DNA was determined some 10 to 48 hours after the DNA damage. The harvested cells were re-suspended with the solution that includes propidium iodide, RNase and NP-40 and analyzed 10 by flow cytometer. If the oligopeptide "candidate substance" induces cells not to accumulate DNA at G2/M by this analysis, the result is positive and the substance potentially abrogated G2/M checkpoint.

Other screening methods can be used to identify selective inhibitors of the G2 15 cell cycle checkpoint. For, the cells are simultaneously treated with an oligopeptide "candidate phosphorylation substrate" and an M phase checkpoint activator, such as colchicine or nocodazol. The DNA content of the cells are analyzed some 10 to 48 hours after the treatment as described above. The candidates that do not disturb the accumulation of the cells at G2/M will be the selected G2 checkpoint abrogators in this screening method.

In one embodiment, G2 checkpoint abrogators at positions 2 and 3 have 20 amino acid residues Gly, Leu, Ser or Arg, and at position 5 to 8 are amino acid residues Ser, Gly, Met, Pro or Glu.

In one embodiment of the invention the compositions are enhancers or 25 augmenters of a DNA damaging anti-cancer treatment. By treating cancer cells simultaneously or sequentially with an anti-cancer treatment and a G2 checkpoint inhibiting composition of the invention, one can effectively kill the cancer cells. Since the most human cancer cells do not have an intact G1 checkpoint, the abrogation of the G2 checkpoint by a G2 checkpoint inhibiting composition of the invention will effectively kill the cancer cells 30 that are treated with a DNA damaging method. The compositions of the invention can be directly used as a drug (e.g., a pharmaceutical compositions) or these oligopeptides could be expressed recombinantly *in vivo*, e.g., from a virus vector or other expression vector, e.g., a plasmid, as an *in vivo* gene therapy.

Jurkat cells were cultured in 10% fetal calf serum with a medium (RPMI 1640) at 37°C/5% CO₂ with: bleomycin at 20 µg/ml; bleomycin at 20 µg/ml and the peptide “4aa” (amino acid sequence is GGSPSM); bleomycin at 20 µg/ml and the peptide AAA (Table 1); bleomycin at 20 µg/ml and the peptide YNP (Table 1). The amount of DNA was
5 analyzed at 0, 6, 12, 24 hours after the addition of ten microgram of bleomycin with or without the oligopeptides “4aa,” “YNP” and “AAA.” The DNA quantity was analyzed by a flow cytometer (FACS) after the addition of a solution comprising propidium iodide, RNase and NP-40.

The results are shown in Figure 6. The left panels are actual results of flow
10 cytometer (FACS) analysis. The right panel indicates the population of cells in each of the cell cycle phases (sub G1, G1, S, and G2/M). The results indicated that YNP peptide abrogated the G2 checkpoint because the cells do not accumulate at G2/M phases.

In another experiment, an M phase checkpoint activator, colchicine, was used instead of bleomycin: colchicine at 2.5 µg/ml; colchicine at 2.5 µg/ml and the peptide “4aa”;
15 colchicine at 2.5 µg/ml and the peptide AAA (Table 1); colchicine at 2.5 µg/ml and the peptide YNP (Table 1), and no treatment. The results are shown in Figure 7. None of the above tested oligopeptides (Table 1), including, YPN, affected the accumulation of the colchicine-treated cells at the G2/M phase. These data indicated that YPN specifically abrogated the cell cycle at the G2 checkpoint.
20

Peptides which were tested and the results of these experiments are further summarized in Figures 8 and 9.

Example 4: Peptides of the invention sensitize cancer cells in *in vivo* animal model

The following example describes studies in an art-accepted animal model which demonstrated that exemplary peptides of the invention are effective agents for
25 selectively sensitizing cancer cells to DNA damaging agents. In particular, nude mouse studies demonstrated the *in vivo* efficacy of the compositions and methods of the invention.

Human colon cancer cell line SW620 were injected subcutaneously into 3 week old Balb/c nude mouse (1x10⁸ cells per mouse). Some two weeks after the injection, the established subcutaneous tumors of diameter 2 to 4 mm were resected and transplanted to
30 syngeneic mice. One week after the transplantation, the injection of cisplatin (CDDP) and peptides (TAT-control and TAT-S216, see Table 1) was started. The peptides were in the

form of recombinant fusion proteins, with TAT being the protein transduction domain having the sequence YGRKKRRQRRR.

Cisplatin (CDDP) at 6 mg/kg was injected once a week into peritoneum. Peptides (at 100 nM) were injected into tumor twice a week. Relative tumor weights were assessed at 3 and 5 weeks. The results are shown in Figure 10, upper panel. Similar experiments were performed with 5-FU instead of cisplatin. The results are shown in Figure 8, lower panel. As shown in Figure 10, the S216-containing fusion protein effectively sensitized the cancer cells to a DNA damaging agent administered to the animal *in vivo*.

Similar experiments were performed with cisplatin (CDDP) and another exemplary peptide of the invention, "random II" or "R-II" (see Table 1). As with S216, RII peptide was in the form of a recombinant fusion protein with TAT. The relative volume of the transplanted subcutaneous tumor with or without cisplatin ("CDDP"), CDDP plus DMSO, CDDP plus TAT-FLAG or CDDP plus TAT-Random II peptide was determined. As shown in Figure 11, the R-II containing fusion protein effectively sensitized the cancer cells to a DNA damaging agent administered to the animal *in vivo*.

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.